Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
Hepatology
    August 2024

  1. Hepatology Highlights.
    Hepatology. 2024;80:255-256.
    >> Share

  2. GARCIA-TSAO G, Kaplan DE
    Reply: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
    Hepatology. 2024;80:E36.
    >> Share

  3. RAMAN KP, Patch D
    Tranexamic acid in variceal bleeding revisited.
    Hepatology. 2024;80:257-259.
    >> Share

  4. JEPSEN P, West J, Kann AE, Kraglund F, et al
    Risk of alcohol-associated liver disease in the offspring of parents with alcohol-associated liver disease: A nationwide cohort study.
    Hepatology. 2024;80:418-427.
    >> Share

  5. WANG Q, Bu Q, Pan B, Yin Y, et al
    Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury.
    Hepatology. 2024;80:E24-E25.
    >> Share

  6. YANG D, Tian T, Li X, Zhang B, et al
    ZNT1 and Zn 2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor.
    Hepatology. 2024;80:312-329.
    >> Share

  7. HLADY RA, Robertson KD
    Epigenetic memory of environmental exposures as a mediator of liver disease.
    Hepatology. 2024;80:451-464.
    >> Share

    July 2024
  8. JEONG JM, Choi SE, Shim YR, Kim HH, et al
    CX3CR1+ macrophages interact with hepatic stellate cells to promote hepatocellular carcinoma through CD8+ T cell suppression.
    Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001021.
    >> Share

  9. CELSA C, Cabibbo G, Fulgenzi CAM, Battaglia S, et al
    Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
    Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001026.
    >> Share


  10. Diagnosis and Management of Hepatocellular Carcinoma.
    Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001010.
    >> Share

  11. ZHANG L, Xie P, Li M, Zhang X, et al
    Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.
    Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000001003.
    >> Share

  12. HUANG Y, Yu F, Ding Y, Zhang H, et al
    Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver.
    Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000000998.
    >> Share

  13. HOOVER JM
    Letter to the Editor: Utilization of beta blockers in patients with portal hypertension and peripheral artery disease.
    Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001008.
    >> Share

  14. KENT D, Ng SS, Syanda AM, Khoshkenar P, et al
    Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
    Hepatology. 2024 Jul 2. doi: 10.1097/HEP.0000000000000969.
    >> Share


  15. Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding.
    Hepatology. 2024;80:E23.
    >> Share


  16. Hepatology Highlights.
    Hepatology. 2024;80:1-2.
    >> Share

  17. LAINE L, Barkun AN, Leontiadis GI
    Letter to the Editor: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
    Hepatology. 2024;80:E15-E16.
    >> Share

  18. KRAWCZYK M, Lammert F
    Letter to the Editor: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
    Hepatology. 2024;80:E11-E12.
    >> Share

  19. RINELLA ME, Lazarus JV, Newsome PN
    Reply: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
    Hepatology. 2024;80:E13-E14.
    >> Share

  20. MA J, Liangpunsakul S
    Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation.
    Hepatology. 2024;80:14-17.
    >> Share

  21. DAVENPORT M
    Serum matrix metalloproteinase-7 (MMP-7): As good as it gets?
    Hepatology. 2024;80:18-19.
    >> Share

  22. WOLTERS F, Oude Elferink RPJ, Beuers U
    PPARalpha, PPARdelta, or both-that is the question!
    Hepatology. 2024;80:8-10.
    >> Share

  23. KOSHIOL J, Krawczyk M
    enHanCCing knowledge of genetic factors in primary liver tumor.
    Hepatology. 2024;80:11-13.
    >> Share

  24. NEIL DAH, Smith ML, Minervini M, Demetris AJ, et al
    Reply: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
    Hepatology. 2024;80:E6-E7.
    >> Share

  25. CAO H, Gu J
    Letter to the Editor: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
    Hepatology. 2024;80:E4-E5.
    >> Share

  26. ABERG F, Asteljoki J, Mannisto V, Luukkonen PK, et al
    Combined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population.
    Hepatology. 2024;80:163-172.
    >> Share

  27. FLORIS A, Chandla S, Lim Y, Barbier-Torres L, et al
    Sumoylation of methionine adenosyltransferase alpha 1 promotes mitochondrial dysfunction in alcohol-associated liver disease.
    Hepatology. 2024;80:102-118.
    >> Share

  28. LOPEZ-PASCUAL A
    Navigating liver disease complexity: Innovations in in vitro modeling and precision medicine.
    Hepatology. 2024;80:20-23.
    >> Share

  29. SCHONFELD M, O'Neil M, Weinman SA, Tikhanovich I, et al
    Alcohol-induced epigenetic changes prevent fibrosis resolution after alcohol cessation in miceresolution.
    Hepatology. 2024;80:119-135.
    >> Share

  30. TONG Y, Wang F, Li S, Guo W, et al
    Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.
    Hepatology. 2024;80:38-54.
    >> Share

  31. SINGAL AK, Shah VH, Malhi H
    Emerging targets for therapy in ALD: Lessons from NASH.
    Hepatology. 2024;80:223-237.
    >> Share


  32. Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2024;80:E21.
    >> Share

  33. PREMKUMAR M, Karvellas CJ, Kulkarni AV, Bhujade H, et al
    Role of Point-of-Care ultrasound (POCUS) in clinical hepatology.
    Hepatology. 2024 Jul 1. doi: 10.1097/HEP.0000000000000990.
    >> Share

    June 2024
  34. GAO D, Ping Yam JW
    Reversal of lipid metabolism as a therapeutic approach for hepatocellular carcinoma.
    Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000001000.
    >> Share

  35. PREMKUMAR M, Kulkarni A, Izzy M
    'Regarding Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography'.
    Hepatology. 2024 Jun 26. doi: 10.1097/HEP.0000000000000988.
    >> Share

  36. LUO X, Yu J
    Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury.
    Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000984.
    >> Share

  37. RATZIU V, Yilmaz Y, Lazas D, Friedman SL, et al
    Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology.
    Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000980.
    >> Share

  38. KANG K, Wu Y
    Letter to the Editor: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
    Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000945.
    >> Share

  39. LI J, Ma X, Xuan Q, Li Q, et al
    Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis B virus surface antigen particles: Implications for pathobiology of chronic hepatitis B.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000972.
    >> Share

  40. YANG M, Song X, Zhang F, Li M, et al
    Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000979.
    >> Share

  41. BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
    Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
    >> Share

  42. LIU Q, Zhang X, Qi J, Tian X, et al
    Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for hepatocellular carcinoma.
    Hepatology. 2024 Jun 19. doi: 10.1097/HEP.0000000000000962.
    >> Share


  43. Process Measures to Improve Outcomes During Peri-Procedure Management of Coagulopathy in Cirrhosis.
    Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000964.
    >> Share

  44. HUANG L, Zou L
    Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
    >> Share


  45. Erratum: Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.
    Hepatology. 2024;79:E171-E172.
    >> Share


  46. Hepatology Highlights.
    Hepatology. 2024;79:1239-1240.
    >> Share

  47. LI Z, Zhang Y, Li Y, Lan J, et al
    Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.
    Hepatology. 2024;79:E169-E170.
    >> Share

  48. LOMBARDI R, Dalbeni A, Mantovani A, Ravaioli F, et al
    Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2024;79:E155-E156.
    >> Share

  49. CALZADILLA-BERTOT L, Jeffrey AW, Jeffrey GP
    Letter to the Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2024;79:E153-E154.
    >> Share

  50. YEH JG, Newsome PN
    Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
    Hepatology. 2024;79:1255-1257.
    >> Share

  51. HANSEN BE, Vandriel SM, Vig P, Garner W, et al
    Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
    Hepatology. 2024;79:1279-1292.
    >> Share

  52. ABDELMALEK MF, Rinella ME
    Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart.
    Hepatology. 2024;79:1252-1254.
    >> Share

  53. ENGSTROM A, Wintzell V, Melbye M, Svanstrom H, et al
    Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
    Hepatology. 2024;79:1401-1411.
    >> Share

  54. ZHAO G, Ma Q, Yang H, Jiang H, et al
    Base editing of the mutated TERT promoter inhibits liver tumor growth.
    Hepatology. 2024;79:1310-1323.
    >> Share

  55. SCHMIDT KA, Simonetto DA
    The telomere tango: Liver disease in the genomic spotlight.
    Hepatology. 2024;79:1249-1251.
    >> Share

  56. SIDALI S, Borie R, Sicre de Fontbrune F, El Husseini K, et al
    Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors.
    Hepatology. 2024;79:1365-1380.
    >> Share

  57. UMBAUGH DS, Nguyen NT, Curry SC, Rule JA, et al
    The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure.
    Hepatology. 2024;79:1352-1364.
    >> Share

  58. WANG A, Blackford AL, Behling C, Wilson LA, et al
    Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
    Hepatology. 2024;79:1381-1392.
    >> Share

  59. JIN Y, Shou Y, Lei Q, Du C, et al
    An entropy weight method to integrate big omics and mechanistically evaluate DILI.
    Hepatology. 2024;79:1264-1278.
    >> Share

  60. AFONSO MB, Marques V, van Mil SWC, Rodrigues CMP, et al
    Human liver organoids: From generation to applications.
    Hepatology. 2024;79:1432-1451.
    >> Share

    May 2024
  61. MANTOVANI S, Mondelli MU
    Platelets harness innate immunity to promote dissemination of hepatocellular carcinoma.
    Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000946.
    >> Share

  62. GUO C, Liu Z, Zhang T
    Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
    Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000947.
    >> Share

  63. MUSSO G, Pinach S, Mariano F, Saba F, et al
    Effect of phospholipid curcumin Meriva(R) on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial.
    Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000937.
    >> Share

  64. MOORE MP, Wang X, Kennelly JP, Shi H, et al
    Low MBOAT7 expression, a genetic risk for MASH, promotes a pro-fibrotic pathway involving hepatocyte TAZ upregulation.
    Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000933.
    >> Share

  65. KANWAL F, Neuschwander-Tetri BA, Loomba R, Rinella ME, et al
    Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
    Hepatology. 2024;79:1212-1219.
    >> Share

  66. NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
    Reply: Concerns regarding the use of Fatty Liver Index in studies of lean NAFLD.
    Hepatology. 2024;79:E130-E131.
    >> Share

  67. ZAHRAWI FM, Mehal WZ
    Letter to the Editor: Concerns regarding the use of fatty liver index in studies of lean NAFLD.
    Hepatology. 2024;79:E129.
    >> Share

  68. STOCKDALE AJ, Degasperi E
    HDV RNA and liver disease progression: What do we know?
    Hepatology. 2024;79:983-985.
    >> Share

  69. DESERT R, Foucher F, Guillout M, Nieto N, et al
    Reply: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
    Hepatology. 2024;79:E141-E143.
    >> Share

  70. WANG TC, Xiao YD, Zhou P
    Letter to the Editor: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
    Hepatology. 2024;79:E140.
    >> Share

  71. LIU H, Li H, Wang DX, Li T, et al
    Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Hepatology. 2024;79:E144-E145.
    >> Share

  72. DALBENI A, Mantovani A, Lombardi R, Ravaioli F, et al
    Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hepatology. 2024;79:E146-E147.
    >> Share

  73. KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
    Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64 Cu PET/CT study in healthy humans.
    Hepatology. 2024;79:1065-1074.
    >> Share

  74. SQUIRES JE, Horslen SP
    Incorporation of genetic testing into the diagnostic algorithms of PALF: The time is now.
    Hepatology. 2024;79:970-972.
    >> Share

  75. DALBENI A, Lombardi R, Henrique M, Zoncape M, et al
    Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Hepatology. 2024;79:1107-1116.
    >> Share

  76. LENZ D, Schlieben LD, Shimura M, Bianzano A, et al
    Genetic landscape of pediatric acute liver failure of indeterminate origin.
    Hepatology. 2024;79:1075-1087.
    >> Share

  77. AJMERA V, Tesfai K, Sandoval E, Lopez S, et al
    Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
    Hepatology. 2024;79:1098-1106.
    >> Share

  78. TONIUTTO P, Shalaby S, Mameli L, Morisco F, et al
    Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review.
    Hepatology. 2024;79:1141-1157.
    >> Share

  79. SANTOS AA, Delgado TC, Marques V, Ramirez-Moncayo C, et al
    Spatial metabolomics and its application in the liver.
    Hepatology. 2024;79:1158-1179.
    >> Share


  80. Erratum: Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma.
    Hepatology. 2024;79:E150-E151.
    >> Share

    April 2024
  81. KUMAR M, Venishetty S
    Reply: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - A randomized controlled trial.
    Hepatology. 2024 Apr 30. doi: 10.1097/HEP.0000000000000916.
    >> Share

  82. ELKRIEF L, Denecheau-Girard C, Magaz M, Praktiknjo M, et al
    Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: A multicenter retrospective study.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000901.
    >> Share

  83. LI X, Zhang Y, Li S, Shi J, et al
    Macrophage hitchhiking for systematic suppression in postablative multifocal hepatocellular carcinoma.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000903.
    >> Share

  84. CHOPRA SY, Rawat VL, Ingle MA, Lad SG, et al
    Letter to Editor: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000915.
    >> Share

  85. LEE YT, Tseng HR, Yang JD
    Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block.
    Hepatology. 2024 Apr 19. doi: 10.1097/HEP.0000000000000898.
    >> Share

  86. GUO C, Liu Z, Fan H, Wang H, et al
    Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.
    Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000879.
    >> Share

  87. HAZARI Y, Chevet E, Bailly-Maitre B, Hetz C, et al
    ER stress signaling at the interphase between MASH and hepatocellular carcinoma.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000893.
    >> Share

  88. PRZYBYSZEWSKI EM, Bhan I, Yarze JC
    Letter to the Editor: On the use of non-selective beta blockers in cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000888.
    >> Share

  89. GARCIA-TSAO G, Kaplan DE
    Reply: On the use of non-selective beta blockers in cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000889.
    >> Share

  90. VOLK ML
    Innovations in Healthcare Delivery for Patients with Cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000892.
    >> Share

  91. MOGHE A, McGuire BM, Levy C
    Acute hepatic porphyrias - a guide for Hepatologists.
    Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000880.
    >> Share

  92. SUN C, Zhou C, Daneshvar K, Ben Saad A, et al
    Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells.
    Hepatology. 2024 Apr 2. doi: 10.1097/HEP.0000000000000822.
    >> Share

  93. LI J, Allen AM, Yin M
    Reply: Comparing quantitative MRI technologies in steatotic liver disease.
    Hepatology. 2024;79:E121-E122.
    >> Share

  94. ALKHOURI N, Harisinghani M
    Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver disease.
    Hepatology. 2024;79:E119-E120.
    >> Share

  95. FRANSES JW, Duda DG
    Scirrhous HCC: Another 'omic thread in the HCC tapestry.
    Hepatology. 2024;79:747-748.
    >> Share

  96. VOLKERT I, Fromme M, Schneider C, Candels L, et al
    Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
    Hepatology. 2024;79:898-911.
    >> Share

  97. LADD AD, Duarte S, Sahin I, Zarrinpar A, et al
    Mechanisms of drug resistance in HCC.
    Hepatology. 2024;79:926-940.
    >> Share


  98. Erratum: Identification and characterization of a hepatic IL-13-producing ILC3-like population potentially involved in liver fibrosis.
    Hepatology. 2024;79:E128.
    >> Share


  99. Erratum: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.
    Hepatology. 2024;79:E127.
    >> Share


  100. April 2024 Hepatology Highlights.
    Hepatology. 2024;79:745-746.
    >> Share

  101. TAFALENG EN, Li J, Wang Y, Hidvegi T, et al
    Variants in autophagy genes MTMR12 and FAM134A are putative modifiers of the hepatic phenotype in alpha1-antitrypsin deficiency.
    Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000865.
    >> Share

  102. TAPPER EB, Warner MA, Shah RP, Emamaullee J, et al
    Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
    Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000856.
    >> Share

    March 2024

  103. Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis.
    Hepatology. 2024 Mar 29. doi: 10.1097/HEP.0000000000000857.
    >> Share

  104. DENG T, Chen G
    Single-cell based molecular classification in systematic treatment of hepatocellular carcinoma: From in silico to bedside.
    Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000874.
    >> Share

  105. CRUZ C, Prado CM, Gillis C, Martindale R, et al
    Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant.
    Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000818.
    >> Share

  106. FENG X, Feng B, Zhou J, Yang J, et al
    Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells.
    Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000831.
    >> Share

  107. GOLDBERG DT, Yaskolka Meir A, Tsaban G, Rinott E, et al
    Novel proteomic signatures may indicate MRI-assessed intrahepatic fat state and changes; the DIRECT PLUS clinical trial.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000867.
    >> Share

  108. ZHAO Q, Chen DP, Chen HD, Wang YZ, et al
    NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000868.
    >> Share

  109. CHEN Y, Deng X, Li Y, Han Y, et al
    Comprehensive molecular classification predicted microenvironment profiles and therapy response for hepatocellular carcinoma.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000869.
    >> Share

  110. CULLARO G, Allegretti AS, Fenton C, Ge J, et al
    The association between mean arterial pressure and acute kidney injury reversal among decompensated cirrhosis patients.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000858.
    >> Share

  111. WIGG AJ, Narayana S, Woodman RJ, Adams LA, et al
    A randomized multicenter trial of a chronic disease management intervention for decompensated cirrhosis. The Australian Liver Failure (ALFIE) trial.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000862.
    >> Share

  112. MEROUEH C, Warasnhe K, Tizhoosh HR, Shah VH, et al
    Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials.
    Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000866.
    >> Share

  113. STERLING RK, Asrani SK, Levine D, Duarte-Rojo A, et al
    AASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000844.
    >> Share

  114. STERLING RK, Patel K, Duarte-Rojo A, Asrani SK, et al
    AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000845.
    >> Share

  115. STERLING RK, Duarte-Rojo A, Patel K, Asrani SK, et al
    AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000843.
    >> Share

  116. ROCKEY DC, Alsawas M, Rojo-Duarte A, Patel K, et al
    Non-invasive liver disease assessment to identify portal hypertension: A systematic review supporting the AASLD Practice Guideline.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000841.
    >> Share

  117. DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
    Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
    >> Share

  118. MARCHETTI A, Pelusi S, Marella A, Malvestiti F, et al
    Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000839.
    >> Share

  119. BU W, Sun X, Xue X, Geng S, et al
    Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000821.
    >> Share

  120. MUNOZ AE, Rodger EG
    Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000846.
    >> Share

  121. SHARPTON S, Loomba R
    Response to Letter to the Editor: emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000848.
    >> Share

  122. GUO Q, Wang J, Wang G, Wang X, et al
    Letter to the Editor: Is right heart assessment vital for evaluating Terlipressin-related outcomes in Hepatorenal Syndrome-AKI?
    Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000832.
    >> Share

  123. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
    Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
    Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
    >> Share

  124. SEMMLER G, Hartl L, Mendoza YP, Simbrunner B, et al
    Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000829.
    >> Share

  125. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
    Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
    >> Share

  126. ROY A, Kajal K, Izzy M, Sihag BK, et al
    Reply: Is right heart assessment vital for evaluating terlipressin-related outcomes in Hepatorenal Syndrome-AKI ?
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000833.
    >> Share

  127. KUMAR M, Venishetty S, Jindal A, Bihari C, et al
    Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000817.
    >> Share


  128. Erratum: An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
    Hepatology. 2024;79:E105.
    >> Share

  129. HOOFNAGLE JH, Doo E
    Letter to the Editor: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2024;79:E91-E92.
    >> Share

  130. LAZARUS JV, Newsome PN, Francque SM, Kanwal F, et al
    Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2024;79:E93-E94.
    >> Share

  131. BARMAN-AKSOZEN J, Minder AE, Schuppan D, Stolzel U, et al
    Letter to the Editor: Contrasting effect of iron supplementation in protoporphyria.
    Hepatology. 2024;79:E87-E88.
    >> Share

  132. LEVY C, Dickey AK, Anderson KE, Keel SB, et al
    Reply: Contrasting effect of iron supplementation in protoporphyria.
    Hepatology. 2024;79:E89-E90.
    >> Share

  133. NICOARA-FARCAU O, Han G, Rudler M, Angrisani D, et al
    Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis.
    Hepatology. 2024;79:624-635.
    >> Share

  134. WANG F, Chen L, Kong D, Zhang X, et al
    Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1alpha transcriptional complex.
    Hepatology. 2024;79:606-623.
    >> Share

  135. LEE BP, Dodge JL, Terrault NA
    National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
    Hepatology. 2024;79:666-673.
    >> Share

  136. BARTEN TRM, Atsma F, van der Meer AJ, Gansevoort R, et al
    Higher need for polycystic liver disease therapy in female patients: Sex-specific association between liver volume and need for therapy.
    Hepatology. 2024;79:551-559.
    >> Share

  137. LEDENKO M, Antwi SO, Patel T
    Geospatial analysis of cyanobacterial exposure and liver cancer in the contiguous United States.
    Hepatology. 2024;79:575-588.
    >> Share

  138. LEVY C, Dickey AK, Wang B, Thapar M, et al
    Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria.
    Hepatology. 2024;79:731-743.
    >> Share


  139. Hepatology Highlights.
    Hepatology. 2024;79:525-526.
    >> Share

    February 2024
  140. WONG YJ, Teng M, Sim A, Thet HM, et al
    Full adherence to cirrhosis quality indicators is associated with lower mortality in acute variceal bleeding: Nationwide audit.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000793.
    >> Share

  141. HASSAN MM, Li D, Han Y, Byun J, et al
    Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000800.
    >> Share

  142. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
    Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
    >> Share

  143. PENG Z, Wei G, Huang P, Matta H, et al
    ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801.
    >> Share

  144. HE B, Huang Z, Qin S, Peng P, et al
    Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth through inhibiting Hippo signaling in hepatocellular carcinoma.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000783.
    >> Share

  145. CALTHORPE L, Chiou SH, Rubin J, Huang CY, et al
    A modified hospital frailty risk score for patients with cirrhosis undergoing abdominal operations.
    Hepatology. 2024 Feb 19. doi: 10.1097/HEP.0000000000000794.
    >> Share

  146. PREMKUMAR M, Kajal K, Izzy M, Sihag BK, et al
    Reply to 'liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus".
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000792.
    >> Share

  147. PAPATHERODORIDIS G, Lampertico P
    Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
    >> Share

  148. ZHU M, Liu Z, Chen S, Luo Z, et al
    Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
    Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000776.
    >> Share

  149. PARK JG, Roh PR, Kang MW, Cho SW, et al
    Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
    Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000772.
    >> Share

  150. DONGELMANS E, Erler N, Adam R, Nadalin S, et al
    Recent outcomes of liver transplantation for Budd Chiari Syndrome - a study of the European Liver Transplant Registry (ELTR) and affiliated centers.
    Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000778.
    >> Share

  151. AGRAWAL D, Ariga KK
    Liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000789.
    >> Share

  152. ALLEGRETTI AS, Patidar KR, Ma AT, Cullaro G, et al
    From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000790.
    >> Share

  153. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
    Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
    >> Share

  154. EHRENBAUER AF, Egge JFM, Gabriel MM, Tiede A, et al
    Comparison of six tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome - A prospective, observational study.
    Hepatology. 2024 Feb 13. doi: 10.1097/HEP.0000000000000770.
    >> Share

  155. RINELLA ME, Castro Narro GE, Krag A, Terrault N, et al
    Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' dagger.
    Hepatology. 2024;79:E16-E17.
    >> Share

  156. CUSI K, Younossi Z, Roden M
    From NAFLD to MASLD: Promise and pitfalls of a new definition dagger.
    Hepatology. 2024;79:E13-E15.
    >> Share

  157. BALAKRISHNAN M, Rehm J
    A public health perspective on mitigating the global burden of chronic liver disease.
    Hepatology. 2024;79:451-459.
    >> Share

  158. KHALID M, Khan ZM, Sheraz Kahloon A
    Letter to the Editor: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
    Hepatology. 2024;79:E18-E19.
    >> Share

  159. KIM Y, Chang Y, Ryu S, Wild SH, et al
    Reply: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
    Hepatology. 2024;79:E20-E21.
    >> Share

  160. BARR RG, Bolondi L
    Contrast-enhanced US for HCC: Finally out from the waiting list?
    Hepatology. 2024;79:267-268.
    >> Share

  161. LYSHCHIK A, Wessner CE, Bradigan K, Eisenbrey JR, et al
    Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe.
    Hepatology. 2024;79:380-391.
    >> Share

  162. HUANG H, Tsui YM, Ho DW, Chung CY, et al
    LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress.
    Hepatology. 2024;79:323-340.
    >> Share

  163. LAZARUS JV, Mark HE, Allen AM, Arab JP, et al
    A global action agenda for turning the tide on fatty liver disease.
    Hepatology. 2024;79:502-523.
    >> Share

  164. MENG Z, Zhou L, Hong S, Qiu X, et al
    Myeloid-specific ablation of Basp1 ameliorates diet-induced NASH in mice by attenuating pro-inflammatory signaling.
    Hepatology. 2024;79:409-424.
    >> Share

  165. SINHA S, Hassan N, Schwartz RE
    Organelle stress and alterations in interorganelle crosstalk during liver fibrosis.
    Hepatology. 2024;79:482-501.
    >> Share


  166. Hepatology Highlights.
    Hepatology. 2024;79:255-256.
    >> Share


  167. Hepatology Highlights.
    Hepatology. 2024;79:255-256.
    >> Share

    January 2024

  168. Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
    Hepatology. 2024 Jan 29. doi: 10.1097/HEP.0000000000000730.
    >> Share

  169. WANG Y, Wang X, Bai B, Shaha A, et al
    Targeting Src SH3 domain-mediated glycolysis of hepatic stellate cells suppresses transcriptome, myofibroblastic activation, and colorectal liver metastasis.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000763.
    >> Share

  170. XIA Y, Wang Y, Xiong Q, He J, et al
    Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of hepatic stellate cells.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000762.
    >> Share


  171. Hepatology highlights.
    Hepatology. 2024 Jan 23. doi: 10.1097/HEP.0000000000000742.
    >> Share

  172. NAKAGAWA H, Lin A
    The translation of oncogenic mRNAs regulated by pseudouridylation: A new player in hepatocellular carcinoma.
    Hepatology. 2024 Jan 22. doi: 10.1097/HEP.0000000000000761.
    >> Share

  173. NIEMIETZ P, Peiseler M, Kohlhepp M, Horn P, et al
    C-C chemokine receptor type 7 (CCR7) regulates hepatic CD8+ T cell homeostasis and response to acute liver injury.
    Hepatology. 2024 Jan 17. doi: 10.1097/HEP.0000000000000757.
    >> Share

  174. TRIPODI A, Primignani M, D'Ambrosio R, Tosetti G, et al
    Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis.
    Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000756.
    >> Share


  175. Hepatology Highlights.
    Hepatology. 2024;79:1-2.
    >> Share

  176. BARGELLINI I, Rimassa L, Masi G
    SIRT and chemotherapy in unresectable iCCA: Ready to take off.
    Hepatology. 2024;79:9-11.
    >> Share

  177. EMANUELE E, Minoretti P
    Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with "Ludwig disease".
    Hepatology. 2024;79:E4.
    >> Share

  178. NEWSOME P, Rinella ME, Lazarus JV, Terrault N, et al
    Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease".
    Hepatology. 2024;79:E5-E6.
    >> Share

  179. ROWE IA
    Prediction of outcomes in patients with acute variceal bleeding.
    Hepatology. 2024;79:15-17.
    >> Share

  180. WANG CC, Cheng YM, Kao JH
    Letter to the Editor: Statement of steatotic liver disease-A great leap toward the global standardization.
    Hepatology. 2024;79:E7-E8.
    >> Share

  181. GARCIA-CRIADO A, Bruix J
    Screening for liver cancer: The good, the bad, and the ugly.
    Hepatology. 2024;79:12-14.
    >> Share

  182. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
    Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
    Hepatology. 2024;79:39-48.
    >> Share

  183. LEE EW, Eghtesad B, Garcia-Tsao G, Haskal ZJ, et al
    AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage.
    Hepatology. 2024;79:224-250.
    >> Share


  184. Hepatology Highlights.
    Hepatology. 2024;79:1-2.
    >> Share

    December 2023
  185. HOFER BS, Brusilovskaya K, Simbrunner B, Balcar L, et al
    Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000740.
    >> Share

  186. VAJRO P, Mandato C
    Letter to the Editor: More on Non-Alcohol/Non-Metabolic Dysfunction-Associated Steatohepatitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000734.
    >> Share

  187. JENG WJ, Chien RN, Liaw YF
    Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
    >> Share

  188. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
    Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
    >> Share

  189. WIEGAND J, Franke A, Stein K, Trautwein C, et al
    Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
    >> Share

  190. WATT KD, Khan MQ
    Reply to "more on non-alcohol/non-metabolic dysfunction-associated steatohepatitis".
    Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000739.
    >> Share

  191. CHEN J, Tu T, Cohen C, Wang S, et al
    Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
    >> Share

  192. ZABRANSKY DJ, Yarchoan M, Ho WJ
    Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
    Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000738.
    >> Share

  193. LU T, Zhang J, Li H, Li G, et al
    Letter to the Editor: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
    Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000733.
    >> Share

  194. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
    Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
    Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
    >> Share

  195. RATZIU V, Francque S, Behling CA, Cejvanovic V, et al
    Artificial intelligence scoring of liver biopsies in a phase ii trial of semaglutide in non-alcoholic steatohepatitis.
    Hepatology. 2023 Dec 19. doi: 10.1097/HEP.0000000000000723.
    >> Share

  196. VOGEL A, Grant RC, Meyer T, Sapisochin G, et al
    Adjuvant and neoadjuvant therapies for hepatocellular carcinoma.
    Hepatology. 2023 Dec 18. doi: 10.1097/HEP.0000000000000726.
    >> Share

  197. SCHULZE RJ, Strom SC, Nyberg SL
    From pain to gain: Leveraging acetaminophen in hepatocyte transplantation for phenylketonuria.
    Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000713.
    >> Share

  198. YU S, Liu X, Xu Y, Pan L, et al
    m6A-mediated gluconeogenic enzyme PCK1 upregulation protects against hepatic ischemia-reperfusion injury.
    Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000716.
    >> Share

  199. YIN C, Zhang C, Wang Y, Liu G, et al
    ALDOB/KAT2A interactions epigenetically modulate TGF-beta expression and T cell functions in hepatocellular carcinogenesis.
    Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000704.
    >> Share

  200. CHAN FF, Yuen VW, Shen J, Chin DW, et al
    Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma.
    Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000709.
    >> Share

  201. MALHI H, Brown RS Jr, Lim JK, Reau N, et al
    Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals.
    Hepatology. 2023;78:1680-1681.
    >> Share

  202. RINELLA ME, Lazarus JV, Ratziu V, Francque SM, et al
    A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2023;78:1966-1986.
    >> Share

  203. DESAI AP, Madathanapalli A, Tang Q, Orman ES, et al
    PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease.
    Hepatology. 2023;78:1788-1799.
    >> Share

  204. ABERG F
    Letter to the Editor: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
    Hepatology. 2023;78:E101-E102.
    >> Share

  205. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
    Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
    Hepatology. 2023;78:E103-E104.
    >> Share

  206. ZHANG X, Yip TC, Tse YK, Hui VW, et al
    Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis.
    Hepatology. 2023;78:1816-1827.
    >> Share

  207. GAO R, Li Y, Xu Z, Zhang F, et al
    Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease.
    Hepatology. 2023;78:1800-1815.
    >> Share


  208. Erratum: Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.
    Hepatology. 2023;78:E110.
    >> Share


  209. Erratum: Diabetes and cirrhosis: Current concepts on diagnosis and management.
    Hepatology. 2023;78:E108.
    >> Share


  210. Erratum: Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
    Hepatology. 2023;78:E107.
    >> Share

  211. MAIWALL R, Piano S, Singh V, Caraceni P, et al
    Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections- Results from the ICA 'Global study' [EABCIR-Global Study].
    Hepatology. 2023 Dec 1. doi: 10.1097/HEP.0000000000000653.
    >> Share


  212. Ending stigmatizing language in alcohol and liver disease: A liver societies' statement dagger.
    Hepatology. 2023;78:1682-1683.
    >> Share

    November 2023
  213. HU YX, Diao LT, Hou YR, Lv G, et al
    PUS1 promotes hepatocellular carcinoma via mRNA pseudouridylation to enhance the translation of oncogenic mRNAs.
    Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000702.
    >> Share

  214. PREMKUMAR M, Kajal K, Reddy KR, Izzy M, et al
    Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000691.
    >> Share

  215. MICHALOPOULOS GK
    Hepatocytes of mice and men: Different regenerative signals?
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000693.
    >> Share

  216. KE L, Rui Z, Fukai W, Yunzheng Z, et al
    Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in hepatocellular carcinoma.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000673.
    >> Share


  217. February 2024 Hepatology Highlights.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000681.
    >> Share

  218. LIU N, Tian J, Steer CJ, Han Q, et al
    MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux.
    Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000672.
    >> Share

  219. KARVELLAS CJ, Bajaj JS, Kamath PS, Napolitano L, et al
    AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patients with cirrhosis.
    Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000671.
    >> Share

  220. QASIM KHAN M, Hassan S, Lizaola-Mayo BC, Bhat M, et al
    Navigating the 'Specific Etiology' steatohepatitis category: Evaluation & management of non-alcohol/non-metabolic dysfunction-associated steatohepatitis.
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000674.
    >> Share

  221. BRENNER DA
    Alternatives to animal testing to assess NASH drugs and hepatotoxicity.
    Hepatology. 2023 Nov 6. doi: 10.1097/HEP.0000000000000669.
    >> Share

  222. SCHERR AL, Nader L, Xu K, Elssner C, et al
    Etiology-independent activation of the LTbeta-LTbetaR-RELB axis drives aggressiveness and predicts poor prognosis in Hepatocellular carcinoma.
    Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000657.
    >> Share

  223. D'AMICO G, Zipprich A, Villanueva C, Sorda JA, et al
    Further decompensation in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements.
    Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000652.
    >> Share

  224. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
    Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening.
    Hepatology. 2023;78:E91-E92.
    >> Share

  225. ARIAS-LOSTE MT, Crespo J, Iruzubieta P
    Letter to the Editor: Updated guidance on NAFLD screening.
    Hepatology. 2023;78:E89-E90.
    >> Share

  226. SEBASTIANI G, Milic J, Tsochatzis EA, Marzolini C, et al
    Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?
    Hepatology. 2023;78:E87-E88.
    >> Share

  227. YANG Z, Ding WX
    The pre-mRNA alternative splicing regulated by SRPK2: A new player in alcohol-associated liver disease?
    Hepatology. 2023;78:1329-1331.
    >> Share

  228. LAZARUS JV, Kopka CJ, Younossi ZM, Allen AM, et al
    It is time to expand the fatty liver disease community of practice.
    Hepatology. 2023;78:1325-1328.
    >> Share

  229. TILG H, Adolph TE, Tacke F
    Therapeutic modulation of the liver immune microenvironment.
    Hepatology. 2023;78:1581-1601.
    >> Share

  230. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
    ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
    Hepatology. 2023;78:1337-1351.
    >> Share

  231. WU Q, Pan C, Zhou Y, Wang S, et al
    Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment.
    Hepatology. 2023;78:1402-1417.
    >> Share

  232. SONG Y, Wei J, Li R, Fu R, et al
    Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-beta/SMAD signaling.
    Hepatology. 2023;78:1433-1447.
    >> Share

  233. CHIU YT, Husain A, Sze KM, Ho DW, et al
    Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC.
    Hepatology. 2023;78:1368-1383.
    >> Share

  234. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
    Metabolic reprogramming and its clinical implication for liver cancer.
    Hepatology. 2023;78:1602-1624.
    >> Share

  235. LEE CM, Yoon EL, Kim M, Kang BK, et al
    Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
    Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000664.
    >> Share

  236. BRAILLON A, Naudet F
    Letter to the Editor: Medications promoting abstinence in alcohol-associated cirrhosis.
    Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000656.
    >> Share

    October 2023
  237. JENG WJ, Chien RN, Liaw YF
    Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
    >> Share

  238. DENG R, Wang Z, Liu Y, Sun J, et al
    Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
    >> Share

  239. GRATACOS-GINES J, Lopez-Pelayo H, Pose E
    Reply: Medications promoting abstinence in alcohol-associated cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000660.
    >> Share

  240. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
    Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
    Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
    >> Share

  241. SONG Y, Ye T, Roberts LR, Larson NB, et al
    Randomization in hepatology: A review of principles, opportunities, and challenges.
    Hepatology. 2023 Oct 24. doi: 10.1097/HEP.0000000000000649.
    >> Share

  242. KAPLAN DE, Bosch J, Ripoll C, Thiele M, et al
    AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000647.
    >> Share

  243. YANG T, Qu X, Wang X, Xu D, et al
    Macrophage STING-YAP axis controls hepatic steatosis by promoting autophagic degradation of lipid droplets.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000638.
    >> Share

  244. CHANG CW, Chen YS, Huang CH, Lin CH, et al
    A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000637.
    >> Share

  245. OLIVA-VILARNAU N, Beusch CM, Sabatier P, Sakaraki E, et al
    Wnt/beta-catenin and NFkappaB signaling synergize to trigger growth-factor-free regeneration of adult primary human hepatocytes.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000648.
    >> Share

  246. CAMPANI C, Vallot A, Ghannouchi H, Allaire M, et al
    Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000636.
    >> Share

  247. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
    Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
    >> Share

  248. DONGELMANS EJ, Sonneveld MJ, Janssen HLA
    Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
    Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
    >> Share

  249. LIAW YF, Jeng WJ, Chien RN
    Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
    Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
    >> Share


  250. Erratum: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
    Hepatology. 2023 Oct 16. doi: 10.1097/HEP.0000000000000621.
    >> Share

  251. VONADA A, Wakefield L, Martinez M, Harding CO, et al
    Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation.
    Hepatology. 2023 Oct 12. doi: 10.1097/HEP.0000000000000631.
    >> Share

  252. CHEN P, Dong Z, Zhu W, Chen J, et al
    Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma.
    Hepatology. 2023 Oct 11. doi: 10.1097/HEP.0000000000000623.
    >> Share

  253. MA S, Chew V
    Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
    Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000626.
    >> Share

  254. THIELE M, Johansen S, Israelsen M, Trebicka J, et al
    Non-invasive assessment of hepatic decompensation.
    Hepatology. 2023 Oct 6. doi: 10.1097/HEP.0000000000000618.
    >> Share

  255. PENNISI G, Enea M, Romero-Gomez M, Bugianesi E, et al
    Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
    Hepatology. 2023 Oct 2. doi: 10.1097/HEP.0000000000000616.
    >> Share

  256. XANTHAKOS S
    Rising tide of NAFLD in youth: A warning bell and call to action.
    Hepatology. 2023;78:1017-1019.
    >> Share

  257. ANTON A, Shalaby S, Hernandez-Gea V
    Coagulation meets senescence in NASH!
    Hepatology. 2023;78:1023-1025.
    >> Share

  258. YONEDA M, Nakajima A
    The role of MRI technology in liver evaluation for NAFLD patients: Advancements and opportunities.
    Hepatology. 2023;78:1020-1022.
    >> Share

  259. CHEN W, Sun Y, Chen S, Ge X, et al
    Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.
    Hepatology. 2023;78:1118-1132.
    >> Share

  260. LI J, Lu X, Zhu Z, Kalutkiewicz KJ, et al
    Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
    Hepatology. 2023;78:1200-1208.
    >> Share

  261. KIM ??? WR, Iwakiri ???? Y, Lok ??? ASF
    What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west.
    Hepatology. 2023;78:1032-1034.
    >> Share

  262. MINCIUNA I, Gallage S, Heikenwalder M, Zelber-Sagi S, et al
    Intermittent fasting-the future treatment in NASH patients?
    Hepatology. 2023;78:1290-1305.
    >> Share

  263. CALZADILLA-BERTOT L, Jeffrey GP, Wang Z, Huang Y, et al
    Predicting liver-related events in NAFLD: A predictive model.
    Hepatology. 2023;78:1240-1251.
    >> Share

  264. SEIMIYA T, Otsuka M, Fujishiro M
    Overcoming T-cell exhaustion: New therapeutic targets in HCC immunotherapy.
    Hepatology. 2023;78:1009-1011.
    >> Share


  265. Erratum: Down-Regulation of the Cyclin-Dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
    Hepatology. 2023;78:E85.
    >> Share

  266. STRAVITZ RT, Fontana RJ, Karvellas C, Durkalski V, et al
    Future directions in acute liver failure.
    Hepatology. 2023;78:1266-1289.
    >> Share

  267. HARTMANN P, Zhang X, Loomba R, Schnabl B, et al
    Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019.
    Hepatology. 2023;78:1168-1181.
    >> Share

  268. KOTULKAR M, Paine-Cabrera D, Abernathy S, Robarts DR, et al
    Role of HNF4alpha-cMyc interaction in liver regeneration and recovery after acetaminophen-induced acute liver injury.
    Hepatology. 2023;78:1106-1117.
    >> Share

  269. DE ANGELIS RIGOTTI F, Wiedmann L, Hubert MO, Vacca M, et al
    Semaphorin 3C exacerbates liver fibrosis.
    Hepatology. 2023;78:1092-1105.
    >> Share

    September 2023
  270. NAHON P, Layese R, Ganne-Carrie N, Moins C, et al
    The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis.
    Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615.
    >> Share

  271. LI M, Wang L, Cong L, Wong CC, et al
    Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000591.
    >> Share

  272. RINELLA ME, Lieu HD, Kowdley KV, Goodman ZD, et al
    A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.
    Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000607.
    >> Share

  273. ZHAO X, Kotha S, Nayyar D, Ma X, et al
    Physiologic changes in the hepatopulmonary syndrome before and after liver transplant: A longitudinal and predictor analysis.
    Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000605.
    >> Share

  274. FAILLI M, Demir S, Del Rio-Alvarez A, Carrillo-Reixach J, et al
    Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response.
    Hepatology. 2023 Sep 20. doi: 10.1097/HEP.0000000000000601.
    >> Share

  275. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
    Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
    >> Share

  276. WATT KD, Paul S, Khan MQ, Siddiqui M, et al
    Obesity management for the hepatologist - what to do, how to do it and why.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000598.
    >> Share

  277. CHEN S, Liao C, Hu H, Liao J, et al
    Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous hepatocellular carcinoma.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000599.
    >> Share

  278. MAESTRI E, Kedei N, Khatib S, Forgues M, et al
    Spatial proximity of Tumor-Immune interactions predicts patient outcome in hepatocellular carcinoma.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000600.
    >> Share

  279. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
    Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
    >> Share


  280. December 2023 Hepatology Highlights.
    Hepatology. 2023 Sep 14. doi: 10.1097/HEP.0000000000000594.
    >> Share

  281. LAZARUS JV, Han H, Mark HE, Alqahtani SA, et al
    The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories.
    Hepatology. 2023;78:911-928.
    >> Share

  282. AWAN MZUA, Patel T
    Letter to the Editor: Dynamic risk profiling of HCC recurrence after curative intent liver resection.
    Hepatology. 2023;78:E55.
    >> Share

  283. HUANG CH, Hsieh SY
    More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC.
    Hepatology. 2023;78:706-708.
    >> Share

  284. YOU M, Gao Y, Fu J, Xie R, et al
    Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC.
    Hepatology. 2023;78:943-958.
    >> Share

  285. LLORENTE C, Rungratanawanich W, Liangpunsakul S
    Intestinal dendritic cells, gatekeepers preventing ethanol-induced liver disease.
    Hepatology. 2023;78:697-701.
    >> Share

  286. UCHIDA T, Imamura M, Hayes CN, Suehiro Y, et al
    HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice.
    Hepatology. 2023;78:929-942.
    >> Share

  287. GOIKOETXEA-USANDIZAGA N, Bravo M, Egia-Mendikute L, Abecia L, et al
    The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent.
    Hepatology. 2023;78:878-895.
    >> Share

  288. WONG C, Dash A, Fredrickson J, Lewin-Koh N, et al
    Fibroblast growth factor receptor 1/Klothobeta agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial.
    Hepatology. 2023;78:847-862.
    >> Share

  289. LAM KH, Ma S
    Noncellular components in the liver cancer stem cell niche: Biology and potential clinical implications.
    Hepatology. 2023;78:991-1005.
    >> Share

  290. WU T, Chen X, Xu K, Dai C, et al
    LIM domain only 7 negatively controls non-alcoholic steatohepatitis in the setting of hyperlipidaemia.
    Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000585.
    >> Share

    August 2023
  291. SHIMADA S, Tanaka S
    The chronicles of hepatocellular carcinoma classification: Subtyping, modeling and treatment.
    Hepatology. 2023 Aug 30. doi: 10.1097/HEP.0000000000000588.
    >> Share

  292. GRATACOS-GINES J, Bruguera P, Perez-Guasch M, Lopez-Lazcano A, et al
    Medications for alcohol use disorder promote abstinence in alcohol-related cirrhosis: results from a systematic review and meta-analysis.
    Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000570.
    >> Share

  293. JENG WJ, Chien RN, Chen YC, Lin CL, et al
    Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis.
    Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000575.
    >> Share

  294. CHIN A, Bastaich DR, Dahman B, Kaplan DE, et al
    Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites.
    Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000577.
    >> Share

  295. GE J, Fontil V, Ackerman S, Pletcher MJ, et al
    Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis.
    Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000583.
    >> Share

  296. PEISELER M, Tacke F
    Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
    Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
    >> Share


  297. November hepatology highlights.
    Hepatology. 2023 Aug 21. doi: 10.1097/HEP.0000000000000565.
    >> Share

  298. KOWALIK MA, Taguchi K, Serra M, Caddeo A, et al
    Metabolic reprogramming in Nrf2-driven proliferation of normal rat hepatocytes.
    Hepatology. 2023 Aug 21. doi: 10.1097/HEP.0000000000000568.
    >> Share

  299. LV Y, Bai W, Zhu X, Xue H, et al
    Development and validation of a prognostic score to identify the optimal candidate for preemptive TIPS in patients with cirrhosis and acute variceal bleeding.
    Hepatology. 2023 Aug 18. doi: 10.1097/HEP.0000000000000548.
    >> Share

  300. TREBICKA J, Garcia-Tsao G
    Controversies regarding albumin therapy in cirrhosis.
    Hepatology. 2023 Aug 7. doi: 10.1097/HEP.0000000000000521.
    >> Share

  301. LI B, Li Y, Zhou H, Xu Y, et al
    Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.
    Hepatology. 2023 Aug 7. doi: 10.1097/HEP.0000000000000553.
    >> Share

  302. BOWLUS CL, Levy C
    Optimizing treatment of primary biliary cholangitis: Is good, good enough?
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
    >> Share

  303. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
    Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
    >> Share

  304. HU Y, Li Z, He W, Wang X, et al
    Letter to the Editor: Is there survival bias? The etiologic analysis for the negative association between fatty liver and mortality in the elderly populations.
    Hepatology. 2023;78:E29-E30.
    >> Share

  305. VAN KLEEF LA, Sonneveld MJ, de Knegt RJ
    Reply: Is there survival bias? The etiologic analysis for the negative association between fatty liver and mortality in the elderly populations.
    Hepatology. 2023;78:E31-E32.
    >> Share

  306. RONOT M, Nahon P, Rimola J
    Screening of liver cancer with abbreviated MRI.
    Hepatology. 2023;78:670-686.
    >> Share

  307. MCCONNELL MJ, Kostallari E, Ibrahim SH, Iwakiri Y, et al
    The evolving role of liver sinusoidal endothelial cells in liver health and disease.
    Hepatology. 2023;78:649-669.
    >> Share

  308. AN J, Oh JH, Oh B, Oh YJ, et al
    Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination-deficient hepatocellular carcinoma.
    Hepatology. 2023;78:452-467.
    >> Share

  309. GUO X, Tan S, Wang T, Sun R, et al
    NAD + salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity.
    Hepatology. 2023;78:468-485.
    >> Share


  310. August Hepatology Highlights.
    Hepatology. 2023;78:369-370.
    >> Share

    July 2023
  311. LI Y, Li B, Xiao X, Qian Q, et al
    Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
    Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549.
    >> Share

  312. SENZOLO M, Shalaby S, Grasso M, Vitale A, et al
    Role of non-neoplastic portal vein thrombosis in the natural history of patients with cirrhosis and first diagnosis of hepatocellular carcinoma.
    Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000538.
    >> Share

  313. EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al
    Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
    Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544.
    >> Share

  314. NOUREDDIN M, Truong E, Mayo R, Martinez-Arranz I, et al
    Serum identification of At-Risk MASH: The Metabolomics-Advanced steatohepatitis fibrosis score (MASEF).
    Hepatology. 2023 Jul 24. doi: 10.1097/HEP.0000000000000542.
    >> Share


  315. October Hepatology Highlights.
    Hepatology. 2023 Jul 24. doi: 10.1097/HEP.0000000000000543.
    >> Share

  316. MA X, Ding WX
    Reply: Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000541.
    >> Share

  317. HU X, Shen J, Wang T, Liu M, et al
    Letter to the Editor: Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitichondria and mitochondrial maladaptation.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000540.
    >> Share


  318. Retraction: Protein kinase a-dependent pSer675-beta-catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000486.
    >> Share

  319. GE J, Digitale JC, Pletcher MJ, Lai JC, et al
    Reply: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000536.
    >> Share

  320. XIANG X, Hao Y, Cheng C, Hu H, et al
    A TGF-beta-dominant chemo-resistant phenotype of hepatoblastoma associated with aflatoxin exposure in children.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000534.
    >> Share

  321. HU Y, Li Z, He W, Wang X, et al
    Letter to the Editor: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000533.
    >> Share

  322. NARASIMMAN M, Hernaez R, Cerda V, Lee M, et al
    Hepatocellular carcinoma surveillance may be associated with potential psychological harms of in patients with cirrhosis.
    Hepatology. 2023 Jul 4. doi: 10.1097/HEP.0000000000000528.
    >> Share

  323. IAVARONE M, Nault JC, Cabibbo G, Torres F, et al
    Indolent cancer and pattern of progression: Two missing parameters in trial design for hepatology.
    Hepatology. 2023 Jul 3. doi: 10.1097/HEP.0000000000000527.
    >> Share


  324. A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD.
    Hepatology. 2023;78:3-5.
    >> Share

  325. CHEEMA MRS
    Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2023;78:E18.
    >> Share

  326. LEE J, Westphal M, Vali Y, Boursier J, et al
    Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.
    Hepatology. 2023;78:258-271.
    >> Share

  327. WEGERMANN K, Diehl AM
    Population-based proteomics: Platforms to advance diagnosis and treatment of metabolic liver diseases.
    Hepatology. 2023;78:8-9.
    >> Share

  328. CHE Y, Chen G, Guo Q, Duan Y, et al
    Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis.
    Hepatology. 2023;78:88-102.
    >> Share

  329. IRFAN R, Kumar S
    Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
    Hepatology. 2023;78:E8.
    >> Share

  330. PENNISI G, Enea M, Falco V, Aithal GP, et al
    Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
    Hepatology. 2023;78:195-211.
    >> Share

  331. DO A, Lim JK
    Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI.
    Hepatology. 2023;78:6-7.
    >> Share

  332. NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
    Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study).
    Hepatology. 2023;78:272-283.
    >> Share

  333. ABOZAID YJ, Ayada I, van Kleef LA, Vallerga CL, et al
    Plasma proteomic signature of fatty liver disease: The Rotterdam Study.
    Hepatology. 2023;78:284-294.
    >> Share

  334. KONG M, Dong W, Kang A, Kuai Y, et al
    Regulatory role and translational potential of CCL11 in liver fibrosis.
    Hepatology. 2023;78:120-135.
    >> Share

  335. GUO C, Liu W, Liu Z, Cai J, et al
    Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury.
    Hepatology. 2023;78:45-57.
    >> Share

  336. ZHU H, Yang B
    Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism.
    Hepatology. 2023;78:E3.
    >> Share

  337. VERMA M, Brahmania M, Fortune BE, Asrani SK, et al
    Patient-centered care: Key elements applicable to chronic liver disease.
    Hepatology. 2023;78:307-318.
    >> Share


  338. July 2023 Hepatology Highlights.
    Hepatology. 2023;78:1-2.
    >> Share

    June 2023

  339. September Hepatology highlights.
    Hepatology. 2023 Jun 13. doi: 10.1097/HEP.0000000000000515.
    >> Share

  340. PINTER M, Reig M, Cabibbo G
    Analysis of individual patient data in patients with hepatocellular carcinoma treated with immunotherapy: A step forward for clinical trial design.
    Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000511.
    >> Share

  341. DHANASEKARAN R, Suzuki H, Lemaitre L, Kubota N, et al
    Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision making.
    Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000513.
    >> Share

  342. TAPPER EB, Lai JC
    Time to embrace PROMIS-29 as the standard health-related quality of life instrument for patients with cirrhosis.
    Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000508.
    >> Share

  343. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
    Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
    Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
    >> Share

  344. YIM SY, Lee JS
    Reply: Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
    Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000501.
    >> Share

  345. HENRY L, Younossi ZM
    Reply: NAFLD/MAFLD: One size does not fit all, certainly not for children!
    Hepatology. 2023;77:E191.
    >> Share

  346. HEGARTY R, Dhawan A
    Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!
    Hepatology. 2023;77:E190.
    >> Share

  347. SARKAR M, Flemming JA
    Letter to the Editor: Influence of maternal NAFLD on infant weight-the real precursor to NAFLD in offspring?
    Hepatology. 2023;77:E180.
    >> Share

  348. LEE JM, Joo I
    The international quest for the imaging diagnosis of liver cancer.
    Hepatology. 2023;77:1839-1842.
    >> Share

  349. CANNELLA R, Dioguardi Burgio M, Sartoris R, Gregory J, et al
    Adherence to LI-RADS and EASL high-risk population criteria: A systematic review.
    Hepatology. 2023;77:1958-1967.
    >> Share

  350. BOMMENA S, Mahmud N, Boike JR, Thornburg BG, et al
    The impact of right atrial pressure on outcomes in patients undergoing TIPS, an ALTA group study.
    Hepatology. 2023;77:2041-2051.
    >> Share

  351. HSU CL, Lang S, Demir M, Fouts DE, et al
    Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome.
    Hepatology. 2023;77:2073-2083.
    >> Share

  352. NAGALO BM, Zhou Y, Loeuillard EJ, Dumbauld C, et al
    Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers.
    Hepatology. 2023;77:1943-1957.
    >> Share

  353. LIM M, Muquith M, Miramontes B, Lee CJ, et al
    Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.
    Hepatology. 2023 Jun 1. doi: 10.1097/HEP.0000000000000494.
    >> Share

    May 2023
  354. AWAN MZUA
    Letter to the editor: Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000493.
    >> Share

  355. JESUDIAN AB, Fortune BE
    The PROs and cons of crystalline lactulose for suspected covert hepatic encephalopathy among patients with cirrhosis and activity impairment: Are we using the right assessments?
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000497.
    >> Share

  356. NEJAK-BOWEN K, Monga SP
    Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
    >> Share


  357. Erratum: Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
    Hepatology. 2023 May 26. doi: 10.1097/HEP.0000000000000450.
    >> Share

  358. CARR RM, Li Y, Chau L, Friedman ES, et al
    An integrated analysis of fecal microbiome and metabolomic features distinguish Non-cirrhotic NASH from healthy control populations.
    Hepatology. 2023 May 25. doi: 10.1097/HEP.0000000000000474.
    >> Share

  359. GILGENKRANTZ H, Paradis V, Lotersztajn S
    Cell metabolism-based therapy for liver fibrosis, repair and hepatocellular carcinoma.
    Hepatology. 2023 May 23. doi: 10.1097/HEP.0000000000000479.
    >> Share

  360. LV Y, Han G
    Reply: Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
    Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000475.
    >> Share

  361. YIN HJ, Wan YM
    Letter to the editor: Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
    Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000476.
    >> Share

  362. KIM BK, Bergstrom J, Loomba R, Tamaki N, et al
    Magnetic resonance Elastography-Based prediction model for hepatic decompensation in NAFLD; a Multi-Center cohort study.
    Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000470.
    >> Share


  363. August Hepatology Highlights.
    Hepatology. 2023 May 19. doi: 10.1097/HEP.0000000000000468.
    >> Share

  364. SINGAL AG, Llovet JM, Yarchoan M, Mehta N, et al
    AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
    Hepatology. 2023 May 19. doi: 10.1097/HEP.0000000000000466.
    >> Share

  365. TONON M, Balcar L, Semmler G, Calvino V, et al
    Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event.
    Hepatology. 2023 May 17. doi: 10.1097/HEP.0000000000000460.
    >> Share

  366. VITTAL A, Niewisch MR, Bhala S, Kudaravalli P, et al
    Progression of liver disease and portal hypertension in dyskeratosis congenita and related telomere biology disorders.
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000461.
    >> Share

  367. HUANG DQ, Tran A, Yeh ML, Yasuda S, et al
    Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase.
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000459.
    >> Share

  368. MALLET M, Silaghi CA, Sultanik P, Conti F, et al
    Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis.
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000456.
    >> Share

  369. JI J, Ji F, Bayarsaikhan E
    Intratumoral microbiota in hepatocellular carcinoma: A new kid on the block?
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000454.
    >> Share

  370. ANDRISANI O
    Two important players in poor prognosis hepatocellular carcinoma (HCC): Extrachromosomal circular DNA (eccDNA) and its passenger, the oncogenic miR-17~92 locus.
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000453.
    >> Share

  371. MEHTA N, Kelley RK, Yao FY
    Refining the approach to down-staging for hepatocellular carcinoma prior to liver transplantation: Patient selection, local-regional treatments, and systemic therapies.
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000452.
    >> Share


  372. Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.
    >> Share

  373. KANZAKI H, Katz C, Hoshida Y
    Matrisomic characterization of hepatocellular carcinoma to inform individualized patient management.
    Hepatology. 2023 May 11. doi: 10.1097/HEP.0000000000000443.
    >> Share

  374. ANSTEE QM, Lucas KJ, Francque S, Abdelmalek MF, et al
    Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study.
    Hepatology. 2023 May 11. doi: 10.1097/HEP.0000000000000439.
    >> Share

  375. LI G, Chen H, Shen F, Smithson SB, et al
    Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis.
    Hepatology. 2023 May 3. doi: 10.1097/HEP.0000000000000433.
    >> Share

  376. SANGHA K, Chang ST, Cheung R, Deshpande VS, et al
    Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
    Hepatology. 2023;77:1702-1711.
    >> Share

  377. EBRAHIMI F, Ludvigsson JF
    Letter to the editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
    Hepatology. 2023;77:E107-E108.
    >> Share

  378. RINELLA ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, et al
    AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
    Hepatology. 2023;77:1797-1835.
    >> Share

  379. KNIGHT GM, Thornburg B, Salem R
    Reply: Discussing the place of TIPS in non-cirrhotic patients with chronic extra hepatic portal vein occlusion refractory to standard of care therapy.
    Hepatology. 2023;77:E93-E94.
    >> Share

  380. GU W, Queck A, Trebicka J, Praktiknjo M, et al
    Reply: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
    Hepatology. 2023;77:E101.
    >> Share

  381. ARTRU F, Rautou PE, Denys A
    Letter to the editor: discussing the place of TIPS in noncirrhotic patients with chronic extrahepatic portal vein occlusion (EHPVO).
    Hepatology. 2023;77:E91-E92.
    >> Share

  382. BERARDI G, Ratti F, Sposito C, Nebbia M, et al
    Model to predict major complications following liver resection for HCC in patients with metabolic syndrome.
    Hepatology. 2023;77:1527-1539.
    >> Share

  383. CUCCHETTI A, Casadei-Gardini A
    Liver resection for HCC in patients with metabolic syndrome: questions answered, questions raised.
    Hepatology. 2023;77:1463-1464.
    >> Share

  384. WEN Y, Emontzpohl C, Xu L, Atkins CL, et al
    Interleukin-33 facilitates liver regeneration through serotonin-involved gut-liver axis.
    Hepatology. 2023;77:1580-1592.
    >> Share

  385. ZHANG S, Wan D, Zhu M, Wang G, et al
    CD11b + CD43 hi Ly6C lo splenocyte-derived macrophages exacerbate liver fibrosis via spleen-liver axis.
    Hepatology. 2023;77:1612-1629.
    >> Share

  386. LUO W, Wang Y, Li Y, Zhang T, et al
    Letter to the editor: Adipose lipolysis is important for ethanol to induce fatty liver in the NIAAA murine model of chronic and binge ethanol feeding.
    Hepatology. 2023;77:E88-E89.
    >> Share

  387. ZABRANSKY DJ, Danilova L, Leatherman JM, Lopez-Vidal TY, et al
    Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments.
    Hepatology. 2023;77:1566-1579.
    >> Share

  388. JUAREZ-FERNANDEZ M, Goikoetxea-Usandizaga N, Porras D, Garcia-Mediavilla MV, et al
    Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression.
    Hepatology. 2023;77:1654-1669.
    >> Share

  389. MATHUR M, Yeh YT, Arya RK, Jiang L, et al
    Adipose lipolysis is important for ethanol to induce fatty liver in the National Institute on Alcohol Abuse and Alcoholism murine model of chronic and binge ethanol feeding.
    Hepatology. 2023;77:1688-1701.
    >> Share

  390. LI S, Xia H, Wang Z, Zhang X, et al
    Intratumoural microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related hepatocellular carcinoma.
    Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000427.
    >> Share

  391. ZOU S, Chen S, Rao G, Zhang G, et al
    Extrachromosomal circular MiR-17-92 amplicon promotes hepatocellular carcinoma.
    Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000435.
    >> Share

  392. AHMED A, Arshad MW, Ibrahim H
    Letter to the editor: Variability in serum creatinine is associated with waitlist and post-liver transplant mortality in patients with cirrhosis.
    Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000429.
    >> Share

  393. CULLARO G
    Reply: Variability in serum creatinine is associated with waitlist and post-liver transplant mortality in patients with cirrhosis.
    Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000434.
    >> Share


  394. May 2023 Hepatology Highlights.
    Hepatology. 2023;77:1461-1462.
    >> Share

    April 2023
  395. KUM DB, Vanrusselt H, Acosta Sanchez A, Taverniti V, et al
    Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
    Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000428.
    >> Share


  396. July 2023 Hepatology Highlights.
    Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000425.
    >> Share

  397. ADAMS LA, Schulte PJ, Allen AM
    Use of non-invasive scores to predict hepatic steatosis: Flaws and caveats.
    Hepatology. 2023 Apr 27. doi: 10.1097/HEP.0000000000000419.
    >> Share

  398. HUNG MH, Chang CW, Wang KC, Chaisaingmongkol J, et al
    Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma via m6A-mediated epitranscriptomic regulation.
    Hepatology. 2023 Apr 26. doi: 10.1097/HEP.0000000000000420.
    >> Share

  399. UFERE NN
    Home is where the liver is?: moving beyond readmissions to time at home as a patient-centered and pragmatic quality measure in cirrhosis care.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000415.
    >> Share

  400. MALHI H, Shah V, Gores GJ
    Thematic reviews: the future of hepatology.
    Hepatology. 2023 Apr 19. doi: 10.1097/HEP.0000000000000409.
    >> Share

  401. TAPPER EB, Ospina E, Salim N, Chen X, et al
    Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient reported outcomes - the Mi-Kristal RCT.
    Hepatology. 2023 Apr 18. doi: 10.1097/HEP.0000000000000408.
    >> Share

  402. DANIEL N, Genua F, Jenab M, Mayen AL, et al
    The role of the gut microbiome in the development of hepatobiliary cancers.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
    >> Share

  403. MAESO-DIAZ R, Du K, Pan C, Guy CD, et al
    Targeting senescent hepatocytes using the THBD-PAR1 inhibitor Vorapaxar ameliorates NAFLD progression.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000401.
    >> Share

  404. JILG N, Baumert TF
    Unfolding the mechanism of hepatocyte injury of HBV precore and core promoter variants.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000400.
    >> Share

  405. HARTL L, Reiberger T, Trauner M
    Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.
    >> Share

  406. UMAR S, Nadeem A, Nadeem M
    Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.
    >> Share

  407. RAABE J, Kaiser KM, ToVinh M, Finnemann C, et al
    Identification and characterisation of a hepatic IL-13 producing ILC3-like population potentially involved in liver fibrosis.
    Hepatology. 2023 Apr 10. doi: 10.1097/HEP.0000000000000350.
    >> Share

  408. HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
    Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
    Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
    >> Share

  409. FRIEDMAN SL, Sanyal AJ
    The future of hepatology.
    Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000389.
    >> Share

  410. ARUMUGAM S, Li B, Boodapati SLT, Nathanson MH, et al
    Mitochondrial DNA and the STING pathway are required for hepatic stellate cell activation.
    Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000388.
    >> Share

  411. TANG D, Kroemer G, Kang R
    Ferroptosis in hepatocellular carcinoma: from bench to bedside.
    Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000390.
    >> Share


  412. June 2023 Hepatology Highlights.
    Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000391.
    >> Share

  413. TIAN Y, Jellinek MJ, Mehta K, Seok SM, et al
    Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000375.
    >> Share

  414. DESERT R, Chen W, Ge X, Viel R, et al
    Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000362.
    >> Share

  415. VILAR-GOMEZ E, Vuppalanchi R, Gawrieh S, Samala N, et al
    CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population.
    Hepatology. 2023;77:1241-1252.
    >> Share

  416. GUERRIERI F, Levrero M
    HBV, mitochondrial stress, and liver fibrosis: chicken or the egg.
    Hepatology. 2023;77:1088-1089.
    >> Share

  417. LIU Z, Tan M, Ding H
    Letter to the Editor: Contrast-enhanced CT and liver surface nodularity for the diagnosis of portosinusoidal vascular disorder: a case-control study.
    Hepatology. 2023;77:E71.
    >> Share

  418. SINGH SP, Mondia N
    Letter to the Editor: Much more needed in natural history of Alagille syndrome.
    Hepatology. 2023;77:E78.
    >> Share

  419. SCHILSKY ML, Roberts EA, Bronstein JM, Dhawan A, et al
    A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.
    Hepatology. 2023;77:1428-1455.
    >> Share

  420. YIP TC, Vilar-Gomez E, Petta S, Yilmaz Y, et al
    Geographical similarity and differences in the burden and genetic predisposition of NAFLD.
    Hepatology. 2023;77:1404-1427.
    >> Share

  421. LI HX, Xie ZQ, Yang ZM, Tang CX, et al
    Letter to the Editor: Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality.
    Hepatology. 2023;77:E67-E68.
    >> Share

  422. AFONSO MB, Islam T, Magusto J, Amorim R, et al
    RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease.
    Hepatology. 2023;77:1319-1334.
    >> Share

  423. TORRES S, Ortiz C, Bachtler N, Gu W, et al
    Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.
    Hepatology. 2023;77:1228-1240.
    >> Share

  424. KARDASHIAN A, Serper M, Terrault N, Nephew LD, et al
    Health disparities in chronic liver disease.
    Hepatology. 2023;77:1382-1403.
    >> Share

  425. LOPEZ-VICARIO C, Sebastian D, Casulleras M, Duran-Guell M, et al
    Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease.
    Hepatology. 2023;77:1303-1318.
    >> Share

  426. YANG F, Jiang S, Zheng Y
    Letter to the Editor: Is eliminating METTL1-mediated accumulation of PMN-MDSCs sufficient to prevent hepatocellular carcinoma recurrence after radiofrequency ablation?
    Hepatology. 2023;77:E62-E63.
    >> Share

  427. DEPRINCE A, Hennuyer N, Kooijman S, Pronk ACM, et al
    Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism.
    Hepatology. 2023;77:1287-1302.
    >> Share

  428. JIANG M, Li F, Liu Y, Gu Z, et al
    Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation.
    Hepatology. 2023;77:1164-1180.
    >> Share

  429. ZENG X, Liao G, Li S, Liu H, et al
    Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation.
    Hepatology. 2023;77:1122-1138.
    >> Share

  430. ZHOU Y, Jia K, Wang S, Li Z, et al
    Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7-acetylated and cytoplasm-translocated G protein GalphaS.
    Hepatology. 2023;77:1106-1121.
    >> Share

    March 2023
  431. ELHENCE H, Dodge JL, Farias AJ, Lee BP, et al
    Quantifying days at home in patients with cirrhosis: a national cohort study.
    Hepatology. 2023 Mar 31. doi: 10.1097/HEP.0000000000000370.
    >> Share

  432. TRIPATHI D, Reiberger T
    Letter to the editor: portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management.
    Hepatology. 2023 Mar 30. doi: 10.1097/HEP.0000000000000359.
    >> Share

  433. KWONG AJ, Zhang KY, Ebel N, Mannalithara A, et al
    MELD 3.0 for adolescent liver transplant candidates.
    Hepatology. 2023 Mar 22. doi: 10.1097/HEP.0000000000000352.
    >> Share

  434. ELIAS G, Schonfeld M, Saleh S, Parrish M, et al
    Sepsis induced endothelial dysfunction drives acute-on-chronic liver failure via Angiopoietin-2-HGF-C/EBPbeta pathway.
    Hepatology. 2023 Mar 22. doi: 10.1097/HEP.0000000000000354.
    >> Share

  435. HONG T, Xiong X, Chen Y, Wang Q, et al
    Parathyroid hormone receptor-1 signaling aggravates hepatic fibrosis through upregulating cAMP response element binding protein-like 2.
    Hepatology. 2023 Mar 21. doi: 10.1097/HEP.0000000000000333.
    >> Share

  436. MAK LY, Yuen MF, Seto WK
    Reply: hepatic steatosis and glycemic burden in chronic hepatitis b.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000374.
    >> Share

  437. HUANG SC, Kao JH
    Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000371.
    >> Share

  438. AHMED HS, Long MT
    Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000378.
    >> Share

  439. LI Z, Zhang L, Li J
    Letter to the Editor: the associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000377.
    >> Share

  440. ZHANG W, Wang MK, Yao D, Zhao HJ, et al
    Letter to the editor: hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000372.
    >> Share

  441. ROWE IA, Villanueva C, Shearer JE, Torres F, et al
    Quantifying the benefit of non-selective beta-blockers in the prevention of hepatic decompensation: a Bayesian re-analysis of the PREDESCI trial.
    Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000342.
    >> Share

  442. ALLAIRE M, Thabut D
    Reply: portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management.
    Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000358.
    >> Share


  443. May 2023 Hepatology Highlights.
    Hepatology. 2023 Mar 8. doi: 10.1097/HEP.0000000000000355.
    >> Share

  444. SMITH ML, Wade JB, Wolstenholme J, Bajaj JS, et al
    Gut microbiome-brain-cirrhosis axis.
    Hepatology. 2023 Mar 6. doi: 10.1097/HEP.0000000000000344.
    >> Share

  445. GE J, Digitale JC, Pletcher MJ, Lai JC, et al
    Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study.
    Hepatology. 2023;77:834-850.
    >> Share

  446. VAN KLEEF LA, de Knegt RJ
    Modifiable risk factors for fatty liver disease: Time to act.
    Hepatology. 2023;77:712-714.
    >> Share

  447. LUO W, Gu Y, Zhang T
    Letter to the editor: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage HCC.
    Hepatology. 2023;77:E51-E52.
    >> Share

  448. SUN Y, Zhang J, Wang H, Wang W, et al
    Letter to the editor: Fatty liver and mortality in populations who are elderly.
    Hepatology. 2023;77:E47-E48.
    >> Share

  449. TARLOW BD, Kim WR, Mannalithara A, Kwo PY, et al
    Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40.
    Hepatology. 2023;77:851-861.
    >> Share

  450. JIANG ST, Xu YY, Lu X
    Letter to the editor: Focus on metabolic dysfunction-associated fatty liver disease, even if patients have a history of excessive alcohol consumption.
    Hepatology. 2023;77:E43-E44.
    >> Share

  451. UDOMPAP P, Therneau TM, Canning RE, Benson JT, et al
    Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population.
    Hepatology. 2023;77:931-941.
    >> Share

  452. XIE J, Huang H, Liu Z, Li Y, et al
    The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study.
    Hepatology. 2023;77:949-964.
    >> Share

  453. FONTANA RJ, Liou I, Reuben A, Suzuki A, et al
    AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.
    Hepatology. 2023;77:1036-1065.
    >> Share

  454. NING C, Jiang ST, Sang XT
    Letter to the editor: Reflection on the no-association between the presence of fatty liver disease and mortality in the elderly.
    Hepatology. 2023;77:E39-E40.
    >> Share

  455. CANIVET CM, Costentin C, Irvine KM, Delamarre A, et al
    Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
    Hepatology. 2023;77:920-930.
    >> Share

  456. VAN KLEEF LA, de Knegt RJ, Brouwer WP
    Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality.
    Hepatology. 2023;77:942-948.
    >> Share

  457. LI S, Zhou B, Xue M, Zhu J, et al
    Macrophage-specific FGF12 promotes liver fibrosis progression in mice.
    Hepatology. 2023;77:816-833.
    >> Share

  458. CRESPO M, Nikolic I, Mora A, Rodriguez E, et al
    Myeloid p38 activation maintains macrophage-liver crosstalk and BAT thermogenesis through IL-12-FGF21 axis.
    Hepatology. 2023;77:874-887.
    >> Share

  459. CHAN CY, Yuen VW, Chiu DK, Goh CC, et al
    Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.
    Hepatology. 2023;77:729-744.
    >> Share

    February 2023
  460. ZANETTO A, Campello E, Senzolo M, Simioni P, et al
    The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review.
    Hepatology. 2023 Feb 27. doi: 10.1097/HEP.0000000000000349.
    >> Share

  461. TAPPER EB, Serper M, Goldberg D
    Implementing pragmatic clinical trials in hepatology.
    Hepatology. 2023 Feb 27. doi: 10.1097/HEP.0000000000000345.
    >> Share

  462. DU K, Maeso-Diaz R, Oh SH, Wang E, et al
    Targeting YAP-mediated hepatic stellate cell death susceptibility and senescence for treatment of liver fibrosis.
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000326.
    >> Share

  463. LI J, Chen J, Lee PMY, Zhang J, et al
    Familial clustering of intrahepatic cholestasis of pregnancy: A nationwide population-based study in Denmark.
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000328.
    >> Share

  464. NICOARA-FARCAU O, Lozano JJ, Alonso C, Sidorova J, et al
    Metabolomics as a tool to predict the risk of decompensation or liver related death in patients with compensated cirrhosis.
    Hepatology. 2023 Feb 23. doi: 10.1097/HEP.0000000000000316.
    >> Share

  465. GAWRIEH S, Lake JE, Debroy P, Sjoquist JA, et al
    Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study.
    Hepatology. 2023 Feb 22. doi: 10.1097/HEP.0000000000000313.
    >> Share

  466. CHENG L, Deepak RNVK, Wang G, Meng Z, et al
    Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKalpha mediating lipid metabolism and tumorigenesis.
    Hepatology. 2023 Feb 21. doi: 10.1097/HEP.0000000000000314.
    >> Share


  467. Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis: Erratum.
    Hepatology. 2023 Feb 21. doi: 10.1097/HEP.0000000000000348.
    >> Share

  468. ZHANG J, Lyu Z, Li B, You Z, et al
    P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000317.
    >> Share

  469. WU N, Zhou T, Carpino G, Baiocchi L, et al
    Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2-/- mice.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310.
    >> Share

  470. KUNDU D, Kennedy L, Zhou T, Ekser B, et al
    p16 INK4A drives non-alcoholic fatty liver disease phenotypes in high fat diet fed mice via biliary e2f1/foxo1/igf-1 signaling.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000307.
    >> Share

  471. AMENT CE, Steinmann S, Evert K, Pes GM, et al
    Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma.
    Hepatology. 2023 Feb 16. doi: 10.1097/HEP.0000000000000322.
    >> Share

  472. HU Y, Li Z, Jiang Y, Wang X, et al
    Letter to the Editor: More efforts for the meta-analysis of the association between hepatic steatosis and HBV-related HCC.
    Hepatology. 2023 Feb 9. doi: 10.1097/HEP.0000000000000332.
    >> Share


  473. April 2023 Hepatology Highlights.
    Hepatology. 2023 Feb 7. doi: 10.1097/HEP.0000000000000325.
    >> Share

  474. SCHRADER JA, Burkard TL, Bruggemann Y, Gomer A, et al
    Epidermal growth factor receptor modulates hepatitis e virus entry in human hepatocytes -HEP-22-1113.
    Hepatology. 2023 Feb 7. doi: 10.1097/HEP.0000000000000308.
    >> Share

  475. ROWE IA, Allen AM
    Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease.
    Hepatology. 2023 Feb 6. doi: 10.1097/HEP.0000000000000327.
    >> Share

  476. PATOULIAS D
    Letter to the Editor: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes?
    Hepatology. 2023 Feb 3. doi: 10.1097/HEP.0000000000000311.
    >> Share

  477. PLAZ TORRES MC, Jaffe A, Perry R, Marabotto E, et al
    Reply: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes?
    Hepatology. 2023 Feb 3. doi: 10.1097/HEP.0000000000000312.
    >> Share


  478. February 2023 Hepatology Highlights.
    Hepatology. 2023;77:339-340.
    >> Share

  479. WANG M, Sarkar M, Mehta N
    Now you see it, now you don't: Estrogen exposure and obesity effects on HCA development and regression.
    Hepatology. 2023;77:341-343.
    >> Share

  480. LARRUE H, Bureau C
    Transjugular intrahepatic portosystemic shunt in portal hypertension: How to go further while staying on track?
    Hepatology. 2023;77:344-346.
    >> Share

  481. LI J, Nguyen MH
    Letter to the editor: Screening for fatty liver disease and fibrosis in the elderly population: A call for action.
    Hepatology. 2023;77:E28-E29.
    >> Share

  482. VANDRIEL SM, Li LT, She H, Wang JS, et al
    Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study.
    Hepatology. 2023;77:512-529.
    >> Share

  483. HABASH N, Ibrahim SH
    The Global Alagille Alliance study: Redefining the natural history of Alagille syndrome.
    Hepatology. 2023;77:347-349.
    >> Share

  484. SHAN J, Megarbane A, Chouchane A, Karthik D, et al
    Genetic predisposition to porto-sinusoidal vascular disorder: A functional genomic-based, multigenerational family study.
    Hepatology. 2023;77:501-511.
    >> Share

  485. HAGSTROM H, Shang Y
    Less is more? Screening for steatosis in older populations.
    Hepatology. 2023;77:350-351.
    >> Share

  486. LIN H, Yip TC, Zhang X, Li G, et al
    Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease.
    Hepatology. 2023;77:573-584.
    >> Share

  487. MONDIA N, Singh SP, Mishra AK
    Letter to the editor: Risk factors of NAFLD in preterm and low birthweight. More questions than answers!
    Hepatology. 2023;77:E17.
    >> Share

  488. VAN KLEEF LA, Sonneveld MJ, Kavousi M, Ikram MA, et al
    Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study.
    Hepatology. 2023;77:585-593.
    >> Share

  489. XU L, Yang Y, Jiang J, Wen Y, et al
    Eosinophils protect against acetaminophen-induced liver injury through cyclooxygenase-mediated IL-4/IL-13 production.
    Hepatology. 2023;77:456-465.
    >> Share

  490. INDIRA CHANDRAN V, Wernberg CW, Lauridsen MM, Skytthe MK, et al
    Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness.
    Hepatology. 2023;77:558-572.
    >> Share

  491. AJOOLABADY A, Kaplowitz N, Lebeaupin C, Kroemer G, et al
    Endoplasmic reticulum stress in liver diseases.
    Hepatology. 2023;77:619-639.
    >> Share

    January 2023
  492. ADEJUMO AC, Yakovchenko V, Morgan TR, Spoutz P, et al
    The road to pandemic recovery: Tracking COVID-19's impact on cirrhosis care and outcomes among 111,558 veterans.
    Hepatology. 2023 Jan 30. doi: 10.1097/HEP.0000000000000306.
    >> Share

  493. LUO J, Gong L, Yang Y, Zhang Y, et al
    Enhanced mitophagy driven by ADAR1-GLI1 editing supports the self-renewal of cancer stem cells in hepatocellular carcinoma.
    Hepatology. 2023 Jan 24. doi: 10.1097/HEP.0000000000000299.
    >> Share

  494. AHMED HS, Wang N, Carr JJ, Ding J, et al
    The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multi-cohort study.
    Hepatology. 2023 Jan 19. doi: 10.1097/HEP.0000000000000286.
    >> Share

  495. HUANG DQ, Tamaki N, Lee HW, Park SY, et al
    Outcome of untreated low-level viremia vs. antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000037.
    >> Share

  496. CUNNINGHAM M, Gupta R, Butler M
    Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000045.
    >> Share

  497. EL HAJRA I, Sanduzzi-Zamparelli M, Sapena V, Munoz-Martinez S, et al
    Outcome of patients with hepatocellular carcinoma and liver dysfunction under Immunotherapy: a systematic review and meta-analysis.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000030.
    >> Share


  498. March 2023 Hepatology Highlights.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000289.
    >> Share

  499. ALLAIRE M, Thabut D
    Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000291.
    >> Share

  500. LIU F, Liao Z, Qin L, Zhang Z, et al
    Targeting VPS72 inhibits ACTL6A/MYC axis activity in hepatocellular carcinoma progression.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000268.
    >> Share

  501. CASTERA L, Cusi K
    Diabetes and cirrhosis: Current concepts on diagnosis and management.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000263.
    >> Share

  502. YU H, Zhou L, Loong JH, Lam KH, et al
    SERPINA12 promotes the tumorigenic capacity of hepatocellular carcinoma stem cells through hyperactivation of AKT/ beta-catenin signaling.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000269.
    >> Share

  503. GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
    Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
    >> Share

  504. GONG L, Wei F, Gonzalez FJ, Li G, et al
    Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000182.
    >> Share

  505. BEHRENDT P, Gouttenoire J
    Editorial in Hepatology Urine: A place where HEV cannot hide!
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000017.
    >> Share

  506. HAO L, Zhong W, Woo J, Wei X, et al
    Conventional type 1 dendritic cells protect against gut barrier disruption via maintaining A. muciniphila in alcoholic steatohepatitis.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000019.
    >> Share

  507. YOUNOSSI Z, Golabi P, Paik J, Henry A, et al
    The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000004.
    >> Share

  508. LV Y, Han G
    Reply to HEP-22-1980 Embolization of large spontaneous shunt for the prevention of hepatic encephalopathy after TIPS: more questions than answers.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000010.
    >> Share

  509. SHORT C, Zhong A, Xu J, Mahdi E, et al
    TWEAK/FN14 promotes profibrogenic pathway activation in Prominin-1-expressing hepatic progenitor cells in biliary atresia.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000026.
    >> Share

  510. LO GH
    Is embolization of large spontaneous shunt effective in the prevention of hepatic encephalopathy after TIPS?
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000007.
    >> Share

  511. LEE SH, So J, Shin D
    Hepatocyte-to-cholangiocyte conversion occurs through transdifferentiation independently of proliferation in zebrafish.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000016.
    >> Share

  512. FU S, Liu M, Zhu C, Zhang H, et al
    Regulatory MAIT cells controlled by beta1 adrenergic receptor signaling contribute to hepatocellular carcinoma progression.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000014.
    >> Share

  513. WANG S, Wang R, Xu N, Wei X, et al
    SULT2B1-CS-DOCK2 axis regulates effector T cell exhaustion in hepatocellular carcinoma microenvironment.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000025.
    >> Share

  514. KODAMA T, Takehara T
    Is it a prime time for germline genetic testing for hepatocellular carcinoma?
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000033.
    >> Share

  515. BHALA N, Ferguson JW, Rajoriya N, Newsome PN, et al
    Using global burden of hepatocellular cancer and liver cirrhosis as a driver to tackle preventable mortality and morbidity nationally and regionally.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000011.
    >> Share

  516. WANG CC, Kao JH
    Letter to the Editor Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000009.
    >> Share

  517. CABIBBO G, Celsa C, Alimenti E, Iavarone M, et al
    Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced hepatocellular carcinoma: the dark side of the moon.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000205.
    >> Share

  518. ZHANG L, Pan Q, Zhang L, Xia H, et al
    Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK/STAT3 signaling.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000041.
    >> Share

  519. FENG Y, Peng B, Li Y, Sun L, et al
    Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000209.
    >> Share

  520. KHORASANI S, Boike J, Duarte-Rojo A
    Will noninvasive screening for fibrosis/steatosis open Pandora's box? Sharing the healthcare burden of state-of-the-art hepatology practice.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000235.
    >> Share

  521. MA F, Liu Y, Hu Z, Xue Y, et al
    Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000042.
    >> Share

  522. CHUNG HH
    Letter to the Editor: The pathological impact of PAR2 on hepatic insulin resistance.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000284.
    >> Share

  523. CHANG D, Truong E, Noureddin M
    Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: Accuracy and routine variables are the success keys.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000211.
    >> Share

  524. TANTAI X, Wang J, Dai S
    Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000271.
    >> Share

  525. DUAN S, Qin N, Pi J, Sun P, et al
    Antagonizing apolipoprotein J chaperone promotes proteasomal degradation of mTOR and relieves hepatic lipid deposition.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000185.
    >> Share

  526. SHARPTON SR, Loomba R
    Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000278.
    >> Share

  527. KARDASHIAN A, Kushner T, Au JS, Flemming JA, et al
    The key role of hepatology providers in optimizing reproductive care in patients with liver disease: a call to action.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000275.
    >> Share

  528. CAO J, Bai DS
    Letter to the editor: Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway.
    Hepatology. 2023;77:E11.
    >> Share

  529. SEMMLER G, Thorhauge KH, Reiberger T, Thiele M, et al
    Letter to the editor: Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD.
    Hepatology. 2023;77:E1-E2.
    >> Share

  530. WADHWANI SI, Lai JC
    The digital determinants of liver disease.
    Hepatology. 2023;77:13-14.
    >> Share

  531. LINDBLAD KE, Lujambio A
    Imaging for better responses to immunotherapy in hepatocellular carcinoma.
    Hepatology. 2023;77:6-9.
    >> Share

  532. HENSON JB, Wegermann K, Patel YA, Wilder JM, et al
    Access to technology to support telehealth in areas without specialty care for liver disease.
    Hepatology. 2023;77:176-185.
    >> Share

  533. GIDENER T, Dierkhising RA, Mara KC, Therneau TM, et al
    Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD.
    Hepatology. 2023;77:268-274.
    >> Share

  534. ZHANG L, Guo GL
    Gut-specific inhibition of PPARalpha as a novel approach of NAFLD treatment.
    Hepatology. 2023;77:15-17.
    >> Share

  535. GOYAL NP, Rosenthal SB, Nasamran C, Behling CA, et al
    Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in children.
    Hepatology. 2023;77:197-212.
    >> Share

  536. HAGSTROM H
    A new model for estimation of significant fibrosis in primary care. SAFE to use?
    Hepatology. 2023;77:18-19.
    >> Share

  537. SRIPONGPUN P, Kim WR, Mannalithara A, Charu V, et al
    The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care.
    Hepatology. 2023;77:256-267.
    >> Share

  538. REN Z, Simons PIHG, Wesselius A, Stehouwer CDA, et al
    Relationship between NAFLD and coronary artery disease: A Mendelian randomization study.
    Hepatology. 2023;77:230-238.
    >> Share

  539. KOMUTA M, Ueno A, Sakamoto M
    The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer.
    Hepatology. 2023;77:10-12.
    >> Share


  540. January 2023 Hepatology Highlights.
    Hepatology. 2023;77:1-2.
    >> Share


  541. January 2023 Hepatology Highlights.
    Hepatology. 2023;77:1-2.
    >> Share


  542. January 2023 Hepatology Highlights.
    Hepatology. 2023;77:1-2.
    >> Share

    December 2022
  543. ZHANG J, Xu Y, Lu X, Zhao H, et al
    Letter to the editor: NAFLD and sarcopenia: Association or causation?
    Hepatology. 2022;76:E119-E120.
    >> Share

  544. JIANG ST, Zhang L, Xu YY, Lu X, et al
    Letter to the editor: Complications following SARS-CoV-2 infection in patients with chronic liver disease.
    Hepatology. 2022;76:E116.
    >> Share

  545. XUN Z, Zhao H
    Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?
    Hepatology. 2022;76:E127-E128.
    >> Share

  546. SHEARER AM, Wang Y, Fletcher EK, Rana R, et al
    PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference.
    Hepatology. 2022;76:1778-1793.
    >> Share

  547. SINN DH, Kang D, Kang M, Guallar E, et al
    Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study.
    Hepatology. 2022;76:1746-1754.
    >> Share

  548. KIM Y, Chang Y, Ryu S, Wild SH, et al
    NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status.
    Hepatology. 2022;76:1755-1765.
    >> Share

  549. SHARMA D, Ben Yakov G, Kapuria D, Viana Rodriguez G, et al
    Tip of the iceberg: A comprehensive review of liver disease in Inborn errors of immunity.
    Hepatology. 2022;76:1845-1861.
    >> Share

  550. RATZIU V, Anstee QM, Wong VW, Schattenberg JM, et al
    An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project.
    Hepatology. 2022;76:1766-1777.
    >> Share

  551. HUANG M, Jiao J, Cai H, Zhang Y, et al
    C-C motif chemokine ligand 5 confines liver regeneration by down-regulating reparative macrophage-derived hepatocyte growth factor in a forkhead box O 3a-dependent manner.
    Hepatology. 2022;76:1706-1722.
    >> Share

  552. FENG R, Kan K, Sticht C, Li Y, et al
    A hierarchical regulatory network ensures stable albumin transcription under various pathophysiological conditions.
    Hepatology. 2022;76:1673-1689.
    >> Share

  553. HONG F, Lin CY, Yan J, Dong Y, et al
    Canopy Homolog 2 contributes to liver oncogenesis by promoting unfolded protein response-dependent destabilization of tumor protein P53.
    Hepatology. 2022;76:1587-1601.
    >> Share

  554. ASIF B, Ortiz V, Conboy CB, Diaz LA, et al
    Hepatology Highlights.
    Hepatology. 2022;76:1555-1556.
    >> Share

    November 2022
  555. CHUNG HH
    Letter to the editor: The perspective of GLP-1/GLP-2 receptors against NASH via diverse regulation.
    Hepatology. 2022;76:E106-E107.
    >> Share

  556. ATTIA D, Gomaa A, Abdel Alem S
    Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD.
    Hepatology. 2022;76:E100.
    >> Share

  557. VAN KLEEF LA, de Knegt RJ
    The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach?
    Hepatology. 2022;76:1243-1245.
    >> Share

  558. AMADOU C, Nabi O, Serfaty L, Lacombe K, et al
    Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
    Hepatology. 2022;76:1438-1451.
    >> Share

  559. SHANG Y, Nasr P, Widman L, Hagstrom H, et al
    Risk of cardiovascular disease and loss in life expectancy in NAFLD.
    Hepatology. 2022;76:1495-1505.
    >> Share

  560. OLIVEIRA CP
    Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression?
    Hepatology. 2022;76:1246-1247.
    >> Share

  561. YOUNOSSI ZM, Paik JM, Al Shabeeb R, Golabi P, et al
    Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
    Hepatology. 2022;76:1423-1437.
    >> Share

  562. RIMOLA J, Sapena V, Brancatelli G, Darnell A, et al
    Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria.
    Hepatology. 2022;76:1318-1328.
    >> Share

  563. VILAR-GOMEZ E, Pirola CJ, Sookoian S, Wilson LA, et al
    PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features.
    Hepatology. 2022;76:1482-1494.
    >> Share

  564. ZHANG X, Wong GL, Yip TC, Cheung JTK, et al
    Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
    Hepatology. 2022;76:1409-1422.
    >> Share

  565. LEI L, Bruneau A, El Mourabit H, Guegan J, et al
    Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis.
    Hepatology. 2022;76:1360-1375.
    >> Share

  566. TOMLINSON JL, Penrice DD, Ramkissoon R, Udompap P, et al
    Hepatology highlights.
    Hepatology. 2022;76:1231-1232.
    >> Share

  567. FOUAD Y, Abdel Dayem WA, Mehrez M
    Letter to the editor: Apples should be compared with apples.
    Hepatology. 2022;76:E101.
    >> Share

    October 2022

  568. Erratum for Jiang L, et al. calcium-binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating extracellular signal-regulated kinase signaling pathway.
    Hepatology. 2022 Oct 26. doi: 10.1002/hep.32796.
    >> Share

  569. LAM YK, Yu J, Huang H, Ding X, et al
    TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk.
    Hepatology. 2022 Oct 11. doi: 10.1002/hep.32802.
    >> Share

  570. RAHAL HK, Tabibian JH, Issaka RB, Quezada S, et al
    Diversity, equity, and inclusion in gastroenterology and hepatology: A survey of where we stand.
    Hepatology. 2022 Oct 11. doi: 10.1002/hep.32757.
    >> Share

  571. WU T, Povero D, Parthasarathy G, Idalsoaga F, et al
    Hepatology highlights.
    Hepatology. 2022;76:901-902.
    >> Share

  572. SUCHMAN K, Da BL
    Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC.
    Hepatology. 2022;76:E78-E79.
    >> Share

  573. DEVARBHAVI H, Kurien SS
    Letter to the editor: A revised electronic version of RUCAM for the diagnosis of drug-induced liver injury.
    Hepatology. 2022;76:E71-E72.
    >> Share

  574. BARROW F, Revelo XS
    The B side of B cells in NAFLD.
    Hepatology. 2022;76:914-916.
    >> Share

  575. PAI RK, Jairath V, Hogan M, Zou G, et al
    Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score.
    Hepatology. 2022;76:1150-1163.
    >> Share

  576. LASCHTOWITZ A, Tacke F
    Many roads lead to Rome: The FGF4-AMP-activated protein kinase-Caspase 6 signal axis in NAFLD and NASH.
    Hepatology. 2022;76:911-913.
    >> Share

  577. MARTINEZ-ARRANZ I, Bruzzone C, Noureddin M, Gil-Redondo R, et al
    Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.
    Hepatology. 2022;76:1121-1134.
    >> Share

  578. KARL M, Hasselwander S, Zhou Y, Reifenberg G, et al
    Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease.
    Hepatology. 2022;76:1135-1149.
    >> Share

  579. SONG L, Wang L, Hou Y, Zhou J, et al
    FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis.
    Hepatology. 2022;76:1105-1120.
    >> Share

  580. WANG H, Zhang B, Li R, Chen J, et al
    KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration.
    Hepatology. 2022;76:967-981.
    >> Share

  581. BAPTISSART M, Bradish CM, Jones BS, Walsh E, et al
    Zac1 and the Imprinted Gene Network program juvenile NAFLD in response to maternal metabolic syndrome.
    Hepatology. 2022;76:1090-1104.
    >> Share

  582. WANG H, Zhou Y, Xu H, Wang X, et al
    Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
    Hepatology. 2022;76:951-966.
    >> Share

  583. BALOG S, Fujiwara R, Pan SQ, El-Baradie KB, et al
    Emergence of highly profibrotic and proinflammatory Lrat(+) Fbln2(+) hepatic stellate cell subpopulation in alcoholic hepatitis.
    Hepatology. 2022 Oct 1. doi: 10.1002/hep.32793.
    >> Share

    September 2022
  584. VIZZUTTI F, Celsa C, Battaglia S, Miraglia R, et al
    Reply to the Letter to the Editor: "Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis - does novelty supplant the standard?"
    Hepatology. 2022 Sep 30. doi: 10.1002/hep.32813.
    >> Share

  585. VAZ K, Little R, Majeed A, Roberts S, et al
    Letter to the Editor: Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis - does novelty supplant the standard?
    Hepatology. 2022 Sep 28. doi: 10.1002/hep.32811.
    >> Share

  586. ALLEGRETTI AS
    NGAL in AKI and cirrhosis - ready for prime time?
    Hepatology. 2022 Sep 28. doi: 10.1002/hep.32807.
    >> Share

  587. YIP TC, Wong VW, Wong GL
    Does hepatic steatosis impact chronic hepatitis B?
    Hepatology. 2022 Sep 24. doi: 10.1002/hep.32803.
    >> Share

  588. MAK LY, Hui RW, Lee CH, Mao X, et al
    Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes.
    Hepatology. 2022 Sep 21. doi: 10.1002/hep.32716.
    >> Share

  589. GAMBINO C, Piano S, Stenico M, Tonon M, et al
    Diagnostic and prognostic performance of urinary Neutrophil Gelatinase-associated Lipocalin in patients with cirrhosis and AKI.
    Hepatology. 2022 Sep 20. doi: 10.1002/hep.32799.
    >> Share

  590. MANNA D, Reghupaty SC, Camarena MDC, Mendoza RG, et al
    Melanoma Differentiation Associated Gene-9/Syndecan Binding Protein (MDA-9/SDCBP) Promotes Hepatocellular Carcinoma (HCC).
    Hepatology. 2022 Sep 19. doi: 10.1002/hep.32797.
    >> Share

  591. JACHS M, Tillmann HL
    Editorial: It's not all about the virus - on the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B.
    Hepatology. 2022 Sep 17. doi: 10.1002/hep.32798.
    >> Share

  592. MAO X, Cheung KS, Peng C, Mak LY, et al
    Steatosis, HBV-related hepatocellular carcinoma, cirrhosis & HBsAg seroclearance: a systematic review and meta-analysis.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32792.
    >> Share

  593. CHEN YT, Su YC, Or YE, Cheng CF, et al
    CD8(+) T cell memory is sustained in mice by hepatic stellate cells.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32788.
    >> Share

  594. BIAGIOLI M, Marchiano S, di Giorgio C, Roselli R, et al
    Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32787.
    >> Share

  595. LIU Y, Zhang J, Xu Y, Lu X, et al
    Letter to the editor: Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients.
    Hepatology. 2022 Sep 14. doi: 10.1002/hep.32785.
    >> Share

  596. VIZZUTTI F, Celsa C, Battaglia S, Miraglia R, et al
    Reply to the Letter to the Editor: "Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients".
    Hepatology. 2022 Sep 13. doi: 10.1002/hep.32784.
    >> Share

  597. LESLIE J, Hunter JE, Collins A, Rushton A, et al
    c-Rel dependant Chk2 signalling regulates the DNA damage response limiting hepatocarcinogenesis.
    Hepatology. 2022 Sep 11. doi: 10.1002/hep.32781.
    >> Share

  598. LEE YT, Fujiwara N, Yang JD, Hoshida Y, et al
    Risk stratification and early detection biomarkers for precision hepatocellular carcinoma screening.
    Hepatology. 2022 Sep 9. doi: 10.1002/hep.32779.
    >> Share

  599. DELLINGER RW, Holmes HE, Hu-Seliger T, Butt RW, et al
    NRPT reduces markers of hepatic inflammation in non-alcoholic fatty liver disease: a double-blind, placebo-controlled clinical trial.
    Hepatology. 2022 Sep 9. doi: 10.1002/hep.32778.
    >> Share


  600. Retracted: Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.
    Hepatology. 2022 Sep 8. doi: 10.1002/hep.32736.
    >> Share

  601. LEUNG DH, Devaraj S, Goodrich NP, Chen X, et al
    Serum Biomarkers Correlated with Liver Stiffness Assessed in a Multi-center Study of Pediatric Cholestatic Liver Disease.
    Hepatology. 2022 Sep 7. doi: 10.1002/hep.32777.
    >> Share

  602. DUAN Z
    Postvaccination COVID-19 related mortality in patients with cirrhosis:who is the culprit?
    Hepatology. 2022 Sep 5. doi: 10.1002/hep.32750.
    >> Share

  603. HUANG H, Wu L, Lu L, Zhang Z, et al
    Single-cell Transcriptomics Uncovers Cellular Architecture and Developmental Trajectories in Hepatoblastoma.
    Hepatology. 2022 Sep 4. doi: 10.1002/hep.32775.
    >> Share

  604. KNORR J, Kaufmann B, Inzaugarat ME, Holtmann TM, et al
    Interleukin-18 signaling promotes activation of hepatic stellate cells in murine liver fibrosis.
    Hepatology. 2022 Sep 4. doi: 10.1002/hep.32776.
    >> Share

  605. VAN ZWOL W, Rimbert A, Wolters JC, Smit M, et al
    Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion.
    Hepatology. 2022 Sep 2. doi: 10.1002/hep.32709.
    >> Share

  606. JENSEN DM, Rzepczynski A, Jensen EE, Reau N, et al
    The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents.
    Hepatology. 2022;76:854-859.
    >> Share

  607. CULLARO G, Verna EC, McCulloch CE, Lai JC, et al
    Improving the Model for End-Stage Liver Disease with sodium by incorporating kidney dysfunction types.
    Hepatology. 2022;76:689-699.
    >> Share

  608. ZABALETA N, Torella L, Weber ND, Gonzalez-Aseguinolaza G, et al
    mRNA and gene editing: Late breaking therapies in liver diseases.
    Hepatology. 2022;76:869-887.
    >> Share

  609. HARRIS EN
    Will inhibition of cellular crosstalk resolve liver fibrosis?
    Hepatology. 2022;76:558-560.
    >> Share

  610. ZHENG M, Allington G, Vilarinho S
    Genomic medicine for liver disease.
    Hepatology. 2022;76:860-868.
    >> Share

  611. CALCAGNO DM, Chu A, Gaul S, Taghdiri N, et al
    NOD-like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH.
    Hepatology. 2022;76:727-741.
    >> Share

  612. LIN Y, Dong MQ, Liu ZM, Xu M, et al
    A strategy of vascular-targeted therapy for liver fibrosis.
    Hepatology. 2022;76:660-675.
    >> Share

  613. ALVA-RUIZ R, Ahn JC, Udompap P, Diaz LA, et al
    Hepatology highlights.
    Hepatology. 2022;76:539-540.
    >> Share

    August 2022
  614. QUECK A, Praktiknjo M, Jansen C, Trebicka J, et al
    Response to the letter to the editor: "Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS".
    Hepatology. 2022 Aug 25. doi: 10.1002/hep.32754.
    >> Share

  615. LUO W, Wang Y, Li Y, Zhang T, et al
    Letter to the editor: Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.
    Hepatology. 2022 Aug 25. doi: 10.1002/hep.32755.
    >> Share

  616. HU S, Monga SP
    Response to the "Letter to the editor: Cautious interpretation of the compensation of insulin-mTORC1 activation to promote liver regeneration in the absence of hepatocyte beta-catenin".
    Hepatology. 2022 Aug 24. doi: 10.1002/hep.32694.
    >> Share

  617. JOHN BV, Dahman B
    COVID-19 related mortality in Cirrhosis is not associated with Proton Pump Inhibitor Exposure.
    Hepatology. 2022 Aug 24. doi: 10.1002/hep.32748.
    >> Share

  618. LO GH
    Could COVID-19 vaccination reduce post-infection mortality in most cirrhotic patients ?
    Hepatology. 2022 Aug 24. doi: 10.1002/hep.32751.
    >> Share

  619. JOHN BV, Dahman B
    COVID-19 Vaccination and mortality in Decompensated Cirrhosis.
    Hepatology. 2022 Aug 24. doi: 10.1002/hep.32749.
    >> Share

  620. LEE HM, Lidofsky SD, Taddei TH, Townshend-Bulson LJ, et al
    Attacking the Public Health Crisis of Hepatocellular Carcinoma at its Roots.
    Hepatology. 2022 Aug 21. doi: 10.1002/hep.32741.
    >> Share

  621. DONNE R, Lujambio A
    The Liver Cancer Immune Microenvironment: Therapeutic Implications for Hepatocellular Carcinoma.
    Hepatology. 2022 Aug 21. doi: 10.1002/hep.32740.
    >> Share

  622. ZONG C, Meng Y, Ye F, Yang X, et al
    AIF1(+) CSF1R(+) MSCs, induced by TNF-alpha, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis.
    Hepatology. 2022 Aug 21. doi: 10.1002/hep.32738.
    >> Share

  623. SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
    Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
    Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
    >> Share

  624. DEMORY A, Peron JM, Calderaro J, Selves J, et al
    Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation.
    Hepatology. 2022 Aug 18. doi: 10.1002/hep.32734.
    >> Share

  625. LOUREIRO D, Tout I, Narguet S, Bed CM, et al
    Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis.
    Hepatology. 2022 Aug 16. doi: 10.1002/hep.32731.
    >> Share

  626. GOUON-EVANS V, Fiorotto R
    Fibroblasts to hepatocytes: a non-stop flight into cell therapy for liver diseases?
    Hepatology. 2022 Aug 11. doi: 10.1002/hep.32725.
    >> Share

  627. LIU T, Wang Q, Zhou L, Zhang P, et al
    Intrahepatic paracrine signaling by CLCF1 ameliorates diet-induced NASH in mice.
    Hepatology. 2022 Aug 11. doi: 10.1002/hep.32719.
    >> Share

  628. WU Y, Hao X, Wei H, Sun R, et al
    TIGIT blockade elicits potent anti-tumor immunity in naturally occurring hepatitis B virus-related hepatocellular carcinoma in mice.
    Hepatology. 2022 Aug 8. doi: 10.1002/hep.32715.
    >> Share

  629. RODRIGUEZ TC, Kwan S, Smith JL, Dadafarin S, et al
    Multi-omics characterization of mouse hepatoblastoma identifies novel YAP1 target genes.
    Hepatology. 2022 Aug 6. doi: 10.1002/hep.32713.
    >> Share

  630. LIU X, Wang K, Wang L, Kong L, et al
    Hepatocyte Ltb4r1 promotes NAFLD development in obesity.
    Hepatology. 2022 Aug 5. doi: 10.1002/hep.32708.
    >> Share

  631. LIANG B, Wang H, Qiao Y, Wang X, et al
    Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation driven hepatocarcinogenesis.
    Hepatology. 2022 Aug 3. doi: 10.1002/hep.32693.
    >> Share

  632. VIZZUTTI F, Celsa C, Calvaruso V, Enea M, et al
    Mortality after transjugular intrahepatic portosystemic shunt in older adult cirrhotic patients: a validated prediction model.
    Hepatology. 2022 Aug 3. doi: 10.1002/hep.32704.
    >> Share

  633. PENUELAS-HARO I, Espinosa-Sotelo R, Crosas-Molist E, Herranz-Iturbide M, et al
    The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing hepatocellular carcinoma progression.
    Hepatology. 2022 Aug 3. doi: 10.1002/hep.32702.
    >> Share

  634. NING C, Zhang XM, Sang XT, Zhao HT, et al
    Letter to the editor: Cautious interpretation of the compensation of insulin-mTORC1 activation to promote liver regeneration in the absence of hepatocyte beta-catenin.
    Hepatology. 2022 Aug 2. doi: 10.1002/hep.32695.
    >> Share

  635. PATTOU F, Lasailly G, Raverdy V, Caiazzo R, et al
    Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two-third full rather than half empty.
    Hepatology. 2022;76:E51-E52.
    >> Share

  636. JIANG ST, Zhang JW, Lu X, Xu YY, et al
    Letter to the editor: Discussion on application scenario of cell-free DNA fragmentomics in primary liver cancer.
    Hepatology. 2022;76:E44.
    >> Share

  637. JINDAL A
    Letter to the editor: Liver outcomes after bariatric surgery in patients with NASH and advanced fibrosis.
    Hepatology. 2022;76:E42.
    >> Share

  638. GUIDOTTI LG, La Vecchia C, Colombo M
    Low-dose aspirin reduces the risk of HBV-associated HCC even when administered short-term: Too good to be true?
    Hepatology. 2022;76:300-302.
    >> Share

  639. PANIGRAHI MK, Anirvan P
    Letter to the editor: Using angiotensin-converting enzyme inhibitors to prevent liver-related events in NAFLD-Revisiting the renin-angiotensin-aldosterone system pathways.
    Hepatology. 2022;76:E32-E33.
    >> Share

  640. MAYO MJ
    Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
    Hepatology. 2022;76:518-531.
    >> Share

  641. VOS MB, Van Natta ML, Blondet NM, Dasarathy S, et al
    Randomized placebo-controlled trial of losartan for pediatric NAFLD.
    Hepatology. 2022;76:429-444.
    >> Share

  642. AGOPIAN VG, Yang JD, Zhu Y, You S, et al
    Early detection of primary liver cancer using plasma cell-free DNA fragmentomics: Do all the pieces come together?
    Hepatology. 2022;76:289-291.
    >> Share

  643. MAO Y, Han CY, Hao L, Lee Y, et al
    p21-activated kinase 4 inhibition protects against liver ischemia/reperfusion injury: Role of nuclear factor erythroid 2-related factor 2 phosphorylation.
    Hepatology. 2022;76:345-356.
    >> Share

  644. VALAINATHAN SR, Sartoris R, Elkrief L, Magaz M, et al
    Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: A case-control study.
    Hepatology. 2022;76:418-428.
    >> Share

  645. PAIS R, Aron-Wisnewsky J, Bedossa P, Ponnaiah M, et al
    Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.
    Hepatology. 2022;76:456-468.
    >> Share

  646. GUNEWARDENA S, Huck I, Walesky C, Robarts D, et al
    Progressive loss of hepatocyte nuclear factor 4 alpha activity in chronic liver diseases in humans.
    Hepatology. 2022;76:372-386.
    >> Share

  647. SOFTIC S, Kohli R
    Pediatric NASH therapies: A speedbump on the road to success.
    Hepatology. 2022;76:292-294.
    >> Share

  648. ZHANG X, Wang Z, Tang W, Wang X, et al
    Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
    Hepatology. 2022;76:317-329.
    >> Share

  649. ZHANG X, Wong GL, Yip TC, Tse YK, et al
    Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease.
    Hepatology. 2022;76:469-482.
    >> Share

  650. HAN B, Francipane MG, Cheikhi A, Johnson J, et al
    Fat-associated lymphoid clusters as expandable niches for ectopic liver development.
    Hepatology. 2022;76:357-371.
    >> Share

  651. XIONG H, Zhang C, Han L, Xu T, et al
    Suppressed farnesoid X receptor by iron overload in mice and humans potentiates iron-induced hepatotoxicity.
    Hepatology. 2022;76:387-403.
    >> Share

    July 2022
  652. SUN N, Zhang C, Lee YT, Tran BV, et al
    HCC EV ECG Score: An Extracellular Vesicle-based Protein Assay for Detection of Early-Stage Hepatocellular Carcinoma.
    Hepatology. 2022 Jul 31. doi: 10.1002/hep.32692.
    >> Share

  653. BAI Y, Yang Z, Xu X, Ding W, et al
    Direct chemical induction of hepatocyte-like cells with capacity for liver repopulation.
    Hepatology. 2022 Jul 26. doi: 10.1002/hep.32686.
    >> Share

  654. QUECK A, Schwierz L, Gu W, Ferstl PG, et al
    Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.
    Hepatology. 2022 Jul 23. doi: 10.1002/hep.32676.
    >> Share

  655. HU S, Cao C, Poddar M, Delgado E, et al
    Hepatocyte beta-Catenin Loss is Compensated by Insulin-mTORC1 Activation to Promote Liver Regeneration.
    Hepatology. 2022 Jul 21. doi: 10.1002/hep.32680.
    >> Share

  656. PAPATHEODORIDI M, Lok AS, Papatheodoridis GV
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma - Authors' reply.
    Hepatology. 2022 Jul 20. doi: 10.1002/hep.32673.
    >> Share

  657. LIU X, Tan S, Liu H, Jiang J, et al
    Hepatocyte-derived MASP1-enriched small extracellular vesicles activate hepatic stellate cells to promote liver fibrosis.
    Hepatology. 2022 Jul 18. doi: 10.1002/hep.32662.
    >> Share

  658. LAI SW
    Aspirin use and the risk of hepatocellular carcinoma.
    Hepatology. 2022 Jul 17. doi: 10.1002/hep.32674.
    >> Share

  659. ZHONG D, Cai J, Hu C, Chen J, et al
    Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
    Hepatology. 2022 Jul 15. doi: 10.1002/hep.32671.
    >> Share

  660. JIN ZC, Chen JJ, Luo B, Zhang WH, et al
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.
    Hepatology. 2022 Jul 15. doi: 10.1002/hep.32672.
    >> Share

  661. POZO-MORALES M, Garteizgogeascoa I, Perazzolo C, So J, et al
    In vivo imaging of calcium dynamics in zebrafish hepatocytes.
    Hepatology. 2022 Jul 13. doi: 10.1002/hep.32663.
    >> Share

  662. YANG F, Jiang ST, Lu X, Xu Y, et al
    Letter to the editor: Several issues to consider in the study of hepatocellular carcinoma progression mechanism.
    Hepatology. 2022 Jul 11. doi: 10.1002/hep.32659.
    >> Share

  663. BITTERMANN T, Lewis JD, Levy C, Goldberg DS, et al
    Sociodemographic and geographic differences in the U.S. epidemiology of autoimmune hepatitis with and without cirrhosis.
    Hepatology. 2022 Jul 10. doi: 10.1002/hep.32653.
    >> Share

  664. CHANG D, Truong E, Mena EA, Pacheco F, et al
    Machine Learning Models Are Superior to Non-Invasive Tests in Identifying Clinically Significant Stages of NAFLD and NAFLD-Related Cirrhosis.
    Hepatology. 2022 Jul 9. doi: 10.1002/hep.32655.
    >> Share

  665. ZHANG Y, Ye S, Lu W, Zhong J, et al
    RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling.
    Hepatology. 2022 Jul 7. doi: 10.1002/hep.32651.
    >> Share

  666. KOVALIC AJ, Lee TP, Da BL
    Letter to the editor: L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
    Hepatology. 2022 Jul 5. doi: 10.1002/hep.32643.
    >> Share

  667. RYDELL GE, Ringlander J, Larsson SB, Hellstrand K, et al
    Letter to the editor: Alu-PCR design may have compromised detection of integrated core HBV DNA.
    Hepatology. 2022;76:E23.
    >> Share

  668. DANAN G, Teschke R
    Letter to the editor: Electronic RUCAM: Major pitfalls call for caution and proper validation.
    Hepatology. 2022;76:E27.
    >> Share

  669. RASCHI E, Caraceni P
    Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria?
    Hepatology. 2022;76:E25-E26.
    >> Share

  670. KIVLIGHN S, Schuur E, Gish RG, Cryer D, et al
    Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol-associated liver disease need our attention.
    Hepatology. 2022;76:E7-E8.
    >> Share

  671. TAO X, Zhao Y, Chen L, Zeng M, et al
    Letter to the editor: Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
    Hepatology. 2022;76:E13-E14.
    >> Share

  672. KAPPUS MR, Patel YA, Duarte-Rojo A
    Improving the fitness of the NASH clinical trial: Standardizing the standard-of-care intervention.
    Hepatology. 2022;76:12-14.
    >> Share

  673. PISCAGLIA F
    Microwave ablation in skilled hands. A treatment opportunity gaining room in the field of single HCC 3-5 cm.
    Hepatology. 2022;76:6-8.
    >> Share

  674. HAYASHI PH, Lucena MI, Fontana RJ, Bjornsson ES, et al
    A revised electronic version of RUCAM for the diagnosis of DILI.
    Hepatology. 2022;76:18-31.
    >> Share

  675. SERPER M, Parikh ND, Thiele G, Ovchinsky N, et al
    Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2022;76:251-274.
    >> Share

  676. LEWIS JH
    Digitizing DILI: Who can? RUCAM? RECAM?
    Hepatology. 2022;76:3-5.
    >> Share

  677. KAWAMURA N, Imajo K, Kalutkiewicz KJ, Nagai K, et al
    Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2022;76:186-195.
    >> Share

  678. STINE JG, Schreibman IR, Faust AJ, Dahmus J, et al
    NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.
    Hepatology. 2022;76:172-185.
    >> Share

  679. DEVARAJ E, Perumal E, Subramaniyan R, Mustapha N, et al
    Liver fibrosis: Extracellular vesicles mediated intercellular communication in perisinusoidal space.
    Hepatology. 2022;76:275-285.
    >> Share

  680. POVERO D, Ahn JC, Arnold J, Udompap P, et al
    Hepatology Highlights.
    Hepatology. 2022;76:1-2.
    >> Share

  681. FAN Y, Jiang ST, Yong-Chang Z
    Letter to the Editor: Some reflection on the research related to METTL1 promoting radiotherapy resistance in hepatocellular carcinoma.
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32644.
    >> Share

  682. SCHMID CD, Olsavszky V, Reinhart M, Weyer V, et al
    ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver.
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32641.
    >> Share

    June 2022
  683. TRAN NH, Munoz S, Thompson S, Hallemeier CL, et al
    Hepatocellular Carcinoma Down-Staging for Liver Transplantation in the Era of Systemic Combined Therapy with Anti-VEGF/TKI and Immunotherapy.
    Hepatology. 2022 Jun 28. doi: 10.1002/hep.32613.
    >> Share

  684. MALHI H, Gores GJ
    What is Hepatology looking for Version 2.0?
    Hepatology. 2022 Jun 26. doi: 10.1002/hep.32637.
    >> Share

  685. JIANG ST, Xu YY, Lu X
    Letter to the Editor: Using intratumoral steatosis to predict the efficacy of combination therapy in nonviral hepatocellular carcinoma.
    Hepatology. 2022 Jun 25. doi: 10.1002/hep.32628.
    >> Share

  686. ZHAO K, Guo F, Wang J, Zhong Y, et al
    Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
    Hepatology. 2022 Jun 19. doi: 10.1002/hep.32622.
    >> Share

  687. YUAN T, Zhou T, Qian M, Du J, et al
    SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
    Hepatology. 2022 Jun 17. doi: 10.1002/hep.32621.
    >> Share

  688. JOHN BV, Doshi A, Ferreira RD, Taddei TH, et al
    Comparison of Infection-induced and Vaccine-induced Immunity Against Coronavirus 2019 in Patients with Cirrhosis.
    Hepatology. 2022 Jun 16. doi: 10.1002/hep.32619.
    >> Share

  689. LI B, Yu D
    Is the intratumor steatosis a novel biomarker for predicting the efficacy of immunotherapy in hepatocellular carcinoma?
    Hepatology. 2022 Jun 15. doi: 10.1002/hep.32616.
    >> Share

  690. XU C, Fan J, Liu D, Tuerdi A, et al
    Alpha-kinase 1 (ALPK1) Agonist, DF-006 Demonstrates Potent Efficacy in Murine and Primary Human Hepatocyte Models of Hepatitis B.
    Hepatology. 2022 Jun 14. doi: 10.1002/hep.32614.
    >> Share

  691. LIAO J, Yi Y, Yue X, Wu X, et al
    METTL1 is required for non-homologous end joining repair and renders hepatocellular carcinoma resistant to radiotherapy.
    Hepatology. 2022 Jun 14. doi: 10.1002/hep.32615.
    >> Share

  692. MA X, Chen A, Melo L, Clemente-Sanchez A, et al
    Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
    Hepatology. 2022 Jun 13. doi: 10.1002/hep.32604.
    >> Share

  693. AHMAD A
    Letter to the Editor: The Precise Relationship Between MELD and Survival Without a Liver Transplant.
    Hepatology. 2022 Jun 11. doi: 10.1002/hep.32602.
    >> Share

  694. XU J, Wang Y, Khoshdeli M, Peach M, et al
    IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH.
    Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.
    >> Share

  695. HOLMAN A, Parikh N, Clauw DJ, Williams DA, et al
    Rethinking the management of pain in cirrhosis: toward precision therapy for pain.
    Hepatology. 2022 Jun 5. doi: 10.1002/hep.32598.
    >> Share

  696. DELTENRE P, Zanetto A, Saltini D, Moreno C, et al
    The role of TIPS in patients with cirrhosis and ascites: recent evolution and open questions.
    Hepatology. 2022 Jun 4. doi: 10.1002/hep.32596.
    >> Share

  697. TESTINO G
    Letter to the editor: Chronic liver disease among adolescents and young adults: Alcohol use disorder identification.
    Hepatology. 2022;75:1662-1663.
    >> Share

  698. JULIEN J, Ayer T, Tapper EB, Barbosa C, et al
    Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study.
    Hepatology. 2022;75:1480-1490.
    >> Share

  699. SANDAHL TD, Gormsen LC, Kjaergaard K, Vendelbo MH, et al
    The pathophysiology of Wilson's disease visualized: A human (64) Cu PET study.
    Hepatology. 2022;75:1461-1470.
    >> Share

  700. QIAN Q, Li Y, Fu J, Leng D, et al
    Switch-associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1.
    Hepatology. 2022;75:1507-1522.
    >> Share

  701. VILAR-GOMEZ E, Nephew LD, Vuppalanchi R, Gawrieh S, et al
    High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population.
    Hepatology. 2022;75:1491-1506.
    >> Share

  702. PSARAKI A, Ntari L, Karakostas C, Korrou-Karava D, et al
    Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases.
    Hepatology. 2022;75:1590-1603.
    >> Share

  703. ALVA-RUIZ R, Wu T, Idalsoaga F, Ramkissoon R, et al
    Hepatology highlights.
    Hepatology. 2022;75:1363-1364.
    >> Share

    May 2022
  704. ZHANG JW, Fang J, Xun Z, Xu Y, et al
    Letter to the Editor: Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in the Real World.
    Hepatology. 2022 May 23. doi: 10.1002/hep.32588.
    >> Share

  705. KIMURA Y, Koyama Y, Taura K, Kudoh A, et al
    Characterization and role of collagen gene expressing hepatic cells following partial hepatectomy in mice.
    Hepatology. 2022 May 23. doi: 10.1002/hep.32586.
    >> Share

  706. JALAN-SAKRIKAR N, Brevini T, Huebert RC, Sampaziotis F, et al
    Organoids and Regenerative Hepatology.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32583.
    >> Share

  707. LI L, Zhang Y, Zhou Y, Hu H, et al
    Quaternary Nanoparticles Enable Sustained Release of Bortezomib for Hepatocellular Carcinoma.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32584.
    >> Share

  708. HARTL L, Haslinger K, Angerer M, Semmler G, et al
    Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32582.
    >> Share

  709. XU W, Cui C, Cui C, Chen Z, et al
    Hepatocellular Cystathionine gamma lyase/Hydrogen sulfide Attenuates Non-Alcoholic Fatty Liver Disease by Activating Farnesoid X Receptor.
    Hepatology. 2022 May 19. doi: 10.1002/hep.32577.
    >> Share

  710. PILLING LC, Atkins JL, Melzer D
    Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: associations in a large community cohort.
    Hepatology. 2022 May 14. doi: 10.1002/hep.32575.
    >> Share

  711. MURAI H, Kodama T, Maesaka K, Tange S, et al
    Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
    Hepatology. 2022 May 14. doi: 10.1002/hep.32573.
    >> Share

  712. BAJAJ JS, Rodriguez MP, Fagan A, McGeorge S, et al
    Impact of Bacterial Infections and SBP Prophylaxis on Phage-Bacterial Dynamics in Cirrhosis.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32571.
    >> Share

  713. KIM KE, Lee J, Shin HJ, Jeong EA, et al
    Lipocalin-2 Activates Hepatic stellate cells and Promotes Non-alcoholic Steatohepatitis in High-Fat Diet-Fed ob/ob mice.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32569.
    >> Share

  714. SMIRNOVA E, Muthiah MD, Narayan N, Siddiqui MS, et al
    Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32568.
    >> Share

  715. MEHTA S, Asrani SK
    The computer will see you now: Prediction of long-term survival in patients with cirrhosis.
    Hepatology. 2022 May 5. doi: 10.1002/hep.32559.
    >> Share

  716. ANDERSEN JB
    Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32558.
    >> Share

  717. GULATI P, Taneja S, Duseja A, Singh V, et al
    Letter to Editor-Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study- Should we extend the boundaries?
    Hepatology. 2022 May 3. doi: 10.1002/hep.32554.
    >> Share

  718. LIU JJ, Xin B, Du L, Chen L, et al
    Pharmaceutical Shp2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32555.
    >> Share

  719. HILSCHER MB, Wells ML, Venkatesh SK, Cetta F, et al
    Fontan-associated liver disease.
    Hepatology. 2022;75:1300-1321.
    >> Share

  720. LEE CH, Lui DTW, Lam KSL
    Letter to the editor: Circulating thrombospondin-2 as a biomarker in patients with NAFLD with and without diabetes-Are we convinced yet?
    Hepatology. 2022;75:1340.
    >> Share

  721. CHUNG HH
    Letter to the editor: The multiple mechanisms of fructose disrupt gut-liver axis and metabolic regulation.
    Hepatology. 2022;75:1338-1339.
    >> Share

  722. ASRANI SK, Ghabril MS, Kuo A, Merriman RB, et al
    Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2022;75:1289-1299.
    >> Share

  723. PAIK JM, Kabbara K, Eberly KE, Younossi Y, et al
    Global burden of NAFLD and chronic liver disease among adolescents and young adults.
    Hepatology. 2022;75:1204-1217.
    >> Share

  724. KUREBAYASHI Y, Matsuda K, Ueno A, Tsujikawa H, et al
    Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments.
    Hepatology. 2022;75:1139-1153.
    >> Share

  725. ZHANG JL, Du BB, Zhang DH, Li H, et al
    OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways.
    Hepatology. 2022;75:1218-1234.
    >> Share

  726. SONG J, Song H, Wei H, Sun R, et al
    Requirement of RORalpha for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s.
    Hepatology. 2022;75:1181-1193.
    >> Share

  727. REN QN, Zhang H, Sun CY, Zhou YF, et al
    Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis.
    Hepatology. 2022;75:1123-1138.
    >> Share

  728. CONBOY CB, Penrice DD, Watkins R, Diaz LA, et al
    Hepatology highlights.
    Hepatology. 2022;75:1071-1072.
    >> Share

  729. QIN Y, Li A, Liu B, Gao M, et al
    Comment on "Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD".
    Hepatology. 2022 May 1. doi: 10.1002/hep.32551.
    >> Share

  730. SANGRO B, Argemi J
    Immunotherapy in hepatocellular carcinoma - No rush despite the hype.
    Hepatology. 2022 May 1. doi: 10.1002/hep.32550.
    >> Share

    April 2022
  731. SHAH PA, Patil R, Harrison SA
    NAFLD-related hepatocellular carcinoma: The growing challenge.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32542.
    >> Share

  732. KUMAR A, Rajani D, Kumar S
    Letter to the editor: HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis B Alaska study.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32544.
    >> Share

  733. YAN T, Luo Y, Yan N, Hamada K, et al
    Intestinal Peroxisome Proliferator-Activated Receptor alpha-Fatty Acid Binding Protein 1 Axis Modulates Nonalcoholic Steatohepatitis.
    Hepatology. 2022 Apr 23. doi: 10.1002/hep.32538.
    >> Share

  734. CHEN L, Dong J, Meng Q, Song Z, et al
    Reply to the comment on "Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury".
    Hepatology. 2022 Apr 19. doi: 10.1002/hep.32530.
    >> Share

  735. IVANICS T, Claasen MP, Patel MS, Hansen BE, et al
    Reply to: Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.
    Hepatology. 2022 Apr 18. doi: 10.1002/hep.32532.
    >> Share

  736. JIANG ST, Zhang JW, Lu X, Xu YY, et al
    Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.
    Hepatology. 2022 Apr 17. doi: 10.1002/hep.32533.
    >> Share

  737. RAO Z, Li F, Guan Z, Zhou H, et al
    Comment on "Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury".
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32529.
    >> Share

  738. XU MX, Tan J, Ge CX, Dong W, et al
    TRIM31 confers protection against nonalcoholic steatohepatitis by deactivating MAP3K7.
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32526.
    >> Share

  739. AHN JC, Lauzon M, Luu M, Noureddin M, et al
    Racial and ethnic disparities in early treatment with immunotherapy for advanced hepatocellular carcinoma in the United States.
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32527.
    >> Share

  740. TRIPATHI D, Bureau C
    Prophylactic embolization of large spontaneous portosystemic shunts with TIPS: A panacea for post TIPS hepatic encephalopathy?
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32525.
    >> Share

  741. ZHU Y, Gu L, Lin X, Zhou X, et al
    P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis.
    Hepatology. 2022 Apr 10. doi: 10.1002/hep.32518.
    >> Share

  742. DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
    Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
    >> Share

  743. KHADERI S, Kanwal F
    Changing Epidemiology of Hepatocellular Cancer in the United States: winning the battle but it is not over yet.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32512.
    >> Share

  744. TCHORZ JS
    Re-tuning hepatocytes improves their functional engraftment.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32513.
    >> Share

  745. GOEPPERT B, Roessler S
    New kid on the block: Netrin-1 as a novel player in the delicate molecular network of hepatic inflammation.
    Hepatology. 2022 Apr 6. doi: 10.1002/hep.32509.
    >> Share

  746. MANDATO C, Vajro P
    Letter to the Editor: The burgeoning field of Progressive Familial Intrahepatic Cholestasis.
    Hepatology. 2022 Apr 5. doi: 10.1002/hep.32489.
    >> Share

  747. KRAMER JR, Natarajan Y, Dai J, Yu X, et al
    Response to letter to the editor from Zhou et al (Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease).
    Hepatology. 2022 Apr 2. doi: 10.1002/hep.32503.
    >> Share

  748. ZHOU Y, Chu W, Wu X, Zhou H, et al
    Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
    Hepatology. 2022 Apr 2. doi: 10.1002/hep.32504.
    >> Share

  749. TOMLINSON JL, Ahn JC, Povero D, Ramkissoon R, et al
    Hepatology Highlights.
    Hepatology. 2022;75:775-776.
    >> Share

  750. AHUJA P, Bi X, Ng CF, Tse MCL, et al
    Src homology 3 domain binding kinase 1 protects against hepatic steatosis and insulin resistance through the Nur77- fibroblast growth factor 21 pathway.
    Hepatology. 2022 Apr 1. doi: 10.1002/hep.32501.
    >> Share

  751. SINGAL AK, Kwo P, Kwong A, Liangpunsakul S, et al
    Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.
    Hepatology. 2022;75:1026-1037.
    >> Share

  752. SINGH SA, Madan K, Gupta S, Indrayan A, et al
    Letter to the editor: Relevance of population-based cutoffs to define frailty in clinical studies.
    Hepatology. 2022;75:1067-1068.
    >> Share

  753. WANG S, Whitlock R, Lai JC, Taneja S, et al
    Reply.
    Hepatology. 2022;75:1068-1069.
    >> Share

  754. JAIN A, Sharma BC
    Reply.
    Hepatology. 2022;75:1066-1067.
    >> Share

  755. COLASANTI T, Di Giamberardino A, Grimaldi A, Cardinale V, et al
    Letter to the editor: Serum thrombospondin-2 as biomarker in liver diseases, a look beyond NASH.
    Hepatology. 2022;75:1056-1057.
    >> Share

  756. PAILHORIES H, Boursier J, Diehl AM
    Determinants of the severity of fatty liver diseases: Need all the pieces to solve the puzzle.
    Hepatology. 2022;75:782-784.
    >> Share

  757. NEIL DAH, Minervini M, Smith ML, Hubscher SG, et al
    Banff consensus recommendations for steatosis assessment in donor livers.
    Hepatology. 2022;75:1014-1025.
    >> Share

  758. KWAN SY, Jiao J, Joon A, Wei P, et al
    Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease.
    Hepatology. 2022;75:955-967.
    >> Share

  759. ZHOU HZ, Li F, Cheng ST, Xu Y, et al
    DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis.
    Hepatology. 2022;75:847-865.
    >> Share

  760. SUBRAMANIAN P, Gargani S, Palladini A, Chatzimike M, et al
    The RNA binding protein human antigen R is a gatekeeper of liver homeostasis.
    Hepatology. 2022;75:881-897.
    >> Share

    March 2022
  761. CULLARO G, Hsu CY, Lai JC
    Variability in Serum Creatinine is Associated with Waitlist and Post-Liver Transplant Mortality in Cirrhosis Patients.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32497.
    >> Share

  762. LEE SH, Yim SY, Jeong YS, Li QX, et al
    Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
    Hepatology. 2022 Mar 29. doi: 10.1002/hep.32490.
    >> Share

  763. JAVITT NB
    Letter to the Editor: Hyperosmolarity during hepatic bile formation:Overlooked significance.
    Hepatology. 2022 Mar 29. doi: 10.1002/hep.32482.
    >> Share

  764. DENG R, Liu S, Shen S, Guo H, et al
    Circulating hepatitis B virus RNA: From biology to clinical applications.
    Hepatology. 2022 Mar 28. doi: 10.1002/hep.32479.
    >> Share

  765. CAI HX, Xin C, Wang XP
    ATP7B gene therapy of autologous reprogrammed hepatocytes alleviates copper accumulation in a murine model of Wilson's disease.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32484.
    >> Share

  766. WANG T, Xu C, Zhang Z, Wu H, et al
    Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32483.
    >> Share

  767. D'ALESSIO A, Fulgenzi CAM, Nishida N, Schonlein M, et al
    Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32468.
    >> Share

  768. CHEN L, Dong J, Liao S, Wang S, et al
    Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32471.
    >> Share

  769. FLEMMING JA, Muaddi H, Djerboua M, Neves P, et al
    Association between social determinants of health and rates of liver transplantation in individuals with cirrhosis.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32469.
    >> Share

  770. CREEDEN JF, Kipp ZA, Xu M, Flight RM, et al
    Hepatic Kinome Atlas: An In-Depth Identification of Kinase Pathways in Liver Fibrosis of Humans and Rodents.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32467.
    >> Share

  771. HOU J
    Drinking vinegar, a potential adjuvant for immunotherapy of hepatocellular carcinoma?
    Hepatology. 2022 Mar 18. doi: 10.1002/hep.32463.
    >> Share

  772. GOLDBERG D, Mantero A, Kaplan D, Delgado C, et al
    Accurate Long-Term Prediction of Death for Patients with Cirrhosis.
    Hepatology. 2022 Mar 12. doi: 10.1002/hep.32457.
    >> Share

  773. LV Y, Chen H, Luo B, Bai W, et al
    Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled trial.
    Hepatology. 2022 Mar 10. doi: 10.1002/hep.32453.
    >> Share

  774. BASS LM, Ye W, Hawthorne K, Leung DH, et al
    The Risk of Variceal Hemorrhage and Pre-Transplant Mortality in Children with Biliary Atresia.
    Hepatology. 2022 Mar 10. doi: 10.1002/hep.32451.
    >> Share

  775. HU C, Xu B, Wang X, Wan WH, et al
    Gut microbiota-derived short-chain fatty acids regulates group 3 innate lymphoid cells in hepatocellular carcinoma.
    Hepatology. 2022 Mar 9. doi: 10.1002/hep.32449.
    >> Share

  776. FOERSTER F, Gairing SJ, Ilyas SI, Galle PR, et al
    Emerging Immunotherapy for Hepatocellular Carcinoma: A Guide for Hepatologists.
    Hepatology. 2022 Mar 7. doi: 10.1002/hep.32447.
    >> Share

  777. BARNAULT R, Verzeroli C, Fournier C, Michelet M, et al
    Hepatic inflammation elicits production of proinflammatory netrin-1 through exclusive activation of translation.
    Hepatology. 2022 Mar 7. doi: 10.1002/hep.32446.
    >> Share

  778. HE Y, Luo J, Zhang G, Jin Y, et al
    Single-cell profiling of human CD127(+) innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma.
    Hepatology. 2022 Mar 4. doi: 10.1002/hep.32444.
    >> Share

  779. NIE YZ, Zheng YW, Taniguchi H
    Improving the repopulation capacity of elderly human hepatocytes by decoding aging-associated hepatocyte plasticity.
    Hepatology. 2022 Mar 4. doi: 10.1002/hep.32443.
    >> Share

  780. LU Z, Liu R, Wang Y, Jiao M, et al
    TET2 Inactivation Restrains IL-10-producing Regulatory B cells to Enable Anti-tumor Immunity in Hepatocellular Carcinoma.
    Hepatology. 2022 Mar 4. doi: 10.1002/hep.32442.
    >> Share

  781. PLAZ TORRES MC, Jaffe A, Perry R, Marabotto E, et al
    Diabetes Medications and Risk of Hepatocellular Carcinoma.
    Hepatology. 2022 Mar 3. doi: 10.1002/hep.32439.
    >> Share


  782. Hepato Liver Cancer logy highlights.
    Hepatology. 2022;75:503-504.
    >> Share

  783. HILSCHER MB, Shah VH
    A NET gain in our understanding of acute liver failure.
    Hepatology. 2022;75:511-513.
    >> Share

  784. LUO MS, Huang GJ
    Letter to the editor: The addition of C-reactive protein and von Willebrand factor to Model for End-Stage Liver Disease-Sodium.
    Hepatology. 2022;75:763-764.
    >> Share

  785. WU JW, Tseng TC, Kao JH
    Letter to the editor: New kid in the playground: HBcrAg and risk of HCC.
    Hepatology. 2022;75:760-761.
    >> Share

  786. BEKKI Y, Fenig Y
    Letter to the editor: The impact of donor liver fibrosis on early allograft dysfunction and ischemia-reperfusion injury.
    Hepatology. 2022;75:754.
    >> Share


  787. Seeking Editor for Clinical Liver Disease.
    Hepatology. 2022;75:i.
    >> Share

  788. VON MEIJENFELDT FA, Stravitz RT, Zhang J, Adelmeijer J, et al
    Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome.
    Hepatology. 2022;75:623-633.
    >> Share

  789. GOIKOETXEA-USANDIZAGA N, Serrano-Macia M, Delgado TC, Simon J, et al
    Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals.
    Hepatology. 2022;75:550-566.
    >> Share

  790. REN R, He Y, Ding D, Cui A, et al
    Aging exaggerates acute-on-chronic alcohol-induced liver injury in mice and humans by inhibiting neutrophilic sirtuin 1-C/EBPalpha-miRNA-223 axis.
    Hepatology. 2022;75:646-660.
    >> Share

  791. TAMAKI N, Imajo K, Sharpton S, Jung J, et al
    Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Hepatology. 2022;75:661-672.
    >> Share

  792. WANG C, Zhang L, Sun Z, Yuan X, et al
    Dedifferentiation-associated inflammatory factors of long-term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32436.
    >> Share

  793. KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
    Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
    >> Share

  794. IBRAHIM SH, Kamath BM, Loomes KM, Karpen SJ, et al
    Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32437.
    >> Share

    February 2022
  795. ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
    Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
    >> Share

  796. SUTHEN SD, Lim CJ, Nguyen PHD, Dutertre CA, et al
    Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in hepatocellular carcinoma.
    Hepatology. 2022 Feb 20. doi: 10.1002/hep.32419.
    >> Share

  797. FAN L, Pan Q, Yang W, Koo SC, et al
    A Developmentally Prometastatic Niche to Hepatoblastoma in Neonatal Liver mediated by the Cxcl1/Cxcr2 Axis.
    Hepatology. 2022 Feb 18. doi: 10.1002/hep.32412.
    >> Share

  798. IVANICS T, Murillo Perez CF, Claasen MP, Patel MS, et al
    Dynamic risk profiling of hepatocellular carcinoma recurrence after curative intent liver resection.
    Hepatology. 2022 Feb 18. doi: 10.1002/hep.32411.
    >> Share

  799. EFE C, Harputluoglu M, Karadag Soylu N, Yilmaz S, et al
    Liver transplantation following SARS-CoV-2 vaccination-induced liver failure.
    Hepatology. 2022 Feb 17. doi: 10.1002/hep.32409.
    >> Share

  800. WANG Z, Yu J, Liang P
    Reply to "Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!"
    Hepatology. 2022 Feb 9. doi: 10.1002/hep.32402.
    >> Share

  801. JINDAL A, Mukund A
    Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!
    Hepatology. 2022 Feb 9. doi: 10.1002/hep.32401.
    >> Share

  802. NOUREDDIN M, Abdelmalek MF
    ACE inhibitors: The Secret to Prevent Cirrhosis Complications and Hepatocellular Carcinoma in NAFLD?
    Hepatology. 2022 Feb 6. doi: 10.1002/hep.32399.
    >> Share

  803. YAKOVCHENKO V, Morgan TR, Miech EJ, Neely B, et al
    Core implementation strategies for improving cirrhosis care in the Veterans Health Administration.
    Hepatology. 2022 Feb 6. doi: 10.1002/hep.32395.
    >> Share

  804. ALVAREZ CS, Petrick JL, Parisi D, McMahon BJ, et al
    Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992-2018.
    Hepatology. 2022 Feb 5. doi: 10.1002/hep.32394.
    >> Share

  805. JEON Y, Kwon SM, Rhee H, Yoo JE, et al
    Molecular and radio-pathologic spectrum between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Hepatology. 2022 Feb 5. doi: 10.1002/hep.32397.
    >> Share

  806. ZANETTO A, Campello E, Spiezia L, Burra P, et al
    Letter to the Editor: is PAI-1 a thrombotic biomarker in NASH cirrhosis?
    Hepatology. 2022 Feb 3. doi: 10.1002/hep.32392.
    >> Share

  807. LEMOINE CP, Superina R
    Letter to the Editor: Is TIPS the best treatment for non-cirrhotic adults with EPHVO and portal hypertension?
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32386.
    >> Share

  808. LUO C, Xin H, Zhou Z, Hu Z, et al
    Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32387.
    >> Share

  809. LEE V, Wong TC
    Reply to "prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant".
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32379.
    >> Share

  810. WATKINS R, Ilyas SI, Penrice DD, Conboy CB, et al
    Hepatology Highlights.
    Hepatology. 2022;75:241-242.
    >> Share

  811. ROGAL S, Hansen L, Patel A, Ufere NN, et al
    AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis.
    Hepatology. 2022 Feb 1. doi: 10.1002/hep.32378.
    >> Share

  812. KARATAYLI E, Lammert F
    Vulnerability to alcohol-associated liver disease: A tale of two systems.
    Hepatology. 2022;75:246-247.
    >> Share

  813. HEY P, Gow P
    Letter to the Editor: Rethinking public health measures to reduce liver injury from therapeutic acetaminophen ingestion.
    Hepatology. 2022;75:495-496.
    >> Share

  814. GIDENER T, Yin M, Dierkhising RA, Allen AM, et al
    Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study.
    Hepatology. 2022;75:379-390.
    >> Share

  815. VAN KLEEF LA, Ayada I, Alferink LJM, Pan Q, et al
    Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    Hepatology. 2022;75:419-429.
    >> Share

  816. RAMANI K, Robinson AE, Berlind J, Fan W, et al
    S-adenosylmethionine inhibits la ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells.
    Hepatology. 2022;75:280-296.
    >> Share

  817. LIN T, Wang S, Munker S, Jung K, et al
    Follistatin-controlled activin-HNF4alpha-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure.
    Hepatology. 2022;75:322-337.
    >> Share

  818. KIM KY, Kim JO, Kim YS, Choi JE, et al
    Genome-wide association of individual vulnerability with alcohol-associated liver disease: A Korean genome and epidemiology study.
    Hepatology. 2022;75:391-402.
    >> Share

    January 2022
  819. JIANG SY, Yang X, Yang Z, Li JW, et al
    Discovery of a INSIG binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting SREBP-mediated lipogenesis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32381.
    >> Share

  820. DE A, Keisham A, Duseja A
    Spontaneous regression of cirrhosis: a paradigm shift in our understanding of the natural history of non-alcoholic steatohepatitis (NASH).
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32374.
    >> Share

  821. JANG H, Lee YB, Moon H, Chung JW, et al
    Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
    >> Share

  822. KUMAR A, Sharma P, Arora A
    Letter to the Editor: In patients with established NASH cirrhosis, is there no role of weight reduction in reversing fibrosis?
    Hepatology. 2022 Jan 29. doi: 10.1002/hep.32375.
    >> Share

  823. LIU F, Zhang W, Liu H
    Letter to the Editor: Hepatocyte Proliferation Peak and beta-Oxidation in Liver Regeneration after Partial Hepatectomy.
    Hepatology. 2022 Jan 26. doi: 10.1002/hep.32357.
    >> Share

  824. PAIK JM, Henry L, Younossi ZM
    Response to: Chronic Liver Disease Among Adolescent and Young Adult: Alcohol Use Disorder Identification- Letter to the Editor. Hepatology 2022.
    Hepatology. 2022 Jan 25. doi: 10.1002/hep.32362.
    >> Share

  825. SAHAI P, Jindal A, Mukund A
    Letter to the Editor: Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
    Hepatology. 2022 Jan 25. doi: 10.1002/hep.32354.
    >> Share

  826. LI YT, Liu CJ, Kao JH, Lin LF, et al
    Metastatic Tumor Antigen 1 Contributes to Hepatocarcinogenesis Posttranscriptionally Through Novel RNA Binding Function.
    Hepatology. 2022 Jan 24. doi: 10.1002/hep.32356.
    >> Share

  827. HAN J, Wang B, Liu W, Wang S, et al
    Declining disease burden of hepatocellular carcinoma in the US, 1992-2017: A population-based analysis.
    Hepatology. 2022 Jan 24. doi: 10.1002/hep.32355.
    >> Share

  828. FANG Y, Liu W, Tang Z, Ji X, et al
    MCT4 inhibition potentiates hepatocellular carcinoma immunotherapy via enhancing T cell infiltration and immune attack.
    Hepatology. 2022 Jan 19. doi: 10.1002/hep.32348.
    >> Share

  829. KHATIB SA, Ma L, Dang H, Forgues M, et al
    Single-cell biology uncovers apoptotic cell death and its spatial organization as a potential modifier of tumor diversity in hepatocellular carcinoma.
    Hepatology. 2022 Jan 16. doi: 10.1002/hep.32345.
    >> Share

  830. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
    Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
    >> Share

  831. WU T, Simonetto DA, Halamka JD, Shah VH, et al
    The Digital Transformation of Hepatology: The Patient is Logged In.
    Hepatology. 2022 Jan 13. doi: 10.1002/hep.32329.
    >> Share

  832. JOHN BV, Deng Y, Schwartz KB, Taddei TH, et al
    Post-Vaccination COVID-19 Infection is Associated with Reduced Mortality in Patients With Cirrhosis.
    Hepatology. 2022 Jan 12. doi: 10.1002/hep.32337.
    >> Share

  833. RAMADORI P, Kam S, Heikenwalder M
    T Cells: Friends and Foes in NASH Pathogenesis and Hepatocarcinogenesis.
    Hepatology. 2022 Jan 12. doi: 10.1002/hep.32336.
    >> Share

  834. SANDMANN L, Cornberg M
    Hepatocellular carcinoma and hepatitis B virus reactivation - a preventable condition not to be missed.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32333.
    >> Share

  835. WANG Z, Liu M, Zhang DZ, Wu SS, et al
    Microwave Ablation versus Laparoscopic Resection as First-line Therapy for Solitary 3-5 cm Hepatocellular Carcinoma.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32323.
    >> Share

  836. FANG ZQ, Ruan B, Liu JJ, Duan JL, et al
    Notch-triggered maladaptation of liver sinusoidal endothelium aggravates nonalcoholic steatohepatitis through eNOS.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32332.
    >> Share

  837. MA H, Kang Z, Foo TK, Shen Z, et al
    Disrupted BRCA1-PALB2 Interaction Induces Tumor Immunosuppression and T-Lymphocyte Infiltration in Hepatocellular Carcinoma Through cGAS-STING Pathway.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32335.
    >> Share

  838. ANDERSSON ER
    Outside influence: the extrahepatic duct as a source for bile duct regeneration.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32334.
    >> Share

  839. MOORE MP, Cunningham RP, Meers GM, Johnson SA, et al
    Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD.
    Hepatology. 2022 Jan 9. doi: 10.1002/hep.32324.
    >> Share

  840. TRANAH TH, Shawcross DL
    The rise and fall and rise again of ammonia as a therapeutic target in hepatic encephalopathy.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32319.
    >> Share

  841. SHIODE Y, Kodama T, Shigeno S, Murai K, et al
    Traf3 inactivation promotes the development of intrahepatic cholangiocarcinoma via NIK-mediated hepatocyte transdifferentiation.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32317.
    >> Share

  842. NG CH, Xiao J, Lim WH, Chin YH, et al
    Placebo Effect on Progression and Regression in Non-Alcoholic Steatohepatitis. Evidence from a Meta-Analysis.
    Hepatology. 2022 Jan 6. doi: 10.1002/hep.32315.
    >> Share

  843. WU H, Li Y, Shi G, Du S, et al
    Hepatic IRF8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-PD-1 therapy.
    Hepatology. 2022 Jan 6. doi: 10.1002/hep.32316.
    >> Share


  844. Hepatology Highlights.
    Hepatology. 2022;75:1-2.
    >> Share

  845. PHAM L, Kennedy L, Baiocchi L, Meadows V, et al
    Mast cells in liver disease progression: An update on current studies and implications.
    Hepatology. 2022;75:213-218.
    >> Share

    December 2021
  846. LABENZ C, Labenz J, Galle PR
    Letter to the Editor: Evidence on the use of L-ornithine L-aspartate in overt hepatic encephalopathy - but does it really improve prognosis?
    Hepatology. 2021 Dec 27. doi: 10.1002/hep.32309.
    >> Share

  847. RIDOLA L, Nardelli S, Gioia S, Faccioli J, et al
    Letter to the editor: Episodic-precipitant induced hepatic encephalopathy treatment: look at new and old precipitants!
    Hepatology. 2021 Dec 24. doi: 10.1002/hep.32306.
    >> Share

  848. MASYUK AI, Masyuk TV, Trussoni CE, Pirius NE, et al
    Autophagy Promotes Hepatic Cystogenesis in Polycystic Liver Disease via Depletion of Cholangiocyte Ciliogenic Proteins.
    Hepatology. 2021 Dec 23. doi: 10.1002/hep.32298.
    >> Share

  849. LAEMMLE A, Haberle J, Willenbring H
    Reply to "The Role of Aquaporin 9 in Modeling of Ornithine Transcarbamylase Deficiency".
    Hepatology. 2021 Dec 21. doi: 10.1002/hep.32290.
    >> Share

  850. KODAMA T, Takehara T
    Reply; Transcriptomics identify thrombospondin-2 as a biomarker for nonalcoholic steatohepatitis and advanced liver fibrosis.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32292.
    >> Share

  851. REMETIC J, Ghallab A, Hobloss Z, Brackhagen L, et al
    Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32289.
    >> Share

  852. RICH NE, Singal AG
    Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?
    Hepatology. 2021 Dec 19. doi: 10.1002/hep.32284.
    >> Share

  853. FRIEDMAN SL, Pinzani M
    Hepatic Fibrosis 2022: Unmet Needs and a Blueprint for the Future.
    Hepatology. 2021 Dec 19. doi: 10.1002/hep.32285.
    >> Share

  854. CARABALLO GALVA LD, Jiang X, Hussein MS, Zhang H, et al
    Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma.
    Hepatology. 2021 Dec 12. doi: 10.1002/hep.32279.
    >> Share

  855. LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
    Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
    Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.
    >> Share

  856. LAI JC, Shui AM, Duarte-Rojo A, Ganger DR, et al
    Frailty, Mortality, and Healthcare Utilization after Liver Transplantation: From the Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study.
    Hepatology. 2021 Dec 4. doi: 10.1002/hep.32268.
    >> Share

  857. XIN B, Yang M, Wu P, Du L, et al
    Enhancing the Therapeutic Efficacy of PD-L1 Antibody for Metastasized Liver Cancer by Overcoming Hepatic Immunotolerance.
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32266.
    >> Share

  858. SAPISOCHIN G, Ivanics T, Heimbach J
    Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32258.
    >> Share

  859. KAWAI H, Osawa Y, Matsuda M, Tsunoda T, et al
    Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32256.
    >> Share


  860. 2021 Hepatology Referees (Volumes 73 and 74).
    Hepatology. 2021;74:3565-3569.
    >> Share

  861. CODISPODO G, Brown RS Jr, Hans A, Roccaro G, et al
    Hepatology Highlights.
    Hepatology. 2021;74:2931-2934.
    >> Share

  862. KUMAR K, Kulkarni A, Jagdish RK
    Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH.
    Hepatology. 2021;74:3559-3560.
    >> Share

  863. AGARWAL A, Sharma S, Saraya A
    Letter to the Editor: Defining the Futility for Rescue Transjugular Intrahepatic Portosystemic Shunt Using the Model for End-Stage Liver Disease Score and Lactate in Variceal Bleed.
    Hepatology. 2021;74:3556-3557.
    >> Share

  864. JINDAL A, Sarin SK, Mukund A
    Letter to the Editor: Salvage TIPS for Refractory Variceal Bleed-More Questions Than Answers!
    Hepatology. 2021;74:3557-3558.
    >> Share

  865. VALENTI LVC, Cherubini A
    To Be or Not to Be: The Quest for Patatin-Like Phospholipase Domain Containing 3 p.I148M Function.
    Hepatology. 2021;74:2942-2944.
    >> Share

  866. GOH GB, Chan WK, Wong VW
    Breastfeeding to Prevent NAFLD.
    Hepatology. 2021;74:2939-2941.
    >> Share

  867. SONG J, Liu Y, Wan J, Zhao GN, et al
    SIMPLE Is an Endosomal Regulator That Protects Against NAFLD by Targeting the Lysosomal Degradation of EGFR.
    Hepatology. 2021;74:3091-3109.
    >> Share

  868. WAN J, Zhang Y, Yang D, Liang Y, et al
    Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway.
    Hepatology. 2021;74:3074-3090.
    >> Share

  869. TILSON SG, Morell CM, Lenaerts AS, Park SB, et al
    Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.
    Hepatology. 2021;74:2998-3017.
    >> Share

  870. SHAH NL, Miller JB, Kalman RS, Kumar S, et al
    AASLD Educating and Engaging in the Digital Age: Editorial from Communications and Technology Committee.
    Hepatology. 2021;74:2935-2938.
    >> Share

  871. PARK Y, Sinn DH, Oh JH, Goh MJ, et al
    The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation-wide Cohort Study.
    Hepatology. 2021;74:2988-2997.
    >> Share

  872. WU T, Luo G, Lian Q, Sui C, et al
    Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis.
    Hepatology. 2021;74:3249-3268.
    >> Share

  873. KUMAR S, Wong R, Newberry C, Yeung M, et al
    Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD.
    Hepatology. 2021;74:3472-3478.
    >> Share

  874. OTT P, Ala A, Askari FK, Czlonkowska A, et al
    Designing Clinical Trials in Wilson's Disease.
    Hepatology. 2021;74:3460-3471.
    >> Share

  875. GARCIA-MACIA M, Santos-Ledo A, Leslie J, Paish HL, et al
    A Mammalian Target of Rapamycin-Perilipin 3 (mTORC1-Plin3) Pathway is essential to Activate Lipophagy and Protects Against Hepatosteatosis.
    Hepatology. 2021;74:3441-3459.
    >> Share

  876. LANGE AP, Usmani AA, Wald C, Gordon FD, et al
    Sinusoidal Obstruction Syndrome in a Young Woman With Antiphospholipid Syndrome on Oral Contraceptives.
    Hepatology. 2021;74:3539-3541.
    >> Share

  877. HAKIM A, Moll M, Brancale J, Liu J, et al
    Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury.
    Hepatology. 2021;74:3394-3408.
    >> Share

  878. BAI W, Al-Karaghouli M, Stach J, Sung S, et al
    Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.
    Hepatology. 2021;74:3301-3315.
    >> Share

  879. RUSYN I, Arzuaga X, Cattley RC, Corton JC, et al
    Key Characteristics of Human Hepatotoxicants as a Basis for Identification and Characterization of the Causes of Liver Toxicity.
    Hepatology. 2021;74:3486-3496.
    >> Share

    November 2021
  880. JAIN A, Sharma BC, Mahajan B, Srivastava S, et al
    "L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial".
    Hepatology. 2021 Nov 25. doi: 10.1002/hep.32255.
    >> Share

  881. GHANY MG, King WC, Lisker-Melman M, Sf Lok A, et al
    Letter to the Editor: HBcrAg and Prediction of Hepatocellular Carcinoma Risk.
    Hepatology. 2021 Nov 20. doi: 10.1002/hep.32251.
    >> Share

  882. LAEMMLE A, Poms M, Hsu B, Borsuk M, et al
    Aquaporin 9 Induction in Human iPSC-derived Hepatocytes Facilitates Modeling of Ornithine Transcarbamylase Deficiency.
    Hepatology. 2021 Nov 16. doi: 10.1002/hep.32247.
    >> Share

  883. KRAMER JR, Natarajan Y, Dai J, Yu X, et al
    Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.
    Hepatology. 2021 Nov 15. doi: 10.1002/hep.32244.
    >> Share

  884. KIM ER, Park JS, Kim JH, Oh JY, et al
    A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32235.
    >> Share

  885. TIAN L, Zhao L, Sze KM, Kam CS, et al
    Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32236.
    >> Share

  886. YANG J, Ye J, Ma T, Tang F, et al
    TRIM11 promotes hepatocellular carcinogenesis through ubiquitin-proteasome mediated degradation of PHLPP1.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32234.
    >> Share

  887. LI H, Lan T, Liu H, Liu C, et al
    IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
    >> Share

  888. WU N, Carpino G, Ceci L, Baiocchi L, et al
    MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
    >> Share

  889. DING MJ, Fang HR, Zhang JK, Shi JH, et al
    E3 ubiquitin ligase RNF5 protects against hepatic ischemia reperfusion injury by mediating PGAM5 ubiquitination.
    Hepatology. 2021 Nov 4. doi: 10.1002/hep.32226.
    >> Share

  890. KAPLAN A, Brown RS Jr, Buckholz A, Hang TP, et al
    Hepatology Highlights.
    Hepatology. 2021;74:2329-2332.
    >> Share

  891. BERNUAU J, Cazals-Hatem D, Vigrain V, Durand F, et al
    Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone.
    Hepatology. 2021;74:2922.
    >> Share

  892. JINDAL A
    Letter to the Editor: Infections in Severe Forms of Alcohol-Associated Liver Disease: Need a Closer Look!
    Hepatology. 2021;74:2926-2927.
    >> Share

  893. BAZARBASHI AN, Li M, Ryou M
    Letter to the Editor: Endoscopic Ultrasound-Guided Coil Therapy for Secondary Prevention After Gastric Variceal Bleeding: A Promising Alternative.
    Hepatology. 2021;74:2914.
    >> Share

  894. LOU L, Li X
    Letter to the Editor: Liver Stiffness by Transient Elastography to Detect Porto-sinusoidal Vascular Liver Disease.
    Hepatology. 2021;74:2910-2911.
    >> Share

  895. CHINNADURAI KK, De A, Duseja A, Singh V, et al
    Letter to the Editor: Is Balloon-Occluded Retrograde Transvenous Obliteration Superior to Endoscopic Cyanoacrylate in Gastric Varices?
    Hepatology. 2021;74:2907-2908.
    >> Share

  896. VOJJALA N, Mehtani R, Singh V
    Letter to the Editor: Acute Liver Injury Due to Therapeutic Doses of Acetaminophen-Confounders Must Be Ruled Out!
    Hepatology. 2021;74:2904.
    >> Share

  897. ZHOU J, Bai L, Zhang XJ, Li H, et al
    Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications.
    Hepatology. 2021;74:2839-2847.
    >> Share

  898. INARRAIRAEGUI M, Sangro B
    Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next?
    Hepatology. 2021;74:2333-2335.
    >> Share

  899. HU Y, He W, Huang Y, Xiang H, et al
    Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD.
    Hepatology. 2021;74:2508-2525.
    >> Share

  900. DIAZ LA, Idalsoaga F, Fuentes-Lopez E, Marquez-Lomas A, et al
    Impact of Public Health Policies on Alcohol-Associated Liver Disease in Latin America: An Ecological Multinational Study.
    Hepatology. 2021;74:2478-2490.
    >> Share

  901. PAISANT A, Bellal S, Lebigot J, Canivet CM, et al
    Imaging Features of Hepatic Small Vessel Neoplasm: Case Series.
    Hepatology. 2021;74:2894-2896.
    >> Share

  902. VAN DALEM J, Driessen JHM, Burden AM, Stehouwer CDA, et al
    Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.
    Hepatology. 2021;74:2467-2477.
    >> Share

  903. SUN H, Meng Q, Shi C, Yang H, et al
    Hypoxia-Inducible Exosomes Facilitate Liver-Tropic Premetastatic Niche in Colorectal Cancer.
    Hepatology. 2021;74:2633-2651.
    >> Share

  904. BURYSKA S, Ahn JC, Allen AM, Simha V, et al
    Familial Hypobetalipoproteinemia: An Underrecognized Cause of Lean NASH.
    Hepatology. 2021;74:2897-2898.
    >> Share

  905. BARCENA-VARELA M, Lujambio A
    Dissecting Early Relapse in Liver Cancer, One Cell at a Time.
    Hepatology. 2021;74:2891-2893.
    >> Share

  906. DRISCOLL J, Wehrkamp C, Ota Y, Thomas JN, et al
    Biological Nanotherapeutics for Liver Disease.
    Hepatology. 2021;74:2863-2875.
    >> Share

  907. SIMON TG, Roelstraete B, Sharma R, Khalili H, et al
    Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
    Hepatology. 2021;74:2410-2423.
    >> Share

  908. JAGDISH RK, Maras JS, Sarin SK
    Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!
    Hepatology. 2021;74:2848-2862.
    >> Share

    October 2021
  909. LAN T, Jiang S, Zhang J, Weng Q, et al
    Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-beta-activated Kinase 1-dependent Signaling.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32221.
    >> Share

  910. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
    Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
    >> Share

  911. MANCUSO A
    Portal vein thrombosis in cirrhosis: the issue of treatment.
    Hepatology. 2021 Oct 28. doi: 10.1002/hep.32216.
    >> Share

  912. LI M, Wong D, Vogel AS, Sack JS, et al
    Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
    Hepatology. 2021 Oct 28. doi: 10.1002/hep.32215.
    >> Share

  913. LUCE E, Steichen C, Allouche M, Messina A, et al
    In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model.
    Hepatology. 2021 Oct 23. doi: 10.1002/hep.32211.
    >> Share

  914. SANYAL AJ, Anstee QM, Trauner M, Lawitz EJ, et al
    Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.
    >> Share

  915. ZHOU J, Guo L, Ma T, Qiu T, et al
    N-Acetylgalactosaminyltransferase-4 protects against hepatic ischaemia/reperfusion injury via blocking ASK1 N-terminal dimerization.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32202.
    >> Share


  916. Correction of HEPATOLOGY 2020;71:259-274.
    Hepatology. 2021 Oct 12. doi: 10.1002/hep.32036.
    >> Share

  917. GRAHAM JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, et al
    Aberrant hepatic trafficking of gut-derived T-cells is not specific to primary sclerosing cholangitis.
    Hepatology. 2021 Oct 11. doi: 10.1002/hep.32193.
    >> Share

  918. SINGAL AG, Nabihah T, Mehta A, Marrero JA, et al
    GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis.
    Hepatology. 2021 Oct 7. doi: 10.1002/hep.32185.
    >> Share

  919. LIU N, Steer CJ, Song G
    MicroRNA-206 Enhances Antitumor Immunity by Disrupting the Communication between Malignant Hepatocytes and Tregs in c-Myc Mice.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32182.
    >> Share

  920. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
    BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
    >> Share

  921. ALLAMNENI C, Vora RS, Bamidele AO, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2021;74:1727-1729.
    >> Share

  922. MCCARRON S, Bathon B, Conlon DM, Abbey D, et al
    Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH.
    Hepatology. 2021;74:1825-1844.
    >> Share

  923. EDELSON JC, Rockey DC
    Letter to the Editor: Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis.
    Hepatology. 2021;74:2313-2314.
    >> Share

  924. LLEO A, Hirschfield GM
    Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
    Hepatology. 2021;74:2307.
    >> Share

  925. VILARINHO S, Ajmera V, Zheng M, Loomba R, et al
    Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.
    Hepatology. 2021;74:2241-2250.
    >> Share

  926. FRANCQUE S
    Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On!
    Hepatology. 2021;74:1730-1733.
    >> Share

  927. ZHOU J, Hu M, He M, Wang X, et al
    TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury.
    Hepatology. 2021;74:2133-2153.
    >> Share

  928. MALESPIN M, May EJ, Nephew LD, Paul S, et al
    AASLD Deepens Commitment to Diversity, Equity, and Inclusion.
    Hepatology. 2021;74:2216-2225.
    >> Share

  929. WALTER A, Rudler M, Olivas P, Moga L, et al
    Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding.
    Hepatology. 2021;74:2085-2101.
    >> Share

  930. GEURTSEN ML, Wahab RJ, Felix JF, Gaillard R, et al
    Maternal Early-Pregnancy Glucose Concentrations and Liver Fat Among School-Age Children.
    Hepatology. 2021;74:1902-1913.
    >> Share

  931. NI M, Zhang J, Sosa R, Zhang H, et al
    T-Cell Immunoglobulin and Mucin Domain-Containing Protein-4 Is Critical for Kupffer Cell Homeostatic Function in the Activation and Resolution of Liver Ischemia Reperfusion Injury.
    Hepatology. 2021;74:2118-2132.
    >> Share

  932. COLUCCI S, Altamura S, Marques O, Dropmann A, et al
    Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFbeta Pathway Activation.
    Hepatology. 2021;74:2186-2200.
    >> Share

  933. IM YR, Hunter H, de Gracia Hahn D, Duret A, et al
    A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD.
    Hepatology. 2021;74:1884-1901.
    >> Share

  934. BARROW F, Khan S, Wang H, Revelo XS, et al
    The Emerging Role of B Cells in the Pathogenesis of NAFLD.
    Hepatology. 2021;74:2277-2286.
    >> Share

  935. CHOI WM, Ryu T, Lee JH, Shim YR, et al
    Metabotropic Glutamate Receptor 5 in Natural Killer Cells Attenuates Liver Fibrosis by Exerting Cytotoxicity to Activated Stellate Cells.
    Hepatology. 2021;74:2170-2185.
    >> Share

  936. CHEN L, Wu N, Kennedy L, Francis H, et al
    Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.
    Hepatology. 2021;74:1845-1863.
    >> Share

  937. DINANI AM, Kowdley KV, Noureddin M
    Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art.
    Hepatology. 2021;74:2233-2240.
    >> Share

  938. YU H, He J, Liu W, Feng S, et al
    The Transcriptional Coactivator, ALL1-Fused Gene From Chromosome 9, Simultaneously Sustains Hypoxia Tolerance and Metabolic Advantages in Liver Cancer.
    Hepatology. 2021;74:1952-1970.
    >> Share

  939. GAWRIEH S, Noureddin M, Loo N, Mohseni R, et al
    Saroglitazar, a PPAR-alpha/gamma Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Hepatology. 2021;74:1809-1824.
    >> Share

  940. LUO X, Xiang T, Wu J, Wang X, et al
    Endoscopic Cyanoacrylate Injection Versus Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial.
    Hepatology. 2021;74:2074-2084.
    >> Share

    September 2021
  941. FANG Y, Zhan Y, Xie Y, Du S, et al
    Integration of Glucose and Cardiolipin Anabolism Confers Radiation Resistance of Hepatocellular Carcinoma.
    Hepatology. 2021 Sep 28. doi: 10.1002/hep.32177.
    >> Share

  942. LI H, Liu G, Wan X, Zhou L, et al
    ZBTB20 regulates plasma triglyceride metabolism by repressing lipoprotein lipase gene transcription in hepatocytes.
    Hepatology. 2021 Sep 28. doi: 10.1002/hep.32176.
    >> Share

  943. GARCIA-TSAO G
    Can we rely on changes in HVPG in patients with cirrhosis?
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32159.
    >> Share

  944. ZHAO C, Lancman JJ, Yang Y, Gates KP, et al
    Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32173.
    >> Share

  945. DRIEVER EG, von Meijenfeldt FA, Adelmeijer J, de Haas RJ, et al
    Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.
    Hepatology. 2021 Sep 24. doi: 10.1002/hep.32169.
    >> Share

  946. ZHAO Y, Gao L, Jiang C, Chen J, et al
    The Transcription Factor ZHX2 Alleviates Nonalcoholic Steatohepatitis by Transcriptional Activation of PTEN.
    Hepatology. 2021 Sep 21. doi: 10.1002/hep.32165.
    >> Share

  947. ZHOU SL, Luo CB, Song CL, Zhou ZJ, et al
    Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32164.
    >> Share

  948. ZHAI LL, Zhen SH, Tang ZG
    Letter to the Editor: Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival.
    Hepatology. 2021 Sep 18. doi: 10.1002/hep.32158.
    >> Share

  949. FANG AP, Zhang YJ, Chen MS, Zhu HL, et al
    Response to "Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival".
    Hepatology. 2021 Sep 18. doi: 10.1002/hep.32160.
    >> Share

  950. WANG S, Whitlock R, Xu C, Taneja S, et al
    Frailty is associated with increased risk of cirrhosis disease progression and death.
    Hepatology. 2021 Sep 15. doi: 10.1002/hep.32157.
    >> Share

  951. HUANG R, Liu J, Wang J, Li J, et al
    Letter to the Editor: Is hepatitis B virus genotype strongly associated with hepatocellular carcinoma risk in patients with chronic hepatitis B?
    Hepatology. 2021 Sep 14. doi: 10.1002/hep.32155.
    >> Share

  952. DUAN J, Wang Z, Duan R, Yang C, et al
    Therapeutic Targeting of Hepatic ACSL4 Ameliorates Non-alcoholic Steatohepatitis in Mice.
    Hepatology. 2021 Sep 12. doi: 10.1002/hep.32148.
    >> Share

  953. CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
    The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
    >> Share

  954. BLOOM PP, Fontana RJ
    With Alcohol as the fuel, COVID is the match: Liver Transplantation for Alcoholic liver disease is increasing in the United States.
    Hepatology. 2021 Sep 8. doi: 10.1002/hep.32141.
    >> Share

  955. SHAH BJ, Onken JE, Edgar L, Jou JH, et al
    Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide For Programs, Faculty, and Fellows.
    Hepatology. 2021 Sep 7. doi: 10.1002/hep.32097.
    >> Share

  956. COLL M, Arino S, Martinez-Sanchez C, Garcia-Pras E, et al
    Ductular Reaction Promotes Intrahepatic Angiogenesis Via Slit2-Robo1 Signaling.
    Hepatology. 2021 Sep 7. doi: 10.1002/hep.32140.
    >> Share

  957. ZHANG X, Yang H, Zeng S, Tian S, et al
    Melanoma-Differentiation-Associated gene 5 protects against nonalcoholic steatohepatitis in mice.
    Hepatology. 2021 Sep 5. doi: 10.1002/hep.32139.
    >> Share

  958. AN J, Kim D, Oh B, Oh YJ, et al
    Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
    >> Share

  959. GORES GJ, Malhi H
    Presenting the New Incoming Editorial Team for HEPATOLOGY: Team Members and Perspectives.
    Hepatology. 2021 Sep 2. doi: 10.1002/hep.32137.
    >> Share

  960. KHAN IW, Ali MA, Lau DTY, Hang TP, et al
    Hepatology Highlights.
    Hepatology. 2021;74:1137-1140.
    >> Share

  961. RAEVENS S, Boret M, De Pauw M, Fallon MB, et al
    Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome.
    Hepatology. 2021;74:1674-1686.
    >> Share

  962. SHARMA S, Gunjan D, Saraya A
    Letter to the Editor: Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Rebleeding: A Paradigm Shift?
    Hepatology. 2021;74:1721-1722.
    >> Share

  963. ZHANG XP, Zhao GD, Liu Q, Liu R, et al
    Letter to the Editor: Recognizing Significant Role of Neoadjuvant Radiotherapy for HCC With Vascular Invasion.
    Hepatology. 2021;74:1719.
    >> Share

  964. SEKAR D, K AP
    Letter to the Editor: H19 Promotes HCC Bone Metastasis by Reducing Osteoprotegerin Expression in a PPP1CA/p38MAPK-Dependent Manner and Sponging miR-200b-3p.
    Hepatology. 2021;74:1713.
    >> Share

  965. CRAXI L
    Letter to the Editor: Comment on "The Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases".
    Hepatology. 2021;74:1710.
    >> Share

  966. ALLEN AM, Neuschwander-Tetri BA
    The Importance of Glycemic Equipoise in NASH.
    Hepatology. 2021;74:1145-1147.
    >> Share

  967. JIANG X, Qian H, Ding WX
    New Glance at the Role of TM6SF2 in Lipid Metabolism and Liver Cancer.
    Hepatology. 2021;74:1141-1144.
    >> Share

  968. WANG SS, Tang XT, Lin M, Yuan J, et al
    Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
    Hepatology. 2021;74:1578-1594.
    >> Share

  969. NIU Y, Lin Z, Wan A, Sun L, et al
    Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.
    Hepatology. 2021;74:1461-1479.
    >> Share

  970. STARLINGER P, Ahn JC, Mullan A, Gyoeri GP, et al
    The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
    Hepatology. 2021;74:1533-1545.
    >> Share

  971. LAGO-HERNANDEZ C, Nguyen NH, Khera R, Loomba R, et al
    Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States.
    Hepatology. 2021;74:1509-1522.
    >> Share

  972. LIU Y, Song J, Yang J, Zheng J, et al
    Tumor Necrosis Factor alpha-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation.
    Hepatology. 2021;74:1300-1318.
    >> Share

  973. BEALS JW, Smith GI, Shankaran M, Fuchs A, et al
    Increased Adipose Tissue Fibrogenesis, Not Impaired Expandability, Is Associated With Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021;74:1287-1299.
    >> Share

  974. ANDREWS TS, MacParland SA
    A Spotlight on the Drivers of Inflammation in Acute Liver Failure.
    Hepatology. 2021;74:1687-1689.
    >> Share

  975. STRATAKIS N, Golden-Mason L, Margetaki K, Zhao Y, et al
    In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood.
    Hepatology. 2021;74:1546-1559.
    >> Share

  976. KUSUMANCHI P, Liang T, Zhang T, Ross RA, et al
    Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury Through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 Signaling.
    Hepatology. 2021;74:1234-1250.
    >> Share

  977. WANG Y, Hylemon PB, Zhou H
    Long Noncoding RNA H19: A Key Player in Liver Diseases.
    Hepatology. 2021;74:1652-1659.
    >> Share

    August 2021
  978. INNES H, Crooks CJ, Aspinall E, Card TR, et al
    Characterising the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.
    Hepatology. 2021 Aug 28. doi: 10.1002/hep.32123.
    >> Share

  979. VARGHESE J, Malleswaran S, Mouleeswaran K
    Letter to the Editor: Toxin-induced Graft Injury following Liver Transplantation for Yellow Phosphorus Poisoning.
    Hepatology. 2021 Aug 28. doi: 10.1002/hep.32124.
    >> Share

  980. PLUMMER MD, Regenstein F
    Light chain deposition disease: an unusual cause of portal hypertension.
    Hepatology. 2021 Aug 27. doi: 10.1002/hep.32118.
    >> Share

  981. FU J, Hu F, Ma T, Zhao WJ, et al
    A conventional immune regulator MAVS blocks hepatic steatosis via maintaining mitochondrial homeostasis.
    Hepatology. 2021 Aug 26. doi: 10.1002/hep.32126.
    >> Share

  982. IMAI N, Nicholls HT, Alves-Bezerra M, Li Y, et al
    Upregulation of Thioesterase Superfamily Member 2 in Skeletal Muscle Promotes Hepatic Steatosis and Insulin Resistance.
    Hepatology. 2021 Aug 25. doi: 10.1002/hep.32122.
    >> Share

  983. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
    >> Share

  984. FAN S, Gao Y, Qu A, Jiang Y, et al
    YAP-TEAD mediates peroxisome proliferator-activated receptor alpha-induced hepatomegaly and liver regeneration in mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32105.
    >> Share

  985. FUCHS CD, Radun R, Dixon ED, Mlitz V, et al
    Hepatocyte-specific deletion of adipose triglyceride lipase (ATGL/PNPLA2) ameliorates dietary induced steatohepatitis in mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32112.
    >> Share

  986. EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
    Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
    >> Share

  987. LIN Y, Cai Q, Chen Y, Shi T, et al
    CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
    >> Share

  988. WADHWANI SI, Ge J, Gottlieb L, Lyles C, et al
    Racial/Ethnic Disparities in Wait List Outcomes Are Only Partly Explained by Socioeconomic Deprivation Among Children Awaiting Liver Transplantation.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32106.
    >> Share

  989. ALLAIRE M, Garcia-Pagan JC, Walter A, Bureau C, et al
    Salvage TIPS in cirrhotic patients with variceal bleeding: MELD, lactates and << a la carte >> decision.
    Hepatology. 2021 Aug 5. doi: 10.1002/hep.32091.
    >> Share

  990. BOSCH J, Chung C, Carrasco-Zevallos OM, Harrison SA, et al
    A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
    Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.
    >> Share

  991. WAHID N, Jesudian A, Buckholz A, Brown RS Jr, et al
    Hepatology Highlights.
    Hepatology. 2021;74:539-542.
    >> Share

  992. FIX OK, Blumberg EA, Chang KM, Chu J, et al
    American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.
    Hepatology. 2021;74:1049-1064.
    >> Share

  993. SAVIANO A, Wrensch F, Ghany MG, Baumert TF, et al
    Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.
    Hepatology. 2021;74:1088-1100.
    >> Share

  994. TROVATO FM, Zia R, Napoli S, Wolfer K, et al
    Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.
    Hepatology. 2021;74:907-925.
    >> Share

  995. CARTER J, Wang S, Friedman SL
    Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis.
    Hepatology. 2021;74:543-546.
    >> Share

  996. FONTANA RJ, Stravitz RT, Durkalski V, Hanje J, et al
    Prognostic Value of the (13) C-Methacetin Breath Test in Adults with Acute Liver Failure and Non-acetaminophen Acute Liver Injury.
    Hepatology. 2021;74:961-972.
    >> Share

  997. REN H, Hu F, Wang D, Kang X, et al
    Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4alpha.
    Hepatology. 2021;74:723-740.
    >> Share

  998. STRAVITZ RT, Fontana RJ, Meinzer C, Durkalski-Mauldin V, et al
    Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure.
    Hepatology. 2021;74:937-949.
    >> Share

  999. LEE D, Zhang MS, Tsang FH, Bao MH, et al
    Adaptive and Constitutive Activations of Malic Enzymes Confer Liver Cancer Multilayered Protection Against Reactive Oxygen Species.
    Hepatology. 2021;74:776-796.
    >> Share

  1000. VEERAMACHANENI H, Subramanian RM
    Combined High-Dose Continuous Renal Replacement Therapy and Plasma Exchange in the Management of Severe Multiorgan System Dysfunction Associated With Acute Liver Failure.
    Hepatology. 2021;74:1124-1126.
    >> Share

  1001. TRIANTOS C, Aggeletopoulou I, Thomopoulos K, Mouzaki A, et al
    Vitamin D-Liver Disease Association: Biological Basis and Mechanisms of Action.
    Hepatology. 2021;74:1065-1073.
    >> Share

    July 2021
  1002. WIN S, Min RWM, Zhang J, Kanel G, et al
    Hepatic mitochondrial SAB deletion or knockdown alleviates diet induced metabolic syndrome, steatohepatitis and hepatic fibrosis.
    Hepatology. 2021 Jul 31. doi: 10.1002/hep.32083.
    >> Share

  1003. ZHANG Z, Ji Z, He J, Lu Y, et al
    GNAI2 exacerbates non-alcoholic steatohepatitis progression via regulating PRDX1-related inflammation and lipophagy.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32078.
    >> Share

  1004. SUDA T, Yoshikawa S, Kanefuji T, Abe S, et al
    Suppression of Noncoding RNAs as Shared Early Genetic Events in Multistep Hepatocarcinogenesis.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32077.
    >> Share

  1005. MA L, Xu A, Kang L, Cong R, et al
    LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance via SP1-induced p62 Transcription in Hepatocellular Carcinoma.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32079.
    >> Share

  1006. LIU G, Wang N, Zhang C, Li M, et al
    ALDOB depletion promotes hepatocellular carcinogenesis through activating insulin receptor signaling and lipogenesis.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32064.
    >> Share

  1007. MCMAHON BJ, Nolen S, Snowball M, Homan C, et al
    Hepatitis B Virus (HBV) Genotype: A Significant Risk Factor in Determining which Patients with Chronic HBV Infection should Undergo Surveillance for Hepatocellular Carcinoma: The Hepatitis B Alaska (HEP-B-AK) Study.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32065.
    >> Share

  1008. HU M, Zhang D, Xu H, Zhang Y, et al
    Salidroside activates the AMP-activated protein kinase pathway to suppress non-alcoholic steatohepatitis.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32066.
    >> Share

  1009. HE Q, Liu M, Huang W, Chen X, et al
    IL-1beta-induced Elevation of SLC7A11 Promotes Hepatocellular Carcinoma Metastasis through Upregulating PD-L1 and CSF1.
    Hepatology. 2021 Jul 20. doi: 10.1002/hep.32062.
    >> Share

  1010. YANG Q, Chen X, Zhang Y, Hu S, et al
    The E3 ubiquitin ligase RNF5 ameliorates nonalcoholic steatohepatitis via ubiquitin-mediated degradation of HRD1.
    Hepatology. 2021 Jul 17. doi: 10.1002/hep.32061.
    >> Share

  1011. PIANO S, Cardenas A
    Metabolomics to predict acute kidney injury in cirrhosis.
    Hepatology. 2021 Jul 16. doi: 10.1002/hep.32060.
    >> Share

  1012. MILLER BM, Oderberg IM, Goessling W
    The Hepatic Nervous System in Development, Regeneration, and Disease.
    Hepatology. 2021 Jul 13. doi: 10.1002/hep.32055.
    >> Share

  1013. ZHENG J, Daniel CR, Hatia RI, Stuff J, et al
    Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A US-Based Study.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32046.
    >> Share

  1014. LAI JC, Tandon P, Bernal W, Tapper EB, et al
    Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32049.
    >> Share

  1015. KIM OK, Nam DE, Hahn YS
    The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
    >> Share

  1016. CAPORALI C, Turco L, Prampolini F, Quaretti P, et al
    Proximal splenic artery embolization to treat refractory ascites in a cirrhotic patient.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32037.
    >> Share

  1017. BUCKHOLZ A, Lucero C, Yang LM, Lau DTY, et al
    Hepatology Highlights.
    Hepatology. 2021;74:1-4.
    >> Share

  1018. WILSON A, Beaton M, Brahmania M
    Letter to the Editor: Nonalcoholic Fatty Liver Disease-One Size May Not Fit All.
    Hepatology. 2021;74:528.
    >> Share

  1019. DIENSTAG JL
    Introducing Raymond T. Chung, M.D., Our 2021 AASLD President.
    Hepatology. 2021;74:12-18.
    >> Share

  1020. SZABO G
    Exosomes and MicroRNA-223 at the Intersection of Inflammation and Fibrosis in NAFLD.
    Hepatology. 2021;74:5-8.
    >> Share

  1021. PARTHASARATHY G, Malhi H
    Macrophage Heterogeneity in NASH: More Than Just Nomenclature.
    Hepatology. 2021;74:515-518.
    >> Share

  1022. NOUREDDIN M
    Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans.
    Hepatology. 2021;74:9-11.
    >> Share

  1023. HUANG Z, Chu L, Liang J, Tan X, et al
    H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging microRNA 200b-3p.
    Hepatology. 2021;74:214-232.
    >> Share

  1024. TAYLOR-WEINER A, Pokkalla H, Han L, Jia C, et al
    A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.
    Hepatology. 2021;74:133-147.
    >> Share

  1025. COPPLE IM, Park BK, Goldring CE
    Gene Signatures Reduce the Stress of Preclinical Drug Hepatotoxicity Screening.
    Hepatology. 2021;74:513-515.
    >> Share

  1026. HAGSTROM H, Adams LA, Allen AM, Byrne CD, et al
    Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement.
    Hepatology. 2021;74:474-482.
    >> Share

  1027. HE Y, Shi M, Wu X, Ma J, et al
    Mutational Signature Analysis Reveals Widespread Contribution of Pyrrolizidine Alkaloid Exposure to Human Liver Cancer.
    Hepatology. 2021;74:264-280.
    >> Share

  1028. KENNEDY L, Meadows V, Sybenga A, Demieville J, et al
    Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.
    Hepatology. 2021;74:164-182.
    >> Share

  1029. WANG H, Song X, Liao H, Wang P, et al
    Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
    Hepatology. 2021;74:248-263.
    >> Share

  1030. JIANG T, Sanchez-Rivera FJ, Soto-Feliciano YM, Yang Q, et al
    Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function.
    Hepatology. 2021;74:233-247.
    >> Share

  1031. GOUDSMIT BFJ, Putter H, Tushuizen ME, Vogelaar S, et al
    Refitting the Model for End-Stage Liver Disease for the Eurotransplant Region.
    Hepatology. 2021;74:351-363.
    >> Share

  1032. BERNARDO-SEISDEDOS G, Bilbao J, Fernandez-Ramos D, Lopitz-Otsoa F, et al
    Metabolic Landscape of the Mouse Liver by Quantitative (31) P Nuclear Magnetic Resonance Analysis of the Phosphorome.
    Hepatology. 2021;74:148-163.
    >> Share

  1033. HOU X, Yin S, Ren R, Liu S, et al
    Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.
    Hepatology. 2021;74:116-132.
    >> Share

  1034. WOOD NL, Kernodle AB, Hartley AJ, Segev DL, et al
    Heterogeneous Circles for Liver Allocation.
    Hepatology. 2021;74:312-321.
    >> Share

  1035. POSE E, Coll M, Martinez-Sanchez C, Zeng Z, et al
    Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections.
    Hepatology. 2021;74:296-311.
    >> Share

    June 2021
  1036. FLEMMING JA, Djerboua M, Groome PA, Booth CM, et al
    NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040.
    Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032.
    >> Share

  1037. GARATE-RASCON M, Recalde M, Jimenez M, Elizalde M, et al
    SLU7 prevents oxidative stress-mediated HNF4alpha degradation preserving hepatic differentiation and protecting from liver damage.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32029.
    >> Share

  1038. HIRAO H, Ito T, Kadono K, Kojima H, et al
    Donor Hepatic Occult Collagen Deposition Predisposes to Peri-transplant Stress and Impacts Human Liver Transplantation.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32030.
    >> Share

  1039. KRIEGERMEIER A, Hyon A, Sommars M, Hubchak S, et al
    Hepatic X-box binding protein 1 and unfolded protein response is impaired in weanling mice with resultant hepatic injury.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32031.
    >> Share

  1040. CHOLANKERIL G, Kanwal F
    Nonalcoholic fatty liver disease and Hepatocellular Carcinoma: Time to Bridge the Gap.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32025.
    >> Share

  1041. TORRENS L, Montironi C, Puigvehi M, Mesropian A, et al
    Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma.
    Hepatology. 2021 Jun 22. doi: 10.1002/hep.32023.
    >> Share

  1042. LIU H, Lee SS
    Diagnostic criteria of cirrhotic cardiomyopathy: out with the old, in with the new?
    Hepatology. 2021 Jun 21. doi: 10.1002/hep.32021.
    >> Share

  1043. JEPSEN P, Tapper EB, Deleuran T, Kazankov K, et al
    Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nationwide cohort study.
    Hepatology. 2021 Jun 16. doi: 10.1002/hep.32019.
    >> Share

  1044. SHI YF, Xie WZ
    Letter to the Editor: Risk Stratification in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32013.
    >> Share

  1045. MAZUMDER NR, Simpson D, Atiemo K, Jackson K, et al
    Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.31742.
    >> Share

  1046. BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
    The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
    >> Share

  1047. LEE YT, Wang JJ, Luu M, Noureddin M, et al
    Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
    >> Share

  1048. JINDAL A, Sharma S
    Biomarkers for predicting renal outcomes in decompensated cirrhosis - Need a closer look!
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32005.
    >> Share

  1049. SOLIPURAM V, Baretti M, Kim AY, Chen LX, et al
    Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31998.
    >> Share

  1050. SHAH V, Iwakiri Y, Boyer JL
    Obituary for Roberto J. Groszmann - the Father of Portal Hypertension.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31996.
    >> Share

  1051. KOZUMI K, Kodama T, Murai H, Sakane S, et al
    Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31995.
    >> Share

  1052. CHO K, Ro SW, Lee HW, Moon H, et al
    YAP/TAZ suppress drug penetration into hepatocellular carcinoma via stromal activation.
    Hepatology. 2021 Jun 8. doi: 10.1002/hep.32000.
    >> Share

  1053. CHEN B, Wu JX, Cheng SH, Wang LM, et al
    Phase II study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31993.
    >> Share

  1054. JINDAL A, Jagdish RK
    Response to terlipressin plus albumin in Hepatorenal syndrome - Need a closer look!
    Hepatology. 2021 Jun 6. doi: 10.1002/hep.31990.
    >> Share

  1055. WONG TC, Lee VH, Law AL, Pang HH, et al
    Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
    Hepatology. 2021 Jun 6. doi: 10.1002/hep.31992.
    >> Share

  1056. YANG W, He H, Wang T, Su N, et al
    Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis.
    Hepatology. 2021 Jun 5. doi: 10.1002/hep.31987.
    >> Share

  1057. MUHAMMAD KHAN M, Alejandra Luna-Cuadros M, Lau DTY, Sehrawat TS, et al
    Hepatology Highlights.
    Hepatology. 2021;73:2085-2088.
    >> Share

  1058. ROSENBLATT R, Lee H, Liapakis A, Lunsford KE, et al
    Equitable access to liver transplant: Bridging the gaps in the social determinants of health.
    Hepatology. 2021 Jun 1. doi: 10.1002/hep.31986.
    >> Share

  1059. KULKARNI AV, Kumar P, Sharma M, Menon B, et al
    Letter to the Editor: Living Donor Liver Transplantation or Deceased Donor Liver Transplantation in High Model for End-Stage Liver Disease Score-Which Is Better?
    Hepatology. 2021;73:2619-2620.
    >> Share

  1060. VUPPALANCHI R, Loomba R
    Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box.
    Hepatology. 2021;73:2095-2098.
    >> Share

  1061. CASSINOTTO C, Boursier J, Paisant A, Guiu B, et al
    Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
    Hepatology. 2021;73:2196-2205.
    >> Share

  1062. LIN Q, Huang Z, Cai G, Fan X, et al
    Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice.
    Hepatology. 2021;73:2206-2222.
    >> Share

  1063. KENNEDY L, Francis H, Alpini G
    Fructose Promotion of Intestinal and Liver Injury: A Sugar by Any Other Name That Isn't So Sweet.
    Hepatology. 2021;73:2092-2094.
    >> Share

  1064. CHO YE, Kim DK, Seo W, Gao B, et al
    Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress.
    Hepatology. 2021;73:2180-2195.
    >> Share

  1065. MARTINS PN, Clavien PA, Jalan R, Ghinolfi D, et al
    A Call for Randomization in Clinical Trials of Liver Machine Perfusion Preservation.
    Hepatology. 2021;73:2586-2591.
    >> Share

  1066. MOON JH, Stormon MO
    Sucrose Toxicity in Infants.
    Hepatology. 2021;73:2607-2609.
    >> Share

  1067. AHN JC, Connell A, Simonetto DA, Hughes C, et al
    Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases.
    Hepatology. 2021;73:2546-2563.
    >> Share

  1068. HOOFNAGLE JH, Bonkovsky HL, Phillips EJ, Li YJ, et al
    HLA-B*35:01 and Green Tea-Induced Liver Injury.
    Hepatology. 2021;73:2484-2493.
    >> Share

  1069. KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
    Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
    Hepatology. 2021;73:2397-2410.
    >> Share

    May 2021
  1070. VIVEIROS A, Schaefer B, Panzer M, Henninger B, et al
    MRI-based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of non-HFE Hemochromatosis Genes.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31982.
    >> Share

  1071. LEPORE A, Choy PM, Lee NC, Carella MA, et al
    Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
    >> Share

  1072. JOHNSTON ME 2ND, Rivas MP, Nicolle D, Gorse A, et al
    Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient Derived Xenograft Models.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31919.
    >> Share

  1073. YI C, Chen L, Ling Z, Liu L, et al
    Lenvatinib Targets FGFR4 to Enhance Antitumor Immune Response of Anti-PD-1 in Hepatocellular Carcinoma.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31921.
    >> Share

  1074. SUN LY, Hu JY, Liang L, Tong XM, et al
    Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
    Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
    >> Share

  1075. JOHN BV, Deng Y, Martin P, Levy C, et al
    Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
    Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
    >> Share

  1076. MEHTA G, Jalan R
    The 'Alter Ego' of Albumin in Cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31908.
    >> Share

  1077. BAJAJ JS, Garcia-Tsao G, Reddy KR, O'Leary JG, et al
    Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31907.
    >> Share

  1078. JANSSON H, Sparrelid E
    Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
    >> Share

  1079. MARTINEZ M, Perito ER, Valentino P, Mack CL, et al
    Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31911.
    >> Share

  1080. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
    Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
    >> Share

  1081. PEISELER M, Tacke F
    An unexpected line of defense: hepatoprotective eosinophils in ischemia-reperfusion injury.
    Hepatology. 2021 May 11. doi: 10.1002/hep.31895.
    >> Share

  1082. VALSAN A, Verma N, Singh V
    Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!
    Hepatology. 2021 May 11. doi: 10.1002/hep.31896.
    >> Share

  1083. ELKRIEF L, Lazareth M, Rautou PE
    Reply to: "Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!"
    Hepatology. 2021 May 11. doi: 10.1002/hep.31894.
    >> Share

  1084. DICHTEL LE
    The GLP-1 Receptor Agonist Semaglutide for the Treatment of Nonalcoholic Steatohepatitis.
    Hepatology. 2021 May 6. doi: 10.1002/hep.31886.
    >> Share

  1085. BIGGINS SW, Angeli P, Garcia-Tsao G, Gines P, et al
    Diagnosis, evaluation, and management of ascites and hepatorenal syndrome.
    Hepatology. 2021 May 3. doi: 10.1002/hep.31884.
    >> Share

  1086. LIU Y, Dou X, Zhou WY, Ding M, et al
    Hepatic SENP2 Controls Systemic Metabolism via SUMOylation-dependent Regulation of Liver-Adipose Tissue Crosstalk.
    Hepatology. 2021 May 2. doi: 10.1002/hep.31881.
    >> Share

  1087. BUCKHOLZ A, Jesudian A, Sehrawat TS, Sehrawat O, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1627-1630.
    >> Share


  1088. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    >> Share

  1089. LEI MML, Lee TKW
    Cancer-Associated Fibroblasts: Orchestrating the Crosstalk Between Liver Cancer Cells and Neutrophils Through the Cardiotrophin-Like Cytokine Factor 1-Mediated Chemokine (C-X-C motif) Ligand 6/TGF-beta Axis.
    Hepatology. 2021;73:1631-1633.
    >> Share

  1090. LEE WM, Kaplowitz N
    Alcohol, Fasting, and Therapeutic Dosing of Acetaminophen: A Perfect Storm.
    Hepatology. 2021;73:1634-1636.
    >> Share

  1091. LOUVET A, Ntandja Wandji LC, Lemaitre E, Khaldi M, et al
    Acute Liver Injury With Therapeutic Doses of Acetaminophen: A Prospective Study.
    Hepatology. 2021;73:1945-1955.
    >> Share

  1092. ASRANI SK, Mellinger J, Arab JP, Shah VH, et al
    Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action.
    Hepatology. 2021;73:2039-2050.
    >> Share

  1093. SUNDARAM V, Jalan R, Shah P, Singal AK, et al
    Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality.
    Hepatology. 2021;73:1932-1944.
    >> Share

  1094. HAFNER S, Seufferlein T, Kleger A, Muller M, et al
    Aseptic Liver Abscesses as an Exceptional Finding in Cogan's Syndrome.
    Hepatology. 2021;73:2067-2070.
    >> Share

  1095. LI Z, Lu X, Liu Y, Zhao J, et al
    Gain of LINC00624 Enhances Liver Cancer Progression by Disrupting the Histone Deacetylase 6/Tripartite Motif Containing 28/Zinc Finger Protein 354C Corepressor Complex.
    Hepatology. 2021;73:1764-1782.
    >> Share

  1096. DAVULURI G, Welch N, Sekar J, Gangadhariah M, et al
    Activated Protein Phosphatase 2A Disrupts Nutrient Sensing Balance Between Mechanistic Target of Rapamycin Complex 1 and Adenosine Monophosphate-Activated Protein Kinase, Causing Sarcopenia in Alcohol-Associated Liver Disease.
    Hepatology. 2021;73:1892-1908.
    >> Share

  1097. MA Y, Brown PM, Lin DD, Ma J, et al
    17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.
    Hepatology. 2021;73:1701-1716.
    >> Share

  1098. DRIEVER EG, Stravitz RT, Zhang J, Adelmeijer J, et al
    VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure.
    Hepatology. 2021;73:1882-1891.
    >> Share

    April 2021
  1099. SHENG J, Kohno S, Okada N, Okahashi N, et al
    Treatment of RB1-intact hepatocellular carcinoma with CDK4/6 inhibitor combination therapy.
    Hepatology. 2021 Apr 30. doi: 10.1002/hep.31872.
    >> Share

  1100. BUCKARMA E, Smoot R
    Hepatocytes Induce Change in Their Neighbors by YAP-ing at Them.
    Hepatology. 2021 Apr 30. doi: 10.1002/hep.31874.
    >> Share

  1101. ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
    Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
    Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
    >> Share

  1102. LUO Y, Gao Y, Liu W, Yang Y, et al
    MYC-Protein Arginine Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
    Hepatology. 2021 Apr 25. doi: 10.1002/hep.31864.
    >> Share

  1103. YANG X, Sun D, Xiang H, Wang S, et al
    Hepatocyte SH3RF2 Deficiency is a Key Aggravator for Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021 Apr 24. doi: 10.1002/hep.31863.
    >> Share

  1104. LIU D, Pang J, Shao W, Gu J, et al
    Hepatic fibroblast growth factor 21 is involved in mediating functions of liraglutide in mice with dietary challenge.
    Hepatology. 2021 Apr 13. doi: 10.1002/hep.31856.
    >> Share

  1105. XU X, Ye L, Zhang Q, Shen H, et al
    Group-2 Innate Lymphoid Cells Promote Hepatocellular Carcinoma Progression via CXCL2-Neutrophil Induced Immunosuppression.
    Hepatology. 2021 Apr 8. doi: 10.1002/hep.31855.
    >> Share

  1106. SUN D, Yang X, Wu B, Zhang XJ, et al
    Therapeutic Potential of G Protein-Coupled Receptors against Nonalcoholic Steatohepatitis.
    Hepatology. 2021 Apr 7. doi: 10.1002/hep.31852.
    >> Share

  1107. WING-SUM CHEU J, Chak-Lui Wong C
    Mechanistic Rationales guiding Combination Hepatocellular Carcinoma Therapies involving Immune Checkpoint Inhibitors.
    Hepatology. 2021 Apr 3. doi: 10.1002/hep.31840.
    >> Share

  1108. KOVALIC AJ, Huang G, Thuluvath PJ, Satapathy SK, et al
    Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis.
    Hepatology. 2021;73:1521-1530.
    >> Share

  1109. FU Y, Zhu R, Bai T, Han P, et al
    Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study.
    Hepatology. 2021;73:1509-1520.
    >> Share

  1110. KAUR SP, Trivedi H, Lau DTY, Bamidele AO, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1245-1247.
    >> Share


  1111. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    >> Share

  1112. DE ZEGHER F, Ibanez L
    Letter to the Editor: Tackling NAFLD in Adolescent Polycystic Ovary Syndrome: Reducing Liver Fat to Mimic Weight Loss.
    Hepatology. 2021;73:1623-1624.
    >> Share

  1113. GOLRIZ M, Ramouz A, Mehrabi A
    Letter to the Editor: Surgical Method for Establishing Posthepatectomy Liver Failure.
    Hepatology. 2021;73:1621.
    >> Share

  1114. DHAR D, Loomba R
    Emerging Metabolic and Transcriptomic Signature of PNPLA3-Associated NASH.
    Hepatology. 2021;73:1248-1250.
    >> Share

  1115. XU H, Tian Y, Tang D, Zou S, et al
    An Endoplasmic Reticulum Stress-MicroRNA-26a Feedback Circuit in NAFLD.
    Hepatology. 2021;73:1327-1345.
    >> Share

  1116. SONG Z, Chen W, Athavale D, Ge X, et al
    Osteopontin Takes Center Stage in Chronic Liver Disease.
    Hepatology. 2021;73:1594-1608.
    >> Share

  1117. ALKHOURI N, Reddy GK, Lawitz E
    Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases.
    Hepatology. 2021;73:1581-1593.
    >> Share

  1118. ARJUNAN V, Hansen A, Deutzmann A, Sze DY, et al
    Spontaneous Regression of Hepatocellular Carcinoma: When the Immune System Stands Up to Cancer.
    Hepatology. 2021;73:1611-1614.
    >> Share

  1119. OSTROUMOV D, Duong S, Wingerath J, Woller N, et al
    Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
    Hepatology. 2021;73:1399-1418.
    >> Share

  1120. CHEN L, Guo P, Li W, Fang F, et al
    Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis.
    Hepatology. 2021;73:1551-1569.
    >> Share

    March 2021
  1121. ROSENBLATT R, Wahid N, Halazun KJ, Kaplan A, et al
    Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States.
    Hepatology. 2021 Mar 29. doi: 10.1002/hep.31837.
    >> Share

  1122. DI-LUOFFO M, Pirenne S, Saandi T, Loriot A, et al
    A novel mouse model of cholangiocarcinoma uncovers a role for Tensin-4 in tumor progression.
    Hepatology. 2021 Mar 26. doi: 10.1002/hep.31834.
    >> Share

  1123. CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
    Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
    >> Share

  1124. KENDRE G, Marhenke S, Lorz G, Becker D, et al
    The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31799.
    >> Share

  1125. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
    >> Share

  1126. VANDERWERKEN D, Wood NL, Segev D, Gentry S, et al
    The Precise Relationship Between MELD and Survival Without a Liver Transplant.
    Hepatology. 2021 Mar 2. doi: 10.1002/hep.31781.
    >> Share

  1127. ZHOU Y, Chen Y, Zhang X, Xu Q, et al
    Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
    Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
    >> Share

  1128. MCHENRY SA, Davidson NO
    Ceramide Salvage, Gut Mucosal Immunoglobulin A Signaling, and Diet-Induced NASH.
    Hepatology. 2021;73:884-886.
    >> Share

  1129. MELLINGER J, Winder GS, Fernandez AC
    Measuring the Alcohol in Alcohol-Associated Liver Disease: Choices and Challenges for Clinical Research.
    Hepatology. 2021;73:1207-1212.
    >> Share

  1130. WEGERMANN K, Suzuki A, Mavis AM, Abdelmalek MF, et al
    Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations.
    Hepatology. 2021;73:1199-1206.
    >> Share

  1131. PAPAROUPA M, Schrader J, Jung C, Boenisch O, et al
    Bilateral Hematothorax Without Hematemesis-An Unusual Presentation of Variceal Bleeding.
    Hepatology. 2021;73:1233-1235.
    >> Share

  1132. GODBEE M, Jakate S, Eswaran S
    A Case of Electronic Nicotine Delivery Systems (ENDS) Liver Injury.
    Hepatology. 2021;73:1230-1232.
    >> Share

  1133. YOUNOSSI ZM, Rinella ME, Sanyal AJ, Harrison SA, et al
    From NAFLD to MAFLD: Implications of a Premature Change in Terminology.
    Hepatology. 2021;73:1194-1198.
    >> Share

  1134. PROTCHENKO O, Baratz E, Jadhav S, Li F, et al
    Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis.
    Hepatology. 2021;73:1176-1193.
    >> Share

    February 2021
  1135. HERCUN J, Parikh E, Kleiner DE, Fuss I, et al
    Recurrent nodular regenerative hyperplasia post-liver transplantation in common variable immunodeficiency.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31775.
    >> Share

  1136. MOHANTY SK, Donnelly B, Temple H, Ortiz-Perez A, et al
    HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31745.
    >> Share

  1137. NASSER-GHODSI N, Mara K, Watt KD
    De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31731.
    >> Share

  1138. DI GUGLIELMO MD, Perito ER
    To Juice or Not to Juice: Fatty Liver Repercussions for Infants.
    Hepatology. 2021;73:483-485.
    >> Share

  1139. PIROLA CJ, Sookoian S
    NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions.
    Hepatology. 2021;73:479-482.
    >> Share

  1140. GEURTSEN ML, Santos S, Gaillard R, Felix JF, et al
    Associations Between Intake of Sugar-Containing Beverages in Infancy With Liver Fat Accumulation at School Age.
    Hepatology. 2021;73:560-570.
    >> Share

  1141. TILG H, Adolph TE, Moschen AR
    Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade.
    Hepatology. 2021;73:833-842.
    >> Share

  1142. AL-NAAMANI N, Krowka MJ, Forde KA, Krok KL, et al
    Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).
    Hepatology. 2021;73:726-737.
    >> Share

  1143. JUNG YS, Stratton SA, Lee SH, Kim MJ, et al
    TMEM9-v-ATPase Activates Wnt/beta-Catenin Signaling Via APC Lysosomal Degradation for Liver Regeneration and Tumorigenesis.
    Hepatology. 2021;73:776-794.
    >> Share

  1144. HU W, Zheng S, Guo H, Dai B, et al
    PLAGL2-EGFR-HIF-1/2alpha Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity.
    Hepatology. 2021;73:674-691.
    >> Share

  1145. ZUO Q, He J, Zhang S, Wang H, et al
    PPARgamma Coactivator-1alpha Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARgamma-Dependent WNT/beta-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis.
    Hepatology. 2021;73:644-660.
    >> Share

    January 2021
  1146. ITOH A, Adams D, Huang W, Wu Y, et al
    Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
    Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
    >> Share

  1147. JAESCHKE H, Ramachandran A
    Letter to the Editor: Does c-Jun N-Terminal Kinase Regulate Acetaminophen Hepatotoxicity by Modulating Nuclear Factor Erythroid 2-Related Factor 2-Dependent Genes or Mitochondrial Oxidant Stress?
    Hepatology. 2021;73:467-468.
    >> Share

  1148. TANG X, Wang XJ
    REPLY.
    Hepatology. 2021;73:468-469.
    >> Share

  1149. CHOI J, Lim YS
    REPLY.
    Hepatology. 2021;73:467.
    >> Share

  1150. CASEY L, Aday A, Rule J, Lee WM, et al
    Letter to the Editor: Response to Letter Concerning Our Pregnancy Manuscript.
    Hepatology. 2021;73:465.
    >> Share

  1151. NORTHUP PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, et al
    Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:366-413.
    >> Share

  1152. SARKAR M, Brady CW, Fleckenstein J, Forde KA, et al
    Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:318-365.
    >> Share

  1153. DE JONGHE S, Weinstock D, Aligo J, Washington K, et al
    Biopsy Pathology and Immunohistochemistry of a Case of Immune-Mediated Drug-Induced Liver Injury With Atabecestat.
    Hepatology. 2021;73:452-455.
    >> Share

  1154. LEONIS MA, Miethke AG, Fei L, Maynor S, et al
    Four Biomarkers Linked to Activation of Cluster of Differentiation 8-Positive Lymphocytes Predict Clinical Outcomes in Pediatric Acute Liver Failure.
    Hepatology. 2021;73:233-246.
    >> Share

  1155. LI YJ, Phillips EJ, Dellinger A, Nicoletti P, et al
    Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury.
    Hepatology. 2021;73:268-281.
    >> Share

  1156. MORENO E, Toussaint MJM, van Essen SC, Bongiovanni L, et al
    E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice.
    Hepatology. 2021;73:303-317.
    >> Share

  1157. GU L, Zhu Y, Lin X, Lu B, et al
    The IKKbeta-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis.
    Hepatology. 2021;73:160-174.
    >> Share

  1158. ZHOU B, Liu C, Xu L, Yuan Y, et al
    N(6) -Methyladenosine Reader Protein YT521-B Homology Domain-Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes.
    Hepatology. 2021;73:91-103.
    >> Share

  1159. CABALLERO-CAMINO FJ, Rivilla I, Herraez E, Briz O, et al
    Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease.
    Hepatology. 2021;73:186-203.
    >> Share

  1160. FENG GS, Hanley KL, Liang Y, Lin X, et al
    Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
    Hepatology. 2021;73 Suppl 1:104-114.
    >> Share

  1161. RIZVI S, Wang J, El-Khoueiry AB
    Liver Cancer Immunity.
    Hepatology. 2021;73 Suppl 1:86-103.
    >> Share

  1162. CARUSO S, O'Brien DR, Cleary SP, Roberts LR, et al
    Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity.
    Hepatology. 2021;73 Suppl 1:14-26.
    >> Share

  1163. LU X, Paliogiannis P, Calvisi DF, Chen X, et al
    Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
    Hepatology. 2021;73 Suppl 1:49-61.
    >> Share

  1164. PEA A, Jamieson NB, Braconi C
    Biology and Clinical Application of Regulatory RNAs in Hepatocellular Carcinoma.
    Hepatology. 2021;73 Suppl 1:38-48.
    >> Share

    December 2020
  1165. NOUREDDIN N, Alkhouri N, Brown KA, Noureddin M, et al
    Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights.
    Hepatology. 2020;72:2228-2230.
    >> Share

  1166. MEHTA N, Yao FY
    Reply.
    Hepatology. 2020;72:2243-2244.
    >> Share

  1167. SELCK TJ, Bok J, Amintavakoli R
    Letter to the Editor: Do Weather and Sunlight Really Affect Alcohol Consumption?
    Hepatology. 2020;72:2239.
    >> Share

  1168. VENTURA-COTS M, Abraldes JG, Bataller R
    Reply.
    Hepatology. 2020;72:2239-2240.
    >> Share

    November 2020
  1169. KWON HM, Moon YJ, Kim KS, Shin WJ, et al
    Prognostic value of B-type natriuretic peptide in liver transplant patients: Implication in post-transplant mortality.
    Hepatology. 2020 Nov 28. doi: 10.1002/hep.31661.
    >> Share

  1170. BARMAN PM, VanWagner LB
    Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions.
    Hepatology. 2020 Nov 20. doi: 10.1002/hep.31647.
    >> Share

  1171. LOUSTAUD-RATTI V, Anneraud A, Carrier P, Debette-Gratien M, et al
    Letter to the Editor: Post-Liver Transplantation Sinusoidal Obstruction Syndrome and immunosuppressive drugs: causality of MMF or tacrolimus?
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31633.
    >> Share

  1172. SMETS L, Verbeek J, Korf H, van der Merwe S, et al
    Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
    Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
    >> Share

  1173. CAVE MC
    Environmental Pollution and the Developmental Origins of Childhood Liver Disease.
    Hepatology. 2020;72:1518-1521.
    >> Share

  1174. JAESCHKE H, Ramachandran A
    Pleiotropic Roles of Platelets and Neutrophils in Cell Death and Recovery During Acetaminophen Hepatotoxicity.
    Hepatology. 2020;72:1873-1876.
    >> Share

  1175. SINGH S, Verma N, Singh V
    Letter to the Editor: MELD-Lactate-the New Kid on the Block.
    Hepatology. 2020;72:1883.
    >> Share

    October 2020
  1176. ANTKOWIAK M, Green RM
    Telomeres, p53, Hepatocyte Nuclear Factor 4alpha, and Liver Disease.
    Hepatology. 2020;72:1166-1168.
    >> Share

  1177. LA MURA V, Villanueva C, Abraldes JG, Bosch J, et al
    Reply.
    Hepatology. 2020;72:1494-1495.
    >> Share

  1178. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
    Hepatology. 2020;72:1310-1326.
    >> Share

    September 2020
  1179. JASPER S, Hakeem AR, Vij M, Sachan D, et al
    First report of toxin-induced graft injury following liver transplantation for Yellow Phosphorus Poisoning.
    Hepatology. 2020 Sep 16. doi: 10.1002/hep.31553.
    >> Share

  1180. CHEN L, Zhou T, White T, O'Brien A, et al
    The apelin-apelin receptor axis triggers cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis.
    Hepatology. 2020 Sep 7. doi: 10.1002/hep.31545.
    >> Share

  1181. JIANG X, Ding WX
    Acyl Coenzyme A Thioesterase 9: A Novel Target for Nonalcoholic Fatty Liver Disease by Shuttling Mitochondrial Short-Chain Fatty Acids?
    Hepatology. 2020;72:797-800.
    >> Share

  1182. GUICCIARDI ME, Nakao Y, Gores GJ
    The Metabolic Sensor Adenosine Monophosphate-Activated Protein Kinase Regulates Apoptosis in Nonalcoholic Steatohepatitis.
    Hepatology. 2020;72:1139-1141.
    >> Share

  1183. KUMAR M
    Reply.
    Hepatology. 2020;72:1160.
    >> Share

  1184. WEISS TS, Melter M, Dayoub R
    Letter to the Editor: Does Augmenter of Liver Regeneration Deficiency Pave the Way for Nonalcoholic Steatohepatitis Progression?
    Hepatology. 2020;72:1156-1157.
    >> Share

  1185. VERMA AK, Gandhi CR
    Reply.
    Hepatology. 2020;72:1157-1158.
    >> Share

    August 2020
  1186. FRISSEN M, Liao L, Schneider KM, Djudjaj S, et al
    Bidirectional role of NLRP3 during acute and chronic cholestatic liver injury.
    Hepatology. 2020 Aug 4. doi: 10.1002/hep.31494.
    >> Share

  1187. WEN Y, Ju C
    MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis.
    Hepatology. 2020;72:772-774.
    >> Share

  1188. SINHA RA, Bruinstroop E, Singh BK, Yen PM, et al
    Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
    Hepatology. 2020;72:770-771.
    >> Share

  1189. GAWRIEH S, Kleiner DE, Chalasani N, Vanderbeck S, et al
    Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;72:785.
    >> Share

  1190. WEI L, Chang PEJ, Anstee QM
    Reply.
    Hepatology. 2020;72:786.
    >> Share

  1191. KWON HM, Hwang GS
    Reply.
    Hepatology. 2020;72:784.
    >> Share

  1192. HUANG JF, Dai CY, Yu ML, Chuang WL, et al
    Letter to the Editor: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter.
    Hepatology. 2020;72:781.
    >> Share

    July 2020
  1193. AMZAL R, Thebaut A, Lapalus M, Almes M, et al
    Pharmacological premature termination codon readthrough of ABCB11 in bile salt export pump deficiency: an in vitro study.
    Hepatology. 2020 Jul 23. doi: 10.1002/hep.31476.
    >> Share

  1194. WANG Y
    Letter to the Editor: Issues of Circular RNAs as MicroRNA Sponges.
    Hepatology. 2020;72:365.
    >> Share

  1195. LI L, Wei Y, Wang H
    REPLY.
    Hepatology. 2020;72:366.
    >> Share

  1196. HOOFNAGLE JH
    FXR Agonists as Therapy for Liver Disease.
    Hepatology. 2020;72:1-3.
    >> Share

  1197. MALLAT A, Lotersztajn S
    Glutamate Signaling in Alcohol-associated Fatty Liver: "Pas de Deux".
    Hepatology. 2020;72:350-352.
    >> Share

  1198. SU T, Iwakiri Y
    Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.
    Hepatology. 2020;72:347-349.
    >> Share

  1199. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    Reply.
    Hepatology. 2020;72:364-365.
    >> Share

  1200. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    REPLY.
    Hepatology. 2020;72:362-363.
    >> Share

  1201. ARASE Y, Kagawa T, Tanaka A
    Reply.
    Hepatology. 2020;72:360-361.
    >> Share

  1202. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
    Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
    Hepatology. 2020;72:359-360.
    >> Share

    June 2020
  1203. ABUD A, Maddur H, Salem R
    Management of symptomatic portal cavernoma cholangiopathy via transplenic portal vein recanalization and TIPS.
    Hepatology. 2020 Jun 5. doi: 10.1002/hep.31411.
    >> Share

  1204. KARDASHIAN A, Ge J, McCulloch CE, Kappus MR, et al
    Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31406.
    >> Share

  1205. THALJI L, Thalji NM, Heimbach JK, Ibrahim SH, et al
    Renal Function Parameters and Serum Sodium Enhance Prediction of Waitlist Outcomes in Pediatric Liver Transplantation.
    Hepatology. 2020 Jun 2. doi: 10.1002/hep.31397.
    >> Share

  1206. LUCEY MR, Singal AK
    Integrated Treatment of Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease: An Evolving Story.
    Hepatology. 2020;71:1891-1893.
    >> Share

    May 2020
  1207. GABR A, Kulik L, Mouli S, Riaz A, et al
    Liver Transplantation Following Yttrium-90 Radioembolization: 15-year Experience in 207-Patient Cohort.
    Hepatology. 2020 May 16. doi: 10.1002/hep.31318.
    >> Share

  1208. ZHOU J, Zhou F, Wang W, Zhang XJ, et al
    Epidemiological Features of NAFLD From 1999 to 2018 in China.
    Hepatology. 2020;71:1851-1864.
    >> Share

  1209. CHEN Y, Liu K, Zhang J, Hai Y, et al
    c-Jun NH2 -Terminal Protein Kinase Phosphorylates the Nrf2-ECH Homology 6 Domain of Nuclear Factor Erythroid 2-Related Factor 2 and Downregulates Cytoprotective Genes in Acetaminophen-Induced Liver Injury in Mice.
    Hepatology. 2020;71:1787-1801.
    >> Share

  1210. GAO W, Jia Z, Tian Y, Yang P, et al
    HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein.
    Hepatology. 2020;71:1678-1695.
    >> Share

  1211. FLEMING BD, Urban DJ, Hall MD, Longerich T, et al
    Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Hepatology. 2020;71:1696-1711.
    >> Share

  1212. XIE C, Zhang LZ, Chen ZL, Zhong WJ, et al
    A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemoresistance.
    Hepatology. 2020;71:1660-1677.
    >> Share

    April 2020
  1213. KHALAF RT, Sokol RJ
    New Insights Into Intestinal Failure-Associated Liver Disease in Children.
    Hepatology. 2020;71:1486-1498.
    >> Share

  1214. XIONG X, Kuang H, Liu T, Lin JD, et al
    A Single-Cell Perspective of the Mammalian Liver in Health and Disease.
    Hepatology. 2020;71:1467-1473.
    >> Share

  1215. IBRAHIM SH, Jonas MM, Taylor SA, Gutierrez Sanchez LH, et al
    Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant.
    Hepatology. 2020;71:1474-1485.
    >> Share

  1216. XIONG J, Liu T, Mi L, Kuang H, et al
    hnRNPU/TrkB Defines a Chromatin Accessibility Checkpoint for Liver Injury and Nonalcoholic Steatohepatitis Pathogenesis.
    Hepatology. 2020;71:1228-1246.
    >> Share

  1217. LIU J, Wu Z, Han D, Wei C, et al
    Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-kappaB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.
    Hepatology. 2020;71:1262-1278.
    >> Share

  1218. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
    Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
    Hepatology. 2020;71:1331-1349.
    >> Share

  1219. CHEN F, Esmaili S, Rogers GB, Bugianesi E, et al
    Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.
    Hepatology. 2020;71:1213-1227.
    >> Share

  1220. ZHANG C, Lin R, Li Z, Yang S, et al
    Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
    Hepatology. 2020;71:1297-1315.
    >> Share

  1221. SHIGETA K, Datta M, Hato T, Kitahara S, et al
    Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
    Hepatology. 2020;71:1247-1261.
    >> Share

    March 2020
  1222. SCHWACHA-EIPPER B, Minciuna I, Banz V, Dufour JF, et al
    Immunotherapy as a downstaging therapy for liver transplantation.
    Hepatology. 2020 Mar 14. doi: 10.1002/hep.31234.
    >> Share

  1223. ISAACS-TEN A, Echeandia M, Moreno-Gonzalez M, Brion A, et al
    Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability.
    Hepatology. 2020 Mar 13. doi: 10.1002/hep.31228.
    >> Share

    February 2020
  1224. NAULT JC, Villanueva A
    Biomarkers for hepatobiliary cancers.
    Hepatology. 2020 Feb 11. doi: 10.1002/hep.31175.
    >> Share

  1225. DEROO R, Trepo E, Holvoet T, De Pauw M, et al
    Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis.
    Hepatology. 2020 Feb 4. doi: 10.1002/hep.31164.
    >> Share

    January 2020
  1226. WALLACE D, Cowling T, PcPhail MJ, Brown SE, et al
    Assessing the time-dependent impact of performance status on outcomes after liver transplantation.
    Hepatology. 2020 Jan 22. doi: 10.1002/hep.31124.
    >> Share

    December 2019
  1227. GAO E, Cheema H, Waheed N, Mushtaq I, et al
    OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
    >> Share

    November 2019
  1228. GYORI GP, Pereyra D, Rumpf B, Hackl H, et al
    Von Willebrand factor facilitates MELD-independent risk stratification on the waiting list for liver transplantation.
    Hepatology. 2019 Nov 27. doi: 10.1002/hep.31047.
    >> Share

  1229. LEE BP, Vittinghoff E, Pletcher MJ, Dodge JL, et al
    Medicaid Policy and Liver Transplant for Alcohol-Related Liver Disease.
    Hepatology. 2019 Nov 8. doi: 10.1002/hep.31027.
    >> Share

  1230. KUTKUT I, Rachwan RJ, Timsina LR, Ghabril MS, et al
    Pre-Liver Transplant Cardiac Catheterization is Associated with Low Rate of Myocardial Infarction and Cardiac Mortality.
    Hepatology. 2019 Nov 7. doi: 10.1002/hep.31023.
    >> Share

  1231. EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
    Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
    Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
    >> Share

    October 2019
  1232. POLI E, Kounis I, Guettier C, Verstuyft C, et al
    Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
    Hepatology. 2019 Oct 9. doi: 10.1002/hep.30984.
    >> Share

  1233. SHAHEEN R, Alsahli S, Ewida N, Alzahrani F, et al
    Biallelic mutations in TTC26 (IFT56) cause severe biliary ciliopathy in humans.
    Hepatology. 2019 Oct 8. doi: 10.1002/hep.30982.
    >> Share

    September 2019
  1234. KIM YC, Jung H, Seok S, Zhang Y, et al
    MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
    >> Share

  1235. DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
    Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
    Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
    >> Share

  1236. ASRANI SK, Jennings LW, Kim WR, Kamath P, et al
    MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.
    Hepatology. 2019 Sep 16. doi: 10.1002/hep.30932.
    >> Share

  1237. TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
    Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
    >> Share

    August 2019
  1238. KWON HM, Moon YJ, Jung KW, Park YS, et al
    Appraisal of cardiac ejection fraction with liver disease severity: Implication in post-liver transplantation mortality.
    Hepatology. 2019 Aug 28. doi: 10.1002/hep.30913.
    >> Share

  1239. MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
    Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016